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Abstract 
Antibody-drug conjugates (ADCs) are a targeted cancer therapy combining the tumor cell 
specificity of antibodies with small-molecule chemotherapy. Despite the widespread use of ADC 
therapeutics, they exhibit a heterogeneous, perivascular distribution in tumors, often leaving 
significant portions of the tumor untargeted. Furthermore, the relationship between the 
heterogeneous distribution of ADCs in tumors and their overall efficacy is poorly understood and 
therefore can be underappreciated. In this thesis, I develop experimental techniques to quantify 
ADC distribution in tumors using near-infrared (NIR) fluorophores, construct a computational 
model to simulate antibody distribution at several length scales, and show, for the first time, that 
the antibody distribution in the tumor plays an important role in the efficacy of ADCs. To better 
characterize the multiscale distribution of ADCs, I first measure the residualization properties of 
common NIR dyes, identifying both non-residualizing and residualizing dyes. Next, I show that 
fluorescent dye structure and dye-to-protein ratio can be optimized for labeling antibodies with 
NIR fluorophores to prevent the dye from impacting antibody pharmacokinetics. I then develop a 
novel dual label, ratio-imaging technique to quantify antibody distribution and metabolism in 
vivo with unprecedented single cell resolution. Using this technique, I show the clinical dose of 
3.6 mg/kg the distribution of T-DM1 is heterogeneous in high HER2 expressing tumors, only 
targeting 10% of tumor cells. Examining the absolute uptake of ADC in targeted cells shows that 
they actually receive more ADC than necessary to kill the cell, despite most of the tumor not 
receiving any ADC. In the second part of my thesis, I develop a multiscale modeling framework 
combining a physiologically-based pharmacokinetic (PBPK) and Krogh Cylinder tissue model to 
 xvi 
predict both the systemic and tumoral distribution of antibodies. Using this model, I predict, and 
verify experimentally, that coadministration of trastuzumab with T-DM1 at 3:1 and 8:1 ratios 
drives a constant dose of T-DM1 deeper into the tumor. Using this dosing strategy, the total 
number of cells targeted increases albeit with a lower average number of ADC molecules per 
cell. These results are consistent across a number of antibodies, targets, and payloads, indicating 
the model can be used to predict ADC distribution in other tumor models. Finally, I test the 
efficacy of coadministration of trastuzumab with T-DM1 in a trastuzumab resistant xenograft 
mouse model. T-DM1 therapy alone showed a significant improvement in efficacy and survival, 
as expected, while trastuzumab alone had no impact. Counterintuitively, coadministration of 
trastuzumab, which has no efficacy in vivo and is antagonistic to T-DM1 in vitro, actually acts 
synergistically with T-DM1 in vivo. Coadministration of trastuzumab at 3:1 and 8:1 trastuzumab 
to T-DM1 dosing levels show a statistically significant improvement in survival over T-DM1 
alone. These results are the first to show that the tumoral distribution of ADCs plays a major role 
in their overall efficacy. Overall, this dissertation provides unique tools to study antibody and 
ADC distribution and metabolism, quantitative computational tools to simulate in vivo 
distribution, and concrete guidance on how to improve efficacy of ADC therapeutics. Although I 
show the importance of the antibody distribution in the tumor for efficacy, additional imaging 
with other ADC systems, lower and more heterogeneous antigen expressing tumors, and the 
antibody distribution in clinical samples will further improve our understanding of the 
relationship between distribution and efficacy.    
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Chapter 1 
Introduction  
 
1.1 Antibody Therapy 
Antibody-based therapeutics have achieved remarkable success in the clinic over the past 
several decades and remain an important treatment strategy for both hematological malignancies 
and solid tumors (1). Since their introduction in 1986, the number of approved antibody-based 
therapeutics has grown at a rate of approximately four per year, and there are now over 60 FDA 
approved therapeutics (2). In fact, in 2017 there was a record number of ten FDA approvals of 
antibody therapeutics (3). Additionally, it is expected that marketing applications will be 
submitted for least 12 antibody therapeutics in 2018, and there are 19 others in late-stage clinical 
trials with endpoints in 2018 (3). The worldwide sales of antibodies have followed this rapid 
growth trend, rising from around $75 billion in 2013 to a projected $125 billion in 2020 (2). 
Improving antibody therapy is imperative since antibody-based therapeutics will continue to be a 
critical part of cancer therapy for the foreseeable future.    
 
Antibodies are large proteins produced by the immune system to specifically bind and 
neutralize foreign pathogens (4). The most common antibody in the blood is the immunoglobulin 
G or IgG. These 150 kDa, “Y-shaped” IgG proteins have two binding arms, known as the 
fragment antigen binding region or Fab, which allows them to recognize an antigen with high 
specificity, and a constant region, known as the Fc region (crystallizable fragment), which allows 
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them to interact with immune cells. The Fab regions contain areas called complementarity 
determining regions (CDRs) that make up the antibody paratope, which binds the epitope on the 
target antigen, similar to the induced fit model of an enzyme binding a substrate (4).  
 
Antibodies are versatile therapeutics that can combine several mechanisms of action (1). 
They are engineered to strongly and specifically bind to a tumor-associated antigen. After 
engaging the target antigen some antibodies, such as cetuximab and trastuzumab, can block 
receptor dimerization, resulting in a loss of downstream signaling and/or kinase activation, and 
ultimately leading to a loss of proliferation and apoptosis (1). Furthermore, receptor binding by 
the antibody can lead to internalization, degradation, and downregulation of the receptor (5). The 
Fc portion of antibodies can also direct the immune system to target and kill tumor cells through 
several mechanisms of action (1,6). Macrophages can phagocytose tumor cells by binding the 
antibody Fc region through the FcgR receptors (6,7). Antibodies coating a tumor cell can also 
bind with complement protein C1q, ultimately leading to complement cascade and complement-
dependent cytotoxicity (CDC) (1,6). Additionally, NK cells binding the antibody with the 
FcgRIIIa leads to antibody-dependent cell-mediated cytotoxicity (ADCC) through 
perforin/granzyme release and lysis of the targeted tumor cell (1,6). A more recent strategy of 
antibody therapy involves blocking immunosuppressive interactions, such as CTLA4-CD80/86 
or PD1-PDL1, to prevent the inactivation of T cells and other immune cells in the tumor (8). 
Finally, antibody-drug conjugates (ADCs) combine the tumor cell specificity of antibodies with 
toxic small molecule drugs to improve discrimination between target and healthy tissue (9). 
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1.2 Antibody Drug Conjugates (ADCs) 
Antibody-drug conjugates (ADCs) are an antibody-based therapeutic where a linker 
connects the antibody backbone and a cytotoxic, small molecule payload (also known as a 
warhead). In contrast to conventional chemotherapy with a small molecule, which does not 
discriminate between tumor and healthy cells, ADCs are a targeted therapy aimed at reaching 
only tumor cells to improve the therapeutic window (Figure 1.1). The antibody binds a tumor-
specific or tumor-associated antigen with high affinity, thereby preferentially delivering the toxic 
payload to the tumor tissue instead of healthy tissue. Once the ADC engages the target antigen, 
the receptor-ADC complex is internalized into lysosomes for degradation. Some ADCs use 
enzymatically cleavable linkers, which will release the payload once in the lysosomes (10–12), 
while other ADCs use non-cleavable linkers, where the payload is released as a lysine-payload 
adduct after the antibody is fully degraded (11,13). Once the payload is released into the cell it is 
able to bind its target, which is commonly microtubules or DNA.  
 
 
Figure 1.1 Antibody-drug conjugate structure and mechanism of action.  
(A)  ADCs are comprised of a small molecule payload, linker, and antibody backbone. (B) ADC 
mechanism of action consists of binding their target antigen, internalization, degradation, and 
payload release. Once the payload is released it can exert its cytotoxic effect on the tumor cell.  
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Although ADCs have found some success in the clinic, they have not fully lived up to 
their potential. Two of the four FDA approved ADCs, brentuximab vedotin (Adcetris), and 
trastuzumab emtansine (Kadcyla, T-DM1), have achieved remarkable success in the treatment of 
relapsed Hodgkin lymphoma/systemic anaplastic large cell lymphoma and breast cancer, 
respectively. For brentuximab vedotin, 34% of patients with relapsed/refractory Hodgkin 
lymphoma achieved in complete remission in one clinical trial (14). In the EMILIA clinical trial, 
T-DM1 improved survival by nearly 6 months compared to standard therapy in heavily 
pretreated patients that were resistant to trastuzumab and taxane chemotherapy (15). Inotuzumab 
ozogamicin (Besponsa) was recently approved in 2017 and after the INO-VATE ALL clinical 
trial showed 80% complete remissions with ADC therapy compared to 29% for standard care for 
relapsed or refractory B-cell precursor acute lymphoblastic lymphoma (ALL) (16).  The fourth 
FDA approved ADC, Mylotarg, was originally approved in year 2001. However, after 9 years it 
was removed from the market after subsequent trials failed to confirm a clinical benefit (17). 
Mylotarg was reapproved in 2017 after it was shown an alternative dosing schedule improved the 
therapeutic index (18). Currently, there are several other promising ADCs in late-stage clinical 
trials that may soon be approved, including mirvetuximab sorvastine, glembatumumab vedotin, 
and oportuzumab monatox (3). While there are several promising ADCs on the horizon, there is 
a need to improve our understanding of why ADCs fail in the clinic to improve the development 
of future ADC therapeutics.  
 
Significant efforts have been made to engineer each part of the ADC, including site-
specific linker conjugation sites on the antibody (19,20), antibody affinity, antibody 
glycosylation (21), more stable linker conjugation chemistries (22), linker stability (11,23), 
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linker hydrophobicity (24), more potent payloads (25–27), varying drug-to-antibody ratios 
(DARs) (28,29), etc. Because there is not a “one size fits all” approach for the development of 
ADCs, each unique ADC therapeutic requires a multifactorial optimization of each component. 
Despite the significant investments into ADC therapy, the tumor distribution is often overlooked 
and rarely mentioned in the literature when considering the efficacy of these therapeutics.   
 
1.3 Antibody Heterogeneity in the Tumor 
A major problem with antibody therapy in cancer is the heterogeneous, perivascular 
distribution of antibodies in solid tumors. These distribution limitations of antibody therapy in 
human patients has been known for several decades. Before the introduction of antibody 
humanization technology, antibodies used for therapy were derived from mouse hybridomas. 
The distribution of mouse antibodies in human clinical samples could easily be detected through 
anti-mouse Fc staining and immunohistochemical or immunofluorescence microscopy (30). For 
example, an anti-melanoma mouse antibody given at doses of 3 and 7 mg/kg localized to highly 
vascular areas, leaving large areas of the tumor untargeted (30,31). At the highest dose of 500 
mg (~7 mg/kg) there was significant interpatient variability, and the total tumor antigen 
saturation ranged from 20% to 90%, while lower doses, around 100 mg, were undetectable in 
some patients (32). Autoradiographic images confirmed that the antibody localized around the 
vasculature and tumor periphery, leaving the poorly vascularized center of some tumors 
untargeted (33). These results are consistent among other mouse (34) and humanized (35) 
antibodies in clinical samples, as well as clinical antibodies in mouse xenografts (36). 
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The lack of antibody penetration into the tumor is due to both the physicochemical 
properties of the antibody and the physiology of the tumor microenvironment. The large size of 
antibodies (150 kDa) limits the rate of extravasation from blood vessels into the tumor tissue 
(37). The elevated interstitial pressure in tumors prevents convective flow from tumor blood 
vessels into the interstitium, thereby limiting the transport of antibody to passive diffusion across 
the endothelium (38). Once in the tumor interstitium, the fast binding rate of the antibody 
relative to its rate of diffusion through the tissue combined with high target expression in the 
tumor results in targeting of cells immediately outside of the vessel. As the antibody-receptor 
complex is internalized and new antigen is trafficked to the cell surface it results in a dynamic 
saturation front, commonly referred to as the “binding site barrier” (39,40). Antibody penetration 
into the tumor is dependent on dose (41), binding affinity (37,42), and target expression (43), and 
several antibody therapies in the clinic still exhibit highly heterogeneous distributions (36), often 
leaving significant portions of the tumor untargeted (44). Additionally, the total amount of 
antibody entering the tumor is low, barely reaching 0.01% of the injected dose per gram of tissue 
in humans (45). Antibody therapy is often given around 5-10 milligrams per kilogram 
bodyweight; however, doses as high as multiple grams per kilogram bodyweight may be needed 
to achieve full tumor saturation. Tumor cells untargeted by antibody therapy may lead to the 
selection of resistant cancer cells (44) or lead to tumor regrowth in between treatments (46).   
 
In ADC therapy the payload is the major driver of toxicity (47), and, because the 
payloads are often highly toxic, ADCs have much lower maximum tolerated doses (MTD) than 
many unconjugated antibody therapeutics. For example, the MTD of the FDA approved ADC 
Kadcyla (trastuzumab emtansine, T-DM1) is 3.6 mg/kg (48), while the unconjugated antibody 
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trastuzumab is well tolerated even at doses as high as 18 mg/kg over three weeks (49). Since 
ADCs are given at lower doses, they traverse only a few cell layers from the vasculature in 
tumors with high antigen expression (36,37,46). However, it is not well understood how this 
perivascular tissue distribution of ADCs impacts their overall efficacy. In fact, during 
development of ADC therapeutics it is rare to see any mention of the ADC tumor distribution, 
and many reviews of ADC therapeutics in the clinic fail to mention their heterogeneous 
distribution (8,50,51). Despite these distribution limitations of antibodies/ADCs and lack of data 
showing ADC distribution, ADC therapy is still effective in the clinic for many patients. This 
dissertation will outline computational and experimental techniques to quantify ADC distribution 
in tumors and develop strategies to improve the tumor penetrance of ADCs.  
 
1.4 Near-infrared (NIR) Fluorescence Imaging 
Currently there is a wide array of tools to understand protein distribution at several length 
scales (52). For example, basic measurements of plasma clearance can be determined using 
radiolabels, fluorescent labels, ELISA, and mass spectrometry to give blood concentration over 
time. Using radioactive labels and/or nuclear imaging, the organ uptake and whole animal 
distribution can be measured in the form of percent-injected dose per gram measurements as well 
as real time imaging with PET/SPECT. Histology can be performed using autoradiography, 
immunohistochemistry, and immunofluorescence to understand the tissue scale distribution. 
Flow cytometry and in vitro measurements are used to quantify fluorescence at the single cell 
scale. However, these conventional methods have several disadvantages and limitations. 
Biophysical techniques, such as ELISA and mass spectrometry, have limited spatial resolution 
(ELISA) and/or difficulty in measuring low concentration proteins in complex samples (e.g. 
 8 
mass spectrometry imaging). Radiolabels cannot achieve cellular and subcellular resolution and 
are more cumbersome to use than fluorescent labels due to radioactive half-life time constraints 
and safety/licensing issues. Immunohistochemistry is not an accurate measure of organ 
distribution with limited ability to measure cellular kinetics. None of these methods are capable 
of measuring cellular kinetics in vivo, and a combination of different techniques with several 
animals is needed to obtain data on all the relevant length scales. NIR wavelengths have low 
tissue autofluorescence and can penetrate to a depth of 1-2 cm for live in vivo imaging. NIR 
fluorescence combines the whole animal and biodistribution capabilities of radiolabels (53) with 
the tissue and cellular kinetic measurements of fluorescence (54). NIR also has higher sensitivity 
than mass spectrometry imaging and visible light fluorescence and is capable of tracking 
metabolic degradation products while reducing the safety concerns, time/half-life constraints, 
and expense of radioactivity.  
 
With the increased interest in novel biologics and in particular antibody-drug conjugates 
(55), there is a need to understand the effect of ADCs from the subcellular scale (e.g. number of 
ADCs each cell receives) to the tissue level (e.g. number of targeted cells in the tumor) to whole 
organ biodistribution. This dissertation outlines techniques using NIR fluorescence to investigate 
the distribution and metabolism of therapeutic proteins at the subcellular and cellular scale in 
vitro, and, importantly, at multiple scales in vivo.  
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Chapter 2 
Residualization Rates of Near Infrared Dyes for the Rational Design of Molecular Imaging 
Agents 
 
2.1 Publication Information 
Cilliers, C., J. Liao, L. Atangcho, and G.M. Thurber. Residualization rates of near 
infrared dyes for the rational design of molecular imaging agents. Molecular Imaging and 
Biology. 2015; 17(6): 757-62. 
  
Modifications have been made to the published document to adapt the content to this text. 
The goal of this chapter is to characterize the residualization rates of several near-infrared (NIR) 
fluorophores. These properties are used to select the wavelength and residualizing nature of NIR 
dyes for molecular imaging agent design. 
 
2.2 Abstract 
Near infrared (NIR) fluorescence imaging is widely used for tracking biological 
molecules in vivo. Clinical and preclinical applications include intraoperative imaging, tracking 
therapeutics, and fluorescent labeling as a surrogate for subsequent radioactive tags. Despite their 
extensive use, one of the fundamental properties of NIR dyes, the residualization rate within cells 
following internalization, has not been systematically studied. This rate is required for the 
rational design of probes and proper interpretation of in vivo results. In this brief report, we 
measure the cellular residualization rate of eight commonly used dyes encompassing three core 
structures (cyanine, BODIPY, and oxazine/thiazine/carbopyronin). We identify residualizing 
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(half-life > 24 hrs) and non-residualizing dyes (half-life < 24 hrs) in both the far red (~650-680 
nm) and near infrared (~740-800 nm) regions. This data will allow researchers to independently 
and rationally select the wavelength and residualizing nature of dyes for molecular imaging 
agent design. 
 
2.3 Background 
Near infrared (NIR) imaging is increasingly being used during the development of novel 
imaging agents either in dual-labeling approaches or interchanging the labeling moiety during 
development (56–58). One of the biggest factors in determining the in vivo distribution of the 
label is the fate of the metabolic product after internalization. Despite the importance of this 
parameter and the well-characterized literature on radioactive tags (59–62), data on the 
residualization of NIR tags is quite limited. Understanding the behavior of the NIR tag following 
local metabolism is critical in selecting fluorophores that will be representative of the 
radiolabeled compounds in preclinical development and designing effective fluorescent imaging 
agents for intraoperative applications. This information is also necessary in predictive 
mechanistic models used in drug and imaging agent design (63,64). In this report, we compare 
the cellular loss of signal following internalization and degradation of labeled antibodies.  
 
The increased use of NIR dyes during the development of molecular imaging agents 
stems from the high spatial and temporal resolution of fluorescence imaging. NIR labeled probes 
can be followed in real-time in vitro and in vivo (65), and imaging techniques exist to monitor 
distribution from the whole animal and organ level down to cellular and subcellular resolution 
(66–68). This allows the researcher to quickly and inexpensively optimize molecular properties 
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of the probe, determine clearance rates and optimal imaging windows, measure uptake in 
different cell types for heterogeneous tissues, and validate the agent in vivo prior to undertaking 
more expensive PET, SPECT, MRI, and CT validation studies. The fluorophore can then be 
replaced by a radioactive tag with similar physiochemical properties, or the dual labeled 
targeting agent can be loaded with a radioactive isotope. NIR probes have significant advantages 
over visible light dyes due to their drastically lower autofluorescence and high tissue penetration 
of light. The low background enables the detection of very low (nM) concentrations of dyes, and 
the high tissue penetration allows longitudinal whole animal imaging to follow the probe 
kinetics. Commercially available instrumentation has increased the use of these techniques in 
preclinical development. 
  
Many different options are available for near-infrared labeling of molecules including 
organic dyes, quantum dots (69), and fluorescent proteins (70). For imaging agent conjugation, 
the organic dyes are the smallest labeling options and therefore least likely to dominate the 
pharmacokinetics and/or disrupt binding. While there has been extensive research into organic 
dye NIR fluorophore development, three of the most common (and commercially available) 
structures are cyanine dyes, red-shifted BODIPY fluorophores, and smaller polycyclic dyes (e.g. 
oxazine (71), thiazine (72), or carbopyronine (73) structures). A diverse set of cyanine dyes are 
available with multiple conjugation chemistries and varying charge, and these dyes are 
commonly used due to their high absorption coefficient and reasonable quantum yield (resulting 
in excellent brightness). Given the diversity in physiochemical properties of these fluorophores 
including a wide range in molecular weight, charge, and pKa, we sought to determine the cellular 
retention rate of fluorescently labeled antibodies for a direct comparison between dyes.  
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Radiolabels and fluorescent dyes are often grouped as ‘residualizing’ or ‘non-
residualizing,’ although this classification is somewhat arbitrary since the half-life of signal 
decay is a continuous spectrum. Often, half-lives less than 24 hours such as iodine are referred to 
as ‘non-residualizing,’ while half-lives greater than 24 hours (e.g. 111In) are considered 
residualizing.  
 
Labels that are trapped within cells for long periods of time (strongly residualizing labels) 
tend to provide higher target to background contrast by remaining within the tissue following 
degradation of the targeting agent. However, these labels often have significant uptake in off-
target tissues that could be problematic either due to high background in clearance organs (liver 
and kidney) or large radiation doses (74). Non-residualizing probes can lower these signal and 
are more representative of intact protein therapeutics for tracking pharmacokinetics. They are 
also better surrogates for non-residualizing radioisotopes in molecular imaging. The cellular half-
life following internalization is a major determinant of whether the label stays within the tissue 
or is cleared following local metabolism. The NIR fluorophores tested in this work include both 
residualizing and non-residualizing dyes. 
 
2.4 Results 
Eight commercially available NIR dyes available as NHS esters were chosen for this 
study. They represent three different classes of molecules with varying optical and 
physiochemical properties (Table 2.1 ). The structures include several cyanine dyes with varying 
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numbers and positions of sulfate groups (Figure 2.1). The structures for AF750 and Atto740 are 
proprietary and are not included in Figure 2.1. 
 
Table 2.1 Physicochemical and optical properties of NIR dyes 
Dye Ex/Em  (nm) 
Extinction 
Coefficient 
(cm-1 M-1) 
MW (kDa) Net Charge 
LogD 
(pH 7.4) 
t1/2  
(day) 
DDAO 648/656 42,000 408 -1  (pKa = 5.0) 2.04 0.99 (±0.4) 
BODIPY-650 651/660 100,000 546 0 0.85 2.43 (±0.3) 
Cy5.5 675/694 250,000 900 -3 -4.72 3.92 (±0.5) 
AF680 684/707 183,000 857 -2 -6.39 2.43 (±0.1) 
Atto740 740/764 120,000 451 +1 NR 0.85 (±0.1) 
SulfoCy7 740/773 240,600 708 -1 0.13 2.92 (±0.3) 
AF750 753/782 290,000 ~1200 NR NR 2.55 (±0.2) 
IRDye 800CW 774/789 240,000 1000 -3 -4.71 2.33 (±0.1) 
 
 
All the dyes were conjugated to cetuximab successfully, although the lipophilic 
BODIPY-650 dye could not be completely purified of free dye after the reaction (data not 
shown). The fluorescent cetuximab molecules specifically labeled the surface of A431 cells 
following 30 minutes at 40 nM (Figure 2.2). The labeled cetuximab molecules were internalized 
and trapped in punctate vesicles throughout the cell with varying degrees of unquenching inside 
the cell. The cyanine dyes retained signal at 24 and 48 hours. DDAO and Atto740 signals were 
lower at 24 hours and not visible at 48 hours. A small amount of unquenching of Atto740 after 
internalization results in the higher microscopy signal at 24 hours but faster half life of cell 
clearance.  
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Figure 2.1 Selected NIR Dye structures.  
Published dye structures used in this study including cyanine-based structures, boron-
dipyrromethene (BODIPY), and the acridine-based (7-hydroxy-9H-(1,3-dichloro-9,9-
dimethylacridin-2-one)) dye DDAO. These structures represent the hydrolyzed NHS ester form 
of the dyes. 
 
To quantify the overall retention over long times, a plate assay was used to measure the 
bulk fluorescence over 168 hours (Figure 2.3). To eliminate the effects of internalization, 
degradation, and un-quenching, the half-life was measured from the time of peak signal onward. 
Half-lives for each of the dyes was calculated using PRISM and are reported in Table 2.1 
Physicochemical and optical properties of NIR dyes. DDAO and Atto740 cleared from the cells 
with a half-life < 24 hours (non-residualizing) while the cyanine based probes all had half-lives 
greater than 48 hours. To check if passive diffusion through membranes could explain the more 
rapid loss of signal from internalized and degraded probe, a PAMPA assay was used to measure 
the membrane permeability of the free dye. The values were low (< 10-6 cm/s) for all the dyes, 
but only DDAO, Atto740, and BODIPY-650 gave measurable signal in the acceptor well. These 
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data point to a passive mechanism of signal loss by diffusion through membranes after 
degradation. 
 
 
Figure 2.2 Confocal microscopy of A431 cells following surface labeling with antibody-dye 
conjugates.  
Confocal microscopy of cells immediately after surface labeling or after 24- and 48-h incubation. 
Punctate spots after incubation show the substantial internalization, while the non-residualizing 
dyes DDAO and Atto740 have little signal at later times. 
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Figure 2.3 Dye residualization quantification and PAMPA Assay.  
The signal intensity for each labeled antibody is plotted from the time of peak signal. To avoid 
fluorophore unquenching effects on the half-life, only the later time points during signal decay 
were used (a, b). To determine if passive diffusion through membranes could explain the loss in 
signal, all the free dyes (carboxylic acid derivatives) were tested in a PAMPA assay to quantify 
their membrane permeability (c). 
 
 
2.5 Discussion 
Understanding the cellular kinetics of NIR dyes is critical for designing imaging agents 
and predicting in vivo behavior. Whether used in direct applications for intraoperative imaging 
(65), in multi-modality imaging (56), or during preclinical development of radiolabeled probes, 
the rate at which the degraded probe diffuses out of cells is a major determinant of the time 
course and concentration of signal within the tissue. In this work, a wide range in the cellular 
residualization rate of NIR dyes was found following uptake by a monoclonal antibody 
(cetuximab) based on the dye properties. 
 
To quantify the cellular half-life, we selected the clinical anti-EGFR antibody cetuximab 
as the model targeting agent. This is a well-studied internalizing antibody (75), and our imaging 
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results showed virtually complete internalization within 24 hours. A431 cells were selected for 
two reasons. First, they express high numbers of EGFR, resulting in a strong signal that can be 
tracked over many days. Second, the cell line exhibits contact inhibition, so they could be 
cultured as a confluent monolayer. This reduced the impact of cell growth during the assay so the 
signal did not drop during repeated cell division. The degree of labeling (DOL) was kept below 1 
for most dyes to minimize the presence of multiple dyes on a single antibody. For future in vivo 
work, this can have a strong impact on distribution (76). Assuming a Poisson distribution, given 
that cetuximab contains greater than 80 lysines, an average DOL of 1 results in a surprisingly 
high 63% of the fluorescence signal originating from antibodies with multiple dyes. Only labeled 
antibodies are detected, and the problem is compounded by antibodies with multiple labels 
giving a higher signal. Since lysine conjugation is not site-specific, the easiest way to ensure a 
large fraction of single labeling is to have a low average DOL. 
 
At early times (within 24 to 48 hours of cell surface labeling), the fluorescence signal is a 
combination of internalization, degradation, pH effects, and subcellular compartmentalization. 
Several dyes showed significant increases in signal as the covalently labeled antibody was 
degraded, resulting in an unquenching effect of the dye. At later times, however, the decrease in 
signal followed a single exponential decay that could be accurately and reproducibly quantified.  
 
The clearance rates of several of the probes can be anticipated from the physiochemical 
properties of the core dye structure. The larger molecular weight cyanine dyes with permanent 
negative charges from sulfonic acid groups do not readily cross endosomal or plasma membranes 
and are retained with a > 2-day half-life. Positively charged dyes can localize to mitochondria 
 18 
(77), while weak bases are trapped within lysosomes. Highly lipophilic dyes can more readily 
cross membranes, but protein binding and partitioning into the membrane may slow cell 
clearance (78). The weak acid, DDAO, has a pKa of 5.0 (79) where most of the dye remains 
charged within the cell. Although the exact mechanism is debated, this allows a portion of the 
uncharged neutral form to cross the lipophilic bilayer while the charged form prevents significant 
partitioning into the membranes. Fluorescein, a visible light fluorescent weak acid (pKa ~ 6.4), 
also washes out of cells quickly (80). The low molecular weight Atto740 also diffused out of 
cells quickly. 
 
BODIPY-650 diffused out of cells at a similar rate as the charged cyanine dyes, but the 
lipophilic neutral dye also brings up additional considerations. BODIPY-650 conjugates show 
strong membrane partitioning and protein binding (68), which likely contributed to the slow loss 
in signal despite measurable membrane permeability (Figure 2.3). Protein binding can also 
impede extravasation into the tissue (81,82). If this mimics the radiolabel of interest or increased 
plasma protein binding is desired to reduce renal filtration, this can be an asset. However, good 
separation between labeled cetuximab and unreacted dye could not be obtained. SDS-PAGE 
analysis of the labeled antibody always showed a significant free dye band indicating that 
unreacted dye could not be removed in aqueous solution. 
 
To test our hypothesis that passive diffusion from the cell dictates the residualization rate, 
the permeability of the dyes was measured using a parallel artificial membrane permeability 
assay (PAMPA). This eliminates any effect from drug transporters such as p-glycoprotein or 
organic anion transporters which can shuttle dyes across membranes (83,84). While the 
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permeability of all the dyes was low, only measurable permeation through the membranes was 
detectable for DDAO, Atto740, and BODIPY-650, providing evidence that these dyes can exit 
the cells by passive diffusion after degradation of the antibody. 
 
While the dye residualization rate has a major impact on imaging properties, several other 
factors need to be considered in the context of imaging agent design. First, the dye properties 
alone are not solely responsible for the rate of washout after cell labeling. The linker region, 
conjugation chemistry, and/or targeting molecule can have a major impact on the residualizing 
behavior of a dye (85), and properly designed linkers can increase cellular retention if desired. In 
this work, the intrinsic rate of several commercially available dyes containing a common NHS 
ester lysine linkage was quantified. Second, plasma protein binding, particularly to albumin, 
affects the extravasation rate of the molecule, especially for smaller probes (82). The number and 
spacing of charges on the dye will impact the extent of protein bound fluorophore (86,87). Third, 
the labeled product may have significantly different distribution depending on the size and 
properties of the targeting moiety (65). Finally, the optical properties impact the background 
signal and light penetration. Dyes in the 630-680 nm range will have significantly lower target to 
background ratios due to a higher contribution of autofluorescence to both the target and 
background signal (88,89). In this work, residualizing and non-residualizing dyes in both the 
630-680 nm and the 700-800 nm range were identified, allowing the researcher flexibility in 
designing probes with the desired wavelength and residualizing properties. 
 
There are several other steps to washout from the tissue in vivo. After exiting the cell, the 
fluorescent degradation product must diffuse through the tissue to a capillary or lymph vessel 
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and intravasate before exiting the tissue. These steps can occur within minutes (90), so the hours 
required for exiting the cell are often the rate-limiting step. The in vitro assay here does not 
capture all the complexity in vivo, however, so care must be taken when extrapolating to animal 
data. 
 
2.6 Conclusion 
Commonly used and commercially available NIR dyes exhibit varying rates of cellular 
retention after internalization. DDAO and Atto740 diffuse out of cells quickly following 
internalization and degradation, while the cyanine-based probes had significant retention in cells 
over several days. Residualizing dyes are useful for studying protein metabolism, signal 
amplification of internalizing targets, and fluorescent surrogates for residualizing radioisotopes. 
For monitoring the distribution of intact protein therapeutics, reducing signal in clearance organs, 
and fluorescent surrogates for non-residualizing radioisotopes such as iodine, the non-
residualizing fluorophores are ideal. Fortunately, this study has identified both residualizing 
behaviors in far-red and near-infrared wavelength dyes, allowing investigators to select the 
wavelength and residualizing properties appropriate for their application. These rates should 
prove useful in experimental design, in vivo data interpretation, and molecular probe 
development. 
 
2.7 Experimental Methods 
Materials  
A-431 cells were obtained from ATCC (Manassas, Virginia). Cetuximab (Bristol-Myers 
Squibb, Princeton, New Jersey) was conjugated according to the manufacturer’s instructions 
 21 
with each of the following dyes: CellTraceTM Far Red DDAO-SE (DDAO) (Life Technologies, 
Eugene, Oregon), IRDye® 800CW NHS Ester (IRDye)(LI-COR, Lincoln, Nebraska), Alexa 
Fluor® 680 NHS Ester (AF680) (Life Technologies, Eugene, Oregon), Alexa Fluor® 750 NHS 
Ester (AF750) (Life Technologies, Eugene, Oregon), Sulfo-Cyanine7 (SulfoCy7) (Lumiprobe 
Corporation, Hallandale Beach, Florida), Cy5.5 (GE Healthcare Bio-Sciences, Pittsburgh, 
Pennslyvania), Bodipy® 650/660-X (BODIPY-650) (Life Technologies, Eugene, Oregon), Atto 
740 NHS Ester (Atto 740) (Sigma-Aldrich Corp., St. Louis, Missouri). Dyes were reacted in 
10% sodium bicarbonate and antibody solution (2 mg/mL) for 2 hours at room temperature. A 
molar ratio of 1.0 was used for all dyes. The antibody-dye conjugates were purified using 800uL 
of 5g/50mL water of Biogel P-6, Fine (Bio-Rad, Hercules, California) in Spin-X centrifuge filter 
tubes (Corning, Corning, New York). The final degree of labeling was determined by the 
absorption at 280 nm corrected for the fluorophore and the max absorption wavelength of each 
dye using a NanoDrop 1000 spectrophotometer. A western blot was performed to ensure that 
there was no free dye remaining.  
 
Residualizing Dye Plate Assay  
The rates of dye cellular dye loss were measured over a period of eight days with the 
Odyssey Imaging System (LI-COR). Cells were plated in 96-well plates overnight at between 
90-100% confluency. The cells were labeled with cetuximab-dye conjugates at 40 nM for 30 
minutes at 37°C, then subsequently washed three times to remove excess probe. The cells were 
washed daily with media (DMEM supplemented with 10% fetal bovine serum, 2% sodium 
bicarbonate, and 1% penicillin/streptomycin) and then scanned with the Odyssey Imaging 
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System to obtain the bulk fluorescence signal for each well. The fluorescent intensities for each 
dye were normalized to the maximum signal achieved after internalization and unquenching.  
 
Confocal Microscopy 
Falcon™ Culture Slides (Fisher Scientific, Pittsburgh, Pennsylvania) were imaged with 
an upright Olympus FV1200 confocal microscope using 405, 633, and 750 nm lasers and a 60x 
objective. Cells were plated overnight at 90-100% confluency. Cells were labeled with each 
antibody-dye conjugates at 0, 24, and 48 hours under the same conditions described above and 
subsequently were washed twice with media. After 48 hours cells were incubated with Hoechst 
33342 for 5 min at room temperature, washed with media, and then imaged. 
 
PAMPA Assay 
Membrane permeability was measured using the BD Gentest™ Pre-coated PAMPA Plate 
System. Briefly, NHS ester derivatives of all dyes were mixed into aqueous solution overnight at 
room temperature to allow dyes to hydrolyze into the unreactive carboxylic acid form. 1 µM 
hydrolyzed dye was used in the donor wells and was incubated for 5 hours at room temperature. 
Donor and acceptor concentrations were obtained using the Odyssey Imaging System and the 
permeability was then calculated according to manufacturer’s instructions. 
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Chapter 3 
Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye 
Structure and Degree of Labeling on Plasma Clearance 
 
3.1 Publication Information 
Cilliers, C., I. Nessler, N. Christodolu, and G. M. Thurber. Tracking Antibody 
Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of 
Labeling on Plasma Clearance. Molecular Pharmaceutics. 2017; 14(5): 1623-33.  
 
Modifications have been made to the published document to adapt the content to this text. 
The previous chapter identified several residualizing NIR fluorophores for molecular imaging. 
This chapter builds on this previous in vitro work by outlining conditions to label the antibodies 
with NIR fluorophores without impacting the pharmacokinetics of the antibody in vivo. 
 
3.2 Abstract 
Monoclonal antibodies labeled with near infrared (NIR) fluorophores have potential use 
in disease detection, intraoperative imaging, and pharmacokinetic characterization of therapeutic 
antibodies in both the preclinical and clinical setting. Recent work has shown conjugation of NIR 
fluorophores to antibodies can potentially alter antibody disposition at a sufficiently high degree 
of labeling (DoL); however, other reports show minimal impact after labeling with NIR 
fluorophores. In this work, we label two clinically approved antibodies Herceptin (trastuzumab) 
and Avastin (bevacizumab) with NIR dyes IRDye 800CW (800CW) or Alexa Fluor 680 
(AF680), at a 1.2 and 0.3 dyes/antibody and examine the impact of fluorophore conjugation on 
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antibody plasma clearance and tissue distribution. At 0.3 DoL, AF680 conjugates exhibited 
similar clearance to unlabeled antibody over 17 days while 800CW conjugates diverged after 4 
days, suggesting AF680 is a more suitable choice for long-term pharmacokinetic studies. At the 
1.2 DoL, 800CW conjugates cleared faster than unlabeled antibodies after several hours, in 
agreement with other published reports. The tissue biodistribution for bevacizumab-800CW and 
-AF680 conjugates agreed well with literature reported biodistributions using radiolabels. 
However, the greater tissue autofluorescence at 680 nm resulted in limited detection above 
background at low (~2 mg/kg) doses and 0.3 DoL for AF680, indicating that 800CW is more 
appropriate for short-term biodistribution measurements and intraoperative imaging. Overall, our 
work shows a DoL of 0.3 or less for non-site specifically labeled antibodies (with a Poisson 
distribution) is ideal for limiting the impact of NIR fluorophores on antibody pharmacokinetics.  
 
3.3 Background 
Monoclonal antibodies are the largest class of biologics and they continue to grow due to 
multiple applications in cancer treatment, autoimmune disorders, and other diseases. Currently 
there are over 50 FDA approved therapeutics, and, as of mid-November 2015, there were 53 in 
phase 3 clinical trials and over 470 in various stages of the clinical pipeline (91). Antibodies 
exhibit complex pharmacokinetics because of their large size, long circulating half-life 
(including FcRn recycling), target mediated drug disposition (TMDD), limited tumor 
penetration, and immunogenic responses, making a priori predictions of monoclonal antibody 
distribution exceedingly difficult. Therefore, robustly characterizing the pharmacokinetics of 
novel next-generation antibodies, antibody-drug conjugates, bispecific antibodies, and other 
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protein scaffolds in the preclinical and clinical setting can aid in development and help produce 
lead therapeutic candidates with a higher likelihood of clinical success.  
 
Bioanalytical methods remain the industry standard for measuring plasma clearance of 
biologics, since any modification (radiolabel, fluorophore, etc.) can potentially modify the 
distribution of an agent (92,93). Conventional techniques for determining antibody disposition 
include plasma clearance measurements using ELISA or LC-MS, and tissue distribution using 
immunohistochemistry and immunofluorescence. However, these bioanalytical techniques do not 
have the high spatial and temporal resolution, the ease of measuring drug metabolism, or the 
direct detection of radiolabeling or fluorescence techniques. Radiolabeling methods made 
significant improvements during early studies with monoclonal antibodies (e.g. (94)) in the 
stability of the conjugation chemistry and without disrupting binding (95). Several results have 
shown negligible changes in plasma clearance relative to unlabeled antibodies (76,96). 
Therefore, radiolabels remain the gold standard for quantifying bulk organ and tissue 
distributions using scintillation counting and in vivo imaging, such as positron emission 
tomography (PET) (97). Although experimental methods are approaching the cellular scale (98), 
their resolution is intrinsically limited by the path length of the positron and imaging equipment. 
Additionally, the time/half-life constraints, safety concerns, and expense of radioactivity limit its 
broad applicability for high-resolution imaging and single-cell measurements. 
 
There is growing interest in using near infrared (NIR) fluorescent dyes as molecular 
imaging agents for pharmacokinetic tracking, disease characterization/detection (99), and 
intraoperative imaging (65,100) due to the high spatial and temporal resolution of fluorescence 
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imaging, low tissue autofluorescence, and deep tissue penetration of light (101–105). For 
example, in a recent publication, we used the high spatial resolution of fluorescence to 
demonstrate the importance of tumor penetration on antibody drug conjugate (ADC) efficacy, 
highlighting one application where tissue-level distribution in addition to organ-level 
biodistribution is important for describing drug effects (106). NIR dyes provide a convenient and 
safe method to quantify pharmacokinetics at the subcellular to tissue level while retaining the 
possibility for quantifying macroscopic organ biodistribution (e.g. (53), although more tissue 
processing is required compared to radiolabeling). Radiolabeling techniques remain the gold 
standard for whole animal imaging and organ biodistribution, but NIR fluorescent dyes can 
complement these results with high resolution tissue distribution (fluorescence microscopy) and 
single-cell data (flow cytometry) while providing biodistribution data for validation between the 
methods (i.e. comparing fluorescence %ID/g (107) with radiolabeled results). Additionally, 
conventional visible light dyes can easily be used with NIR dyes for multichannel flow 
cytometry or immunofluorescence (81).  
 
Despite these advantages for high resolution and single cell imaging, NIR fluorescence 
labeling techniques have room for improvement to lower the impact of labeling on distribution 
and clearance (just as radiolabeling techniques did decades ago (76,108–110)). In particular, 
there is no consensus on the optimum degree of labeling (DoL), or average number of dyes per 
antibody that should be used to prevent the dye from altering antibody pharmacokinetics. Some 
recent work with the NIR fluorophore IRDye800CW (800CW, LI-COR) demonstrates that 
antibody clearance can be altered upon fluorophore conjugation (76,107,111,112), and higher 
degrees of labeling result in increased liver uptake. While this may not be an issue for imaging 
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and detection applications, it would limit the use for pharmacokinetic characterization of 
antibodies. These groups also showed that lower degrees of labeling result in a reduced impact 
on distribution; however, some of these studies were performed with dual radiolabeled and 
fluorophore labeled antibodies, thereby preventing independent comparisons between unlabeled 
and labeled antibodies.  
 
In this work, we examined the effects of conjugation of 800CW and another commonly 
used fluorophore, Alexa Fluor 680 (AF680), on the pharmacokinetics of two clinically approved 
antibodies, Herceptin (trastuzumab) and Avastin (bevacizumab). We selected 800CW because of 
its clinical relevance for NIR intraoperative imaging and literature precedent and compared it to 
AF680 (excited in far-red and emitting in near infrared) because of the similar cyanine based 
structures and residualization properties (113). Our previous work with NIR labeled 
peptidomimetics also showed that AF680 has one of the lowest plasma protein binding rates of 
all the NIR dyes tested (114). We used a 1.2 and 0.3 DoL of each dye, measured plasma 
clearance by fluorescence and ELISA, and performed tissue biodistribution experiments to see if 
fluorophore conjugation altered antibody distribution. Additionally, we labeled the clinically 
approved antibody-drug conjugate (ADC) Kadcyla (trastuzumab emtansine) with AF680 and 
tracked its tumor distribution out to seven days as an example application studying tissue 
pharmacokinetics.  
 
3.4 Results 
A space-filling model of a full IgG1 antibody (PDB code: 1igy) (96,115) (gray) 
conjugated to a single molecule of AF680 (blue) and 800CW (red) shows the relative size 
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difference between a typical antibody and dye (Figure 3.1).  Both dyes are shown non-
specifically conjugated to lysines on the heavy chain of the antibody. Lysines, which are a 
common site for non-specific conjugation of small molecules or fluorescent dyes using ester 
chemistry, are shown in green. (The number and placement of lysine residues will vary between 
antibodies.) For bevacizumab and trastuzumab there are 86 and 90 lysines, respectively, with a 
majority appearing on the heavy chain (62 and 64, respectively) (116). Figure 3.1 shows the 
chemical structure of AF680 and 800CW conjugated to the amine of a lysine on the antibody 
(117). Both cyanine dyes share a similar structure and have similar hydrophilicity; however, 
AF680 has one less sulfate group, giving it a net -2 charge compared to 800CW’s net -3 charge. 
Also, the optical properties for AF680 and 800CW make them ideal for use with the 700 and 800 
channels of the Odyssey CLx, respectively. 
 
Figure 3.1 Dye structures and relative size of dyes to antibody.  
Space filling model of an IgG (PDB ID: 1igy) (115) with both AF680 (blue) and 800CW (red) 
attached to lysines (green) on the heavy chain (A). Dye structures were exported from 
MarvinSketch as a pdb file and merged with the IgG in Pymol. (B) Chemical structure of AF680 
(top) and 800CW (bottom). 
 
After conjugation and purification, all antibody-dye conjugates were run on SDS-PAGE 
and the gel was scanned on the Odyssey CLx to ensure free dye was removed (Figure 3.2). This 
 29 
indicates less than 3% free dye remaining (118). Differences in relative labeling of the heavy or 
light chain could cause differences in antibody pharmacokinetics between the dyes; however, the 
relative intensities of heavy to light chain are similar, indicating any observed differences are 
likely due to the dye and not differences in labeling location. Absorbance spectra used for DoL 
characterization is shown in Figure 3.3.  
 
Figure 3.2 SDS-PAGE of antibody-dye conjugates and free dye.  
After reaction and purification all conjugates were run on SDS-PAGE and scanned on the 
Odyssey CLx NIR scanner to ensure free dye was removed. Window leveling adjusted for 
similar brightness from heavy chain. Tras, trastuzumab; Bev, bevacizumab. 
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Figure 3.3 Antibody-dye absorbance spectra.  
After reaction and purification, the absorbance spectrum for each antibody-dye conjugate was 
used to determine the DoL as described in the methods section. DoL was determined by dividing 
bulk fluorophore concentration by antibody concentration. Tras, trastuzumab; Bev, bevacizumab. 
 
Plasma clearance for each antibody-dye conjugate was determined by fluorescence and 
the total antibody clearance by ELISA. The plasma concentration as measured by fluorescence 
and ELISA was normalized to the initial concentration and fit to a biexponential decay using 
PRISM. Table 3.1 shows the fitted parameter values. Figure 3.4 and Figure 3.5 show the 
biexponential decay of the normalized plasma clearance over 4 days (top) and 17 days (bottom). 
The absolute plasma concentration time profiles are shown in Figure 3.6. At a 1.2 DoL, the 
fluorescent Tras-800CW exhibited faster clearance than the total trastuzumab, even 8 hours post-
injection (which have non-overlapping error bars) (Figure 3.4). At longer times, the beta phase 
clearance diverges significantly indicating 800CW altered the pharmacokinetics of the antibody. 
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These data agree with Conner et al. where the clearance of a different antibody-800CW 
conjugate showed faster clearance at a similar DoL of 1.5 (76). At a 0.3 DoL, however, both 
Tras-800CW and Bev-800CW showed similar clearance over the first several days, and only 
after 4 days does the clearance diverge significantly. The AUC for the normalized plasma 
clearance (Table 3.2) shows the fluorescence AUC is significantly different from the total 
antibody AUC for all 800CW conjugates at 17 days. The serum stability of Tras-AF680 and 
Tras-800CW was also measured over 17 days (Figure 3.7, Figure 3.8). Tras-AF680 and Tras-
800CW maintain 95% and 85% of their initial signal at day 4 and >80% and >60% by day 17, 
respectively; indicating serum stability/dye quenching is not the cause of faster clearance. The 
lack of free dye formation in plasma (Figure 3.9) and serum stability samples indicates that dye 
deconjugation is likely not causing the faster clearance of fluorescent antibody. 
Table 3.1 Plasma clearance fitted biexponential parameters from PRISM. 
Conjugate % alpha alpha (day-1) beta (day-1) AUC 
Bev-0.3-680-F 61.6 4.410 0.054 7.27 
Bev-0.3-680-E 55.3 7.741 0.065 6.94 
Bev-0.3-800-F 60.5 4.123 0.166 2.53 
Bev-0.3-800-E 58.9 5.817 0.056 7.41 
Tras-1.2-680-F* 60.6 3.316 0.083 4.92 
Tras-1.2-680-E* 58.4 3.063 0.038 11.10 
Tras-1.2-800-F 70.8 3.917 0.181 1.79 
Tras-1.2-800-E 55.3 3.505 0.054 8.38 
Tras-0.3-680-F 61.6 3.403 0.080 5.01 
Tras-0.3-680-E 80.9 1.083 0.011 18.01 
Tras-0.3-800-F 66.6 2.383 0.174 2.20 
Tras-0.3-800-E 78.5 1.234 0.011 21.05 
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Figure 3.4 Antibody-800CW conjugate plasma clearance.  
Normalized clearance as measured by fluorescence (red) and ELISA (blue) for trastuzumab with 
a DOL of 1.2 and 0.3 (left and middle, respectively), and bevacizumab with a 0.3 DOL (right) 
for 800CW conjugates. Clearance over the first 4 days is shown on top. Trast, trastuzumab; Bev, 
bevacizumab.  
 
 
Figure 3.5 Antibody-AF680 conjugate plasma clearance.  
Normalized clearance as measured by fluorescence (red) and ELISA (blue) for trastuzumab with 
a DoL of 1.2 and 0.3 (left and middle, respectively), and bevacizumab with a 0.3 DoL (right) for 
AF680 conjugates. Clearance over the first 4 days is shown on top. Trast, trastuzumab; Bev, 
bevacizumab. 
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Figure 3.6 Absolute concentrations of antibody-dye conjugate plasma clearance.  
The plasma concentration as measured by fluorescence (red) and ELISA (blue) for trastuzumab-
dye conjugates with a low (1.2) and tracer (0.3) DOL (left and middle, respectively), and 
bevacizumab-dye conjugates with a tracer DOL (right). ELISA concentrations are higher due to 
the 550µg of total antibody versus 50µg of labeled antibody. Figure 3.4 and Figure 3.5 was 
generated by normalizing each data set to the initial concentration. Tras, trastuzumab; Bev, 
bevacizumab. 
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Figure 3.7 SDS-PAGE of serum stability samples.  
Serum stability samples show intact antibody out to 17 days and no detectable formation of free 
dye. 
 
 
 
Figure 3.8 Antibody-dye conjugate serum stability.  
Both Tras-AF680 and Tras-800CW show slight loss in fluorescence over 17 days (80% and 60% 
of initial, respectively); however, the loss in fluorescence does not account for the rapid drop in 
fluorescent signal seen with 800CW in Figure 3.4. Therefore, the loss of fluorescent signal in 
Figure 3.4 is due to clearance of the antibody-dye conjugate, not loss of fluorescence from the 
dye being in serum. Tras-AF680 and Tras-800CW, both with a DoL of 1.2, were mixed with 
fetal bovine serum (FBS) at 30nM. The serum/antibody-dye aliquots were thawed rapidly in a 
37°C water bath and incubated at 37°C for the number of days shown. The samples were thawed 
and placed at 37°C in reverse order (17 day time point first) so the samples could all be measured 
on the same day. 15 µL of each sample was scanned in a 384 well plate on the Odyssey CLx, and 
the experiment was performed in triplicate.  
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Figure 3.9 Fluorescence SDS-PAGE of bevacizumab-dye conjugate blood samples.  
SDS-PAGE of bevacizumab-AF680 (A) and bevacizumab-800CW (B) plasma clearance 
samples. Over the course of the experiment bevacizumab-dye conjugates remain intact and there 
is no detectable formation of free dye. 
 
 
In comparison, AF680 exhibits less impact on the pharmacokinetics of the antibodies 
(Figure 3.5). Even at a 1.2 DoL, Tras-AF680 shows similar clearance to total antibody out to 9 
days. At a 0.3 DoL both trastuzumab and bevacizumab exhibited similar clearance over 17 days. 
Although the biexponential fit for Tras-AF680 appears to have a faster beta phase decay, the data 
points are overlapping at each point. For Bev-AF680, the clearance is nearly identical. 
Furthermore, the fluorescence AUC does not differ significantly from total antibody for any 
AF680 conjugates (Table 3.2), even at the higher DoL. These results indicate a 0.3 DoL of 
AF680 does not significantly affect antibody disposition for these antibody-dye conjugates.  
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Table 3.2 Normalized AUC for antibody-dye conjugates. 
Conjugate AUCday 0-3 (day) AUCday 0-17 (day) 
Tras-1.2-800-F 0.92 ± 0.03* 1.77 ± 0.07* 
Tras-1.2-800-E 1.41 ± 0.39 4.92 ± 1.16 
Tras-1.2-680-F 1.26 ± 0.15 3.81 ± 0.41 
Tras-1.2-680-E 1.39 ± 0.38 5.45 ± 1.82 
Tras-0.3-680-F 1.27 ± 0.25 3.69 ± 1.10 
Tras-0.3-680-E 1.26 ± 0.06 3.59 ± 0.92 
Tras-0.3-800-F 1.13 ± 0.18 2.14 ± 0.48* 
Tras-0.3-800-E 1.26 ± 0.03 3.77 ± 0.53 
Bev-0.3-680-F 1.24 ± 0.06 4.48 ± 0.25 
Bev-0.3-680-E 1.33 ± 0.15 4.70 ± 0.59 
Bev-0.3-800-F 1.11 ± 0.06 2.45 ± 0.16* 
Bev-0.3-800-E 1.24 ± 0.20 4.70 ± 1.08 
 
For non-site specific labeling techniques, such as conjugation to surface lysine residues 
using N-hydroxysuccinimide (NHS) chemistry, the number of possible labeling sites is relatively 
large. Therefore, the number of dyes per antibody is anticipated to result in a Poisson distribution 
(119–121). Assuming the non-specific lysine conjugation of fluorophores follows this 
distribution, Figure 3.10 shows the expected fractions of the number of dyes per antibody in 
samples with a DoL of 0.3 and 1.2. For the 0.3 DoL, the distribution of antibody labeling is 
approximately 75% unlabeled, 22% singly labeled, and <5% with 2 or more dyes per antibody. 
At the higher DoL of 1.2, the fraction of unlabeled antibody decreases (30%) and the percentage 
of singly labeled increases (36%); however, the fraction of antibody with 2 or more labels also 
dramatically increases to 44%. When using fluorescence detection, the unlabeled antibodies do 
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not contribute to overall signal, and antibodies with 2 dyes would contribute twice as much 
signal (assuming no quenching effects). Accounting for these two phenomena, Figure 3.10 
shows the expected theoretical contributions to the overall fluorescent signal from a DoL of 0.3 
and 1.2 (assuming no self-quenching). For a DoL of 0.3, 74% of the measured fluorescence 
signal is expected to be from antibodies with a single dye, while only 30% of the signal is 
expected to be from singly labeled antibodies at a DoL of 1.2. Importantly, the percentage of 
signal from antibodies with 3 or more dyes is less than 4% of the total signal for a DoL of 0.3. 
Conversely, over a third of the signal for DoL 1.2 comes from 3 or more dyes per antibody. The 
1.2 DoL also caused a slight increase in the Kd compared to no difference with 0.3 DoL (Figure 
3.10). 
 
Reduced autofluorescence in the NIR region of the electromagnetic spectrum has 
prompted the use of NIR fluorescent dyes in tissue biodistribution studies with the Odyssey CLx 
scanner (53,76,106,122). Whole organ fluorescence scans suffer from depth of imaging artifacts 
and provide arbitrary values (requiring the digest and dilution) but agree qualitatively with the 
organ digest results (Figure 3.11). Previous studies have compared 800CW to radiolabels and 
have found antibody disposition is not significantly altered at sufficiently low DoL (107,111). 
Because tissue autofluorescence is higher in the 680 nm region of the spectrum (relevant for 
AF680) compared to the 800 nm region, we chose to compare the biodistribution of AF680 and 
IRDye labeled antibodies. To limit variability between animals, we compared the distribution in 
the same mice using both the 700 and 800 channels on the Odyssey CLx (since there is 
negligible cross talk between the dyes in the different channels). The biodistribution of Bev-
AF680 and Bev-800CW, both with a 0.3 DoL, 48 hours after IV administration is shown in 
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Figure 3.12. For comparison, the biodistribution 48 hours after tail-vein injection of radiolabeled 
bevacizumab was plotted from Paudyal et al. (123). This data set was chosen because of the 
matching times, use of a residualizing label (as are IRDye800CW and AF680 (113)) and lack of 
flushing the organs (which will remove blood signal but could also alter tissue values). Paudyal 
and colleagues quantified the distribution of a 20 µg dose of 64Cu-DOTA-bevacizumab after 
blocking any specific interactions (123). The biodistribution of Bev-800CW agrees well with the 
radiolabeled data, with no significant differences between any of the organs. Although 800CW 
appears to impact antibody clearance over longer times, at 48 hours the similar plasma clearance 
(Figure 3.4, Figure 3.5) and systemic distribution (Figure 3.12) does not appear to significantly 
alter the distribution at a 0.3 DoL. Bev-AF680 distribution also agrees well with the radiolabeled 
data for the liver, kidney, and spleen; however, the signal to noise ratio (SNR) is less than or 
equal to one (Figure 3.12) for several organs because of the higher autofluorescence in the 700 
channel, the 0.3 DoL and moderate dose (~2.0 mg/kg). In particular, the heart and lungs show 
much lower uptake for Bev-AF680 likely because the detectable signal is still in the range of 
background autofluorescence for this dosing level, resulting in a significant difference from Bev-
800CW and 64Cu-DOTA-bevacizumab (123). For the liver and kidney, the SNR is higher and 
specific signal can be detected over background. The lower autofluorescence and 
correspondingly high SNR for all of the organs make 800CW more suitable for whole organ 
distribution studies. AF680 at a 0.3 DoL may also be used in organ biodistribution studies, but to 
improve the SNR ratio in some organs may require higher doses than the 50 µg/mouse dose used 
in this study.   
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Figure 3.10 Theoretical dye per antibody distribution and fluorescence contribution.  
(A) Expected number of dyes per antibody for DoL 1.2 and 0.3, assuming Poisson distribution. 
Theoretical fluorescence contribution for antibodies with 1, 2, 3, or 4+ dyes per antibody at a 0.3 
(B) and 1.2 (C) DoL. (D, E) Binding curves and affinities of unlabeled trastuzumab and 
trastuzumab-dye conjugates. Tras, trastuzumab. 
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Figure 3.11 Fluorescence scan of whole organs.  
(A) 700-channel scan of negative (uninjected) organs and bevacizumab-AF680 48 hours after 
injection. (B) 800-channel scan of negative (uninjected) organs and bevacizumab-AF680 48 
hours after injection. Before further processing for biodistribution, whole organs were scanned 
on the Odyssey Clx. Qualitatively the signal intensity from organ scans matches the quantitative 
uptake from biodistributions Figure 3.12. Window leveling is the same for each channel. Li, 
liver; Lu, lung; K, kidneys; S, spleen; H, heart; M, muscle; P, pancreas. 
 
 
Figure 3.12 Bevacizumab biodistribution at 0.3 DoL.  
(A) Biodistribution of Bev-800CW and Bev-AF680 48 hours post tail-vein injection. (B) Signal 
to noise ratio (SNR) in each organ for 800CW and AF680. 
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Despite the higher autofluorescence in whole organ biodistribution experiments, AF680 
signal is high enough to detect the distribution of antibodies in NCI-N87 tumors by histology 
following clinical doses (e.g. 3.6 mg/kg for ado-trastuzumab emtansine/Kadcyla). The NCI-N87 
tumor cell line is a human gastric carcinoma cell line that highly expresses HER2 (~1 x 106 
receptors per cell). As an application of the direct detection provided by NIR fluorophores, we 
conjugated AF680 to the clinically approved antibody-drug conjugate (ADC) T-DM1 and 
tracked the tumor distribution over 1 week. Administration of T-DM1-AF680 at the clinical dose 
of 3.6 mg/kg resulted in a heterogeneous distribution in NCI-N87 tumor xenografts (Figure 
3.13). Injection of Hoechst 33342 and immunofluorescence staining with anti-mouse CD31 
further show that antibody disposition is limited to cells adjacent to tumor vasculature. The 
heterogeneous and perivascular distribution of the intact and internalized antibody (AF680 is a 
residualizing dye (113)) is maintained over 7 days, while anti-Fc staining shows a loss of intact 
antibody (Figure 3.14). This is consistent with the continuous internalization and degradation of 
HER2 (124), which results in antibody targeting cells close to the vessels and a majority of the 
tumor never receiving the therapeutic (37).  
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Figure 3.13 Fluorescence histology following injection of T-DM1-AF680.  
Fluorescent tumor histology following injection of clinical dose (3.6 mg/kg) of T-DM1-AF680 
(green) imaged at 1, 3, 5, and 7 days post-injection. 30 minutes prior to sacrifice Hoechst 33342 
(blue) was injected at 15 mg/kg to highlight functional vasculature. Ex vivo staining was done 
with anti-mouse CD31-AF555 (red) to show all (functional and non-functional) tumor 
vasculature. Scale bar is 500µm. Window leveling is different for each image. 
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Figure 3.14 Immunofluorescence histology of T-DM1-AF680 with antihuman Fc staining. 
Comparison of fluorescence detection of directly labeled antibody with a residualizing probe 
versus immunofluorescence detection of intact antibody over 5 days following administration of 
3.6 mg/kg T-DM1-AF680 (green). Hoechst 33342 (blue) was administered 30min prior to 
sacrifice. Anti-mouse CD31-AF555 (red) and anti-human IgG Fc–AF488(cyan) were labeled ex 
vivo. Scale bar is 200µm. 
 
 
3.5 Discussion 
Here we present a study of two commonly used NIR fluorophores (Figure 3.1) and their 
effects on the pharmacokinetics of two clinically approved antibodies. The goal of the 
investigation was to identify labeling conditions with a minimal impact on antibody distribution 
for use in pharmacokinetic studies. Our results agree with other literature reports of 800CW 
causing increased antibody clearance and altered tissue distribution (compared to unlabeled or 
radiolabeled antibodies) at DoLs greater than 1.0 (Figure 3.4) but lower impact at early times (< 
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4 days) at tracer levels (DoL = 0.3 or less). Building on these results, we tested an additional NIR 
fluorophore, AF680, which has reduced plasma protein binding compared to 800CW (114). 
AF680 antibody-dye conjugates showed nearly identical plasma clearance compared to 
unlabeled antibodies at 0.3 DoL, and even at 1.2 DoL did not have a significantly different 
normalized AUC (Figure 3.5, Table 3.2). These results should help clarify conflicting reports in 
the literature, delineate the impact of NIR labeling on plasma clearance, biodistribution, and 
tissue penetration studies, and aid in the selection of labeling conditions for different 
applications. In particular, the ability of fluorescence to provide cellular and subcellular 
resolution images (e.g. histology) and quantitative single cell data (e.g. flow cytometry) make 
fluorescence an attractive technique for providing high resolution pharmacokinetic data that 
cannot be obtained by other current methods.  
 
Both dyes have relative strengths and weaknesses highlighted by these results. 
IRDye800CW is currently being tested in the clinic with antibodies (e.g. Trial:  NCT01508572) 
making it an attractive option for antibody labeling. (The only FDA approved cyanine dye, 
indocyanine green (ICG), does not have a functional group for labeling. After NHS ester 
functionalization, fluorescence is significantly quenched after antibody conjugation (125).) The 
maximum uptake of antibodies in tumors often occurs after only a couple days, so for imaging 
and diagnostic applications the negligible impact of 800CW at short times (less than 4 days) 
would have a low impact during this time. In fact, a higher DoL will likely maximize tumor 
signal, which is important for depth of detection (65,88). The increase in signal from the larger 
number of dyes per antibody outweighs the reduction in signal from lower tumor uptake (%ID/g) 
due to faster clearance. However, 800CW’s impact on antibody disposition at longer times may 
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limit its broad applicability in studying pharmacokinetic distribution of antibodies. Conversely, 
AF680 may be a more suitable choice for antibody clearance studies (provided the DoL is low) 
and tissue distribution studies at longer time periods (e.g. greater than 4 days) despite having 
greater autofluorescence than 800CW. The higher 680 nm tissue autofluorescence, however, 
makes AF680 less appropriate for biodistribution studies at low doses and low degrees of 
labeling.  
 
When labeling an antibody with any fluorophore for in vivo delivery, these results 
highlight the importance of keeping the DoL low to maximize the signal from singly labeled 
proteins (Figure 3.10). The ease of labeling proteins non-site specifically with NHS-ester/lysine 
chemistry make this convenient for studying antibody distribution in preclinical models. The 
large number of surface accessible lysines, however, results in a Poisson distribution. Because 
any unlabeled antibodies are not fluorescently detected, and antibodies labeled with 2 or more 
dyes have approximately twice (or more) the fluorescence as a singly labeled antibody, the total 
signal is skewed towards antibodies with several dyes, which are more likely to have altered 
distribution. Figure 3.10 shows that although the 1.2 DoL has an average of ~1 dye per antibody, 
the Poisson distribution results in a surprising 70% of the fluorescence signal coming from 
antibodies with 2 or more dyes. While the Poisson distribution is well-known, once the unlabeled 
antibodies and weighting of the fluorescence signal is taken into account it is somewhat striking 
that an average DoL of 1 is too high for measuring singly labeled antibodies. Over-labeling 
antibodies with radiolabels, small molecules, or fluorescent dyes has been shown to cause rapid 
clearance (24,28,95,96,109); therefore, maximizing the signal from singly labeled antibodies by 
using a DoL of 0.3 or less is critical for applications requiring negligible impact on clearance. 
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For both 800CW and AF680, these results indicate a DoL of 0.3 or less has the least impact due 
to less than 5% of total signal coming from antibodies with 3 or more dyes. Although using a 
lower DoL results in less overall signal, the negligible background in the NIR, and the 
exceptional brightness and photostability of these dyes make both practical options for protein 
distribution studies. Alternatively, site-specific labeling, such as maleimide-cysteine chemistry, 
may give improved pharmacological behavior (19,23) and signal, but these techniques typically 
require modification of the antibody amino acid sequence, which could also alter stability, 
distribution, and clearance.  
 
Several other groups have examined 800CW as a tool for tracking antibody disposition. 
Cohen et al. studied the effects of fluorophore labeling on an 89Zr labeled antibody and showed 
antibodies with 0.5 dyes per antibody did not show significantly different biodistribution than 
cetuximab or bevacizumab with only the radiolabel (107,111). As they increased the DoL for 
800CW, the biodistribution started to diverge from the lower DoL and radiolabeled-only 
antibodies. In particular, liver uptake increased and other organ uptake decreased with higher 
800CW DoL for both bevacizumab and cetuximab (107,111). These results suggest a sufficiently 
high DoL of 800CW causes increased liver uptake, consistent with other reports showing 
increased hepatic uptake of radiolabels with high DoL’s (108). However, as Conner et al. 
mentioned, even at lower DoL the effects of 800CW may be masked by the radiolabel/desferal 
moiety (76). These authors studied differences in plasma clearance and biodistribution against 
unlabeled and 125I antibodies and found the dye altered the pharmacokinetics. In this study they 
used 800CW with a DOL of 1.2 - 1.4 and showed high liver uptake and faster plasma clearance 
than radiolabeled or ELISA measurements. Our results are consistent with these findings, where 
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labeling with 800CW can increase plasma clearance at times longer than 4 days. Mouse liver has 
been shown to take up proteins with a high negative charge density (95,126), therefore it is 
paramount to keep a low DoL (for both fluorophores and radiolabels) to minimize possible 
alteration of protein pharmacokinetics. Additionally, disruption of FcRn or FcRγ binding could 
result in faster clearance or altered antibody distribution. Although the exact mechanism of 
altered distribution is unclear, our work suggests a 0.3 DoL results in an undetectable difference 
in antibody pharmacokinetics. Importantly, we examined the pharmacokinetics and 
biodistribution in healthy animals, while these antibodies will likely be used in animals with 
tumors, where TMDD may play a role. However, the similar clearance (Figure 3.4, Figure 3.5), 
biodistribution (Figure 3.12), and microscopic tumor distribution (Figure 3.13, Figure 3.14) 
(106), suggests the labeled antibodies accurately capture the pharmacokinetics of unlabeled 
antibody.   
 
The published studies on the biodistribution of various antibodies and other proteins with 
800CW and encouraging plasma clearance results with AF680 warranted a comparison of the 
dye effects on measured biodistribution. For both Bev-800CW and Bev-AF680 at a 0.3 DoL the 
plasma clearance was not significantly different at 48 hours from unlabeled antibodies (measured 
with ELISA), prompting us to compare the systemic biodistribution. The biodistribution 
measured with both dyes (Figure 3.12) agreed well for organs where there was sufficient signal 
intensity relative to autofluorescence variability (liver and kidney); however, the SNR was too 
low in several other organs to distinguish signal from the higher background for AF680. The 
Bev-800CW 48 hour biodistribution agreed well with another published biodistribution study 
using the residualizing 64Cu-labeled bevacizumab at 48 hours, supporting the aforementioned 
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studies showing similar antibody disposition at low DoL (123). These data also qualitatively 
agree with other published biodistribution data of bevacizumab (111,127), although in some of 
these studies the mice were exsanguinated (resulting in less measured organ uptake) or the 
biodistribution measurements were performed at different times post injection, making direct 
comparisons difficult. For imaging agents, 800CW provides a superior SNR and contrast to noise 
ratio (CNR) compared to AF680, making it a more suitable choice for live in vivo imaging.  
 
Despite the higher autofluorescence in the 680 nm range, the signal from AF680 is 
sufficient to detect in targeted tumors for several days at clinical doses (Figure 3.13). Both 
AF680 and 800CW can be detected in tumors using fresh-frozen tissue sectioning. Here we used 
thicker (16 µm) slices versus a more typical 5 µm slice thickness to improve signal detection. 
Both dyes can be excited with a 635 nm and 750 nm laser, respectively (~40% of the maximum 
absorption for AF680 and 55-60% of the maximum absorption for 800CW) and detected with 
PMTs. Since both dyes are residualizing, the signal results from the total targeted antibody in 
comparison to Fc labeling (Figure 3.14), for example (36), which only labels intact protein. This 
can be useful for applications such as studying ADC’s, where the degraded antibody correlates 
with the released payload (e.g. non-cleavable, impermeable small molecules), so NIR detection 
can be used as a surrogate for small-molecule delivery (13). 
 
We examined two dyes in detail for this study based on their current use in clinical trials 
(800CW) and the low plasma protein binding (and associated low non-specific dye interactions) 
of AF680 (114). There are a variety of other NIR dyes with different physicochemical properties 
that are commercially available, although not all of them have disclosed structures. For example, 
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our lab has examined the residualization rates, permeability, and plasma protein binding of 
several NIR dyes (113,114). Although some of these fluorophores may have similar properties in 
vitro, their in vivo behavior may differ significantly. We have shown that the zwitterionic dye 
ZW800 has similar plasma protein binding as AF680 (114) and beneficial rapid clearance when 
conjugated to small molecule imaging agents, consistent with literature reports (87). 
Additionally, its fluorescence is in the optimal 800 nm range. However, in contrast to labeling 
small molecules, after conjugation to an antibody there was a gradual change in the absorbance 
spectra upon incubation in plasma and a rapid loss of fluorescent signal after injecting in vivo 
(data not shown). In our hands, therefore, this dye is more suitable for rapidly cleared imaging 
agents than monoclonal antibodies. This result emphasizes that although the structures of other 
cyanine-based dyes (Cy5.5, SulfoCy7, etc.) may be similar to AF680 and 800CW, they each 
affect antibody disposition differently (e.g. (104,112)). Similar to radiolabeling techniques, the 
modification of any protein, however slight, can affect different proteins in unique ways, 
particularly if the modified residue (e.g. lysine, cysteine, tyrosine, etc.) is located in an important 
binding region for that molecule. The slow clearance of antibodies and complex interactions with 
the immune system and FcRn receptor make them sensitive even to small interactions from 
fluorophores or surface residues/charges (128–130). The conjugation of fluorophores to smaller 
proteins or agents may not have much of an impact on the distribution if they are rapidly cleared 
by the kidneys6, but similar methods of validation for distribution should be employed. This 
work can be used to help guide the selection of fluorophores depending on the particular 
application in a manner analogous to the selection of chelators and radioisotopes for 
radiolabeling techniques. 
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3.6 Conclusion 
In conclusion, to limit the impact of non-site-specific fluorophore labeling on antibody 
pharmacokinetics, these results show that the DoL should be kept at or below 0.3 dyes/antibody. 
At this tracer DoL, AF680 showed negligible impact on plasma clearance out to 17 days 
compared to unlabeled antibody, while 800CW showed similar clearance out to 4 days but faster 
clearance at later times. Both dyes can be used with tissue distribution studies; however, the 
greater autofluorescence for AF680 requires higher doses to achieve a sufficient SNR while the 
signal from 800CW is well above the autofluorescence background in the 800 nm range. For 
short-term in vivo studies (less than 4 days), the reduced autofluorescence, greater SNR and 
CNR, and increased tissue penetration of light for 800CW makes it suitable for tissue 
biodistribution studies or live in vivo imaging. Although both dyes have distinct advantages and 
limitations, the efficient optical properties, stability, ease of use, and low autofluorescence for 
both fluorophores provide broad utility in studying protein pharmacokinetics in the preclinical 
setting. 
 
3.7 Experimental Methods 
Antibodies and Imaging Agents 
Trastuzumab (Herceptin, Roche), bevacizumab (Avastin, Roche), and trastuzumab 
emtansine (T-DM1, Kadcyla, Roche) were obtained from the University of Michigan pharmacy. 
Alexa Fluor 680 NHS Ester (AF680, ThermoFisher Scientific) and IRDye800CW (800CW, LI-
COR) were conjugated to each antibody following the manufacturers’ instructions as previously 
described (106,113). Briefly, dyes were reacted at an antibody concentration of 2 mg/mL in PBS 
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with 10% sodium bicarbonate (v/v) for 2 hours at 25°C and then purified using Biogel P-6, Fine 
(Bio-Rad) in Spin-X centrifuge filter tubes (Corning) (113). Dye to antibody molar ratios of 3.0 
and 0.5 were used for the 1.2 and 0.3 degrees of labeling, respectively. The degree of labeling 
was determined by using a NanoDrop 2000c Spectrophotometer (ThermoFisher Scientific) to 
measure fluorophore absorption and the protein absorbance at 280nm, corrected for the 
fluorophore. The degree of labeling is defined as the average dye to protein concentration ratio. 
Sample absorption spectra are shown in Figure 3.3. After purification, conjugates were run on 
SDS-PAGE and scanned on an Odyssey CLx to ensure all free dye was removed (Figure 3.2). 
Binding affinities were performed as previously described (103) using HCC1954 cells. Briefly, 
titrations of unlabeled antibody and antibody-dye conjugates were incubated with 50,000 
HCC1954 cells on ice for 3 hours and washed. After the primary incubation, cells were further 
incubated with antihuman IgG Fc-AlexaFluor488 at 40nM for 30min on ice, washed, and 
subsequently run on an Attune Focusing Cytometer (Applied Biosystems). Kd was estimated 
using PRISM and is reported as Kd ± standard error.   
 
Plasma Clearance 
All animal studies were approved and conducted in compliance with the Institutional 
Animal Care and Use Committee (IACUC) of the University of Michigan. Animal studies were 
conducted in C57BL/6J or Foxn1 nude (Jackson Laboratories) mice. Plasma clearance was 
measured after tail-vein injection of 500 µg unlabeled stock antibody with 50 µg labeled 
antibody at the different DoL’s described above (N=3 for each DoL). Plasma concentration was 
determined by fluorescence and ELISA for each sample. Plasma samples were obtained through 
retroorbital sampling 10 µL of whole blood, mixing with 15 µL PBS-EDTA (10mM), 
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centrifugation at 3000xg for 1 minute, and freezing 18 µL of the resulting plasma. The 
concentration of fluorescent probe was determined by scanning 15 µL of plasma on the NIR 
Odyssey CLx Scanner (LI-COR) and comparing the signal intensity to a calibration curve of 
known concentration to signal intensity at the same scan settings. Plasma concentration as 
measured by fluorescence and ELISA was normalized to the initial value and then the clearance 
was fit to a biexponential decay using PRISM (GraphPad). Absolute plasma concentrations at 1 
min were compared with theoretical initial concentrations based on the dose and estimated 
plasma volume of the mouse. The area under the curve (AUC) for normalized clearance for 
ELISA and fluorescence was determined for each conjugate at 3 and 17 days using the 
trapezoidal rule. The normalized fluorescence AUC was compared to normalized ELISA AUC 
by a one tailed, paired Student’s t-test, and a significance level of p < 0.05 was considered 
significant.  
 
Total Antibody ELISA 
Immulon IV 96 well plates (Fisher Scientific, 14-245-153) were coated with mouse anti-
human IgG Fc antibody (BioLegend, 409302) overnight at 4°C and 1 µg/mL in PBS. Wells were 
then washed 3 times (PBS with 0.05% Tween-20), blocked with 2% PBS-BSA, 0.05% Tween-20 
for 2 hour at room temperature, and washed 3 more times. Samples were diluted at least 1:100 in 
diluent (PBS, 1% BSA, 0.05% Tween-20) and incubated for 1 hour at room temperature. After 
sample incubation, plates were washed 3 times, and the detection antibody, mouse anti-human 
IgG Fc HRP (Southern Biotech, 9040-05), was diluted 1:10000 in diluent, added to each well, 
and incubated for 1 hour at room temperature. Plates were then washed 4 times and developed 
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using TMB substrate (Fisher Scientific, ENN301). Assay ranges for both trastuzumab and 
bevacizumab were between 6 ng/mL and 1.2 µg/mL.  
 
Biodistribution 
The biodistribution of bevacizumab conjugates was determined as previously described 
(53,106,122). Briefly, 48 hours after tail-vein injection of 50 µg of bevacizumab-dye conjugate 
(assumed to be in a linear clearance range due to no target binding and negligible Fc receptor 
saturation), animals were euthanized and organs were resected. Organs were then homogenized 
by mechanical disruption, incubated with RIPA buffer (Fisher Scientific, NC9517624)/PBS 
solution supplemented with 6 mg/mL collagenase IV (Fisher Scientific, NC9919937) for 1.5 
hours, disruption using a FB-120 Sonic Dismembrator, and incubated in RIPA buffer/0.025% 
trypsin-EDTA solution for 1.5 hours. After homogenization, organs were serially diluted and 
scanned on the Odyssey CLx scanner to ensure fluorescence detection was in the linear range. 
The signal intensity was compared to a calibration curve and normalized to organ weight and 
homogenate volume in order to compute the percent injected-dose per gram (%ID/g). Calibration 
standards were made in mouse plasma and subjected to the same incubations above. The signal 
to noise ratio (SNR) was also calculated for each organ. The SNR is defined as the organ 
fluorescence minus the autofluorescence signal from control (uninjected) mice divided by the 
standard deviation of autofluorescence from the control mice. The %ID/g for each organ for 
Bev-AF680 and Bev-800CW was compared by a two-tailed, paired Student’s t-test. Each organ 
for Bev-AF680 and Bev-800CW were compared to Paudyal et al. (123) by a two-tailed, unpaired 
Student’s t- test. A significance level of p < 0.05 was considered significant.   
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Fluorescence Histology of Antibody Distribution 
As previously described (81,106), the tumor distribution of T-DM1-AF680 was analyzed 
using fluorescence microscopy at 1, 3, 5, and 7 days. Briefly, nude mice were inoculated with 
5x106 NCI-N87 cells in the rear flanks and the clinical dose (3.6 mg/kg) of T-DM1-AF680 was 
administered via tail-vein injection once the longest axis of the tumor was approximately 10-
12mm. Before euthanizing mice at the aforementioned times, Hoechst 33342 (ThermoFisher 
Scientific, H3570) was administered via tail-vein at 15 mg/kg to label functional vasculature in 
the tumor31. After euthanizing the mice, tumors were resected, flash frozen in OCT using 
isopentane chilled on dry ice and cut for histology on a cryostat (16 µm slices). Before imaging, 
slices were stained with anti-mouse CD31 (BioLegend, 102402) conjugated with Alexa Fluor 
555, and mouse anti-human IgG Fc antibody (BioLegend, 409302) conjugated with Alexa Fluor 
488. Microscopy was performed using an upright Olympus FV1200 confocal microscope 
equipped with a 20x objective and 405, 488, 543, and 635 lasers. Tumor images were obtained 
by stitching smaller images with the Olympus software. Images were exported and analyzed 
using ImageJ image analysis software as described previously (81,106). 
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Chapter 4      
Absolute Quantification of Protein Metabolism with Single Cell Resolution In Vivo Using 
Near-Infrared Ratio Imaging 
 
4.1 Abstract 
Current tools for studying the pharmacokinetics of biologics, such as radiolabeling or 
mass spectrometry, lack single-cell resolution to quantify specific cell binding, heterogeneous 
tissue distribution, and cellular metabolism in vivo. This protocol describes a robust dual-labeling 
technique using two near-infrared dyes with widely differing residualization rates to efficiently 
measure therapeutic protein distribution and metabolism in vivo at the single cell level. Example 
applications are shown for four biologics with varying rates of cellular metabolism. Organ level 
biodistribution, tissue level confocal microscopy, and cellular level flow cytometry were used to 
image the multi-scale distribution of these agents in tumor xenograft mouse models. The 
technique reveals highly heterogeneous delivery of these proteins to tumors. The single-cell 
metabolism results show the delay between peak tumor uptake and maximum protein 
metabolism. This method should have broad applicability in tracking the tissue and cellular 
distribution of novel protein therapeutics for drug development. 
 
4.2 Background 
Therapeutic proteins remain one of the fastest growing areas of pharmaceutical 
development in the treatment of many diseases, including cancer and autoimmune disorders 
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(1,131). The widely varying physicochemical properties of these novel proteins, including 
molecular weight, molecular radius, avidity, charge, etc., can result in unexpected 
pharmacokinetics, making it difficult to predict their distribution (52). Although these agents act 
at the molecular scale, it is necessary to quantify both the microscopic (sub-cellular and cellular) 
and macroscopic (tissue and organ) distribution in order to bridge the understanding between 
pharmacokinetics (PK) and pharmacodynamics (PD) and design effective therapeutics (132). For 
example, in the case of antibody-drug conjugates (ADCs), there is a need to understand the 
metabolism and payload release at the subcellular scale, the average number and variability of 
payload molecules required to achieve cell death in vivo at the cellular scale (46), the number of 
cells in the tumor receiving a therapeutic dose at the tissue scale, and the healthy tissue exposure 
and resulting toxicity at the whole organ level (133). 
 
The approach outlined in this chapter is based on the different residualization properties 
of two NIR fluorescent dyes, which are used to distinguish intact versus degraded protein 
(63,85,113). The residualization properties of different imaging agents including radiolabels and 
other visible light fluorophores have been known for many years (80,85). For example, 125I is a 
non-residualizing label and 111In, 68Ga, 98Zr are residualizing agents (134). In an elegant 
approach, Ferl et al. dually labeled different engineered protein variants with residualizing 111In 
and non-residualizing 125I radioisotopes to measure in vivo metabolism (60). Motivated by this 
approach, the residualization properties of NIR fluorophores were measured (113), and both 
residualizing and non-residualizing dyes were identified. Using a dual non-residualizing and 
residualizing label, the local intact and metabolized protein can be detected (63). With 
radiolabels, the non-residualizing 125I approximates the intact protein, while the 111In 
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approximates the cumulative uptake (59). To model the degradation within each organ, a known 
quantity of each isotope was injected and the relative amount of 125I to 111In was measured over 
time. The current approach is similar in concept but uses NIR fluorescence to increase the 
resolution. This allows measurement of the distribution across multiple length scales using the 
higher spatial resolution of fluorescence and ability to quantify kinetic rates such as 
extravasation (at the tissue level) and internalization (at the cellular level). NIR wavelengths 
have low tissue autofluorescence and can theoretically penetrate to a depth of 1-2 cm for live in 
vivo imaging (99,135). NIR fluorescence combines the whole animal and biodistribution 
capabilities of radiolabels (53,107) with the tissue and cellular kinetic measurements of 
fluorescence (54). The method also takes advantage of the sensitivity of NIR imaging (higher 
than current mass spectrometry imaging and visible light fluorescence) and metabolic tracking of 
degradation products while reducing safety concerns, time/half-life constraints, and expense of 
radioactivity. It allows for the investigation of both distribution and metabolism of therapeutic 
proteins at the subcellular and cellular scale in vitro, and, importantly, at multiple scales in vivo 
in the same animal, providing insight into heterogeneity and inter-animal variability.  
 
We apply the dual label technique to four well-characterized proteins, EGF, cetuximab, 
T-DM1, and anti-A33 antibody, both in vitro and in vivo to demonstrate the wide applicability of 
the technique for the measurement of cellular metabolism and tissue distribution of other novel 
protein therapeutics. The ability to track the delivery of therapeutic proteins from whole animal 
to subcellular resolution enables investigation of the multi-scale distribution of lead compounds 
in vitro and in vivo and facilitates the development of predictive models for lead compound 
selection. 
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4.3 Results 
Two NIR fluorescent dyes were chosen that have widely differing residualization rates 
(113) and do not overlap spectrally. Figure 4.1 shows a graphic depiction of the technique. As 
the labeled protein binds to the surface, gets internalized, and subsequently degraded, low 
molecular weight degradation products labeled with DDAO and IRDye are released (red and 
green stars in Figure 4.1, respectively). The low molecular weight, lipophilicity, and moderate 
pKa allow DDAO to passively diffuse out of the cell upon protein degradation, while the larger, 
highly charged, hydrophilic IRDye remains trapped in lysosomes (113). DDAO therefore 
approximates the intact protein, since it is cleared upon degradation, while IRDye approximates 
the cumulative uptake in the cell, since it is ‘trapped’ within the cell (63). This method was 
chosen over alternative mechanisms, such as pH effects (136) or quenching/FRET, because it is 
irreversible (unlike pH effects) and does not require a high degree of labeling or larger dye-
quencher conjugate. The plasma clearance of the dually labeled antibody was measured as 
described in Chapter 3 and it showed similar clearance to antibody only labeled with IRDye 
(Figure 4.1). This indicates that the addition of the DDAO does not impact clearance of the 
antibody. Figure 4.2 shows a sample absorbance spectrum for the dually labeled antibody. 
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Figure 4.1 Dual label NIR fluorescence imaging technique concept.  
(a) Graphic depiction of dually labeled antibody binding the cell, internalizing, and degrading. 
The non-residualizing DDAO (red star) leaks out of the cell, while the residualizing IRDye 
(green star) is trapped. (b) DDAO and IRDye dye chemical structures, molecular weights, 
maximum excitation/emission, and logD (pH 7.4) calculated by MarvinSketch. (c) The plasma 
concentration over time of IRDye or dually labeled (IRDye and DDAO) trastuzumab is cleared 
at the same rate (which is equal to unlabeled trastuzumab over 3-4 days) (137). DoL, degree of 
labeling. 
 
Figure 4.2 Example absorbance spectra of dually labeled T-DM1.  
CF, correction factor at specified wavelength; ɛ, molar extinction coefficient; DoL, degree of 
labeling. 
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Three model compounds were selected for in vitro and in vivo validation based on their 
rate of internalization (Figure 4.3). EGF is internalized and degraded quickly with a 17 min half-
life (138), cetuximab is slower at an approximately 2 hour half-life (138), and the tight-junction 
associated A33 target and antibody is the slowest with a 56 hour half-life (139) representing a 
wide range of internalization rates for validation. A431 cells were used for EGF and cetuximab, 
and LS-174T cell lines were used with A33 due to high expression of their respective targets 
(140,141). Plasma clearance for each agent over 24 hours was fit using a biexponential decay in 
PRISM and the values are reported in Figure 4.4.  
 
To test the system in vitro, cetuximab and A33 were dually labeled with DDAO and 
IRDye800CW, while a 1:1 ratio of EGF-DDAO to EGF-IRDye was used. The clinical ADC 
Kadcyla (T-DM1) that targets HER2 was also tested in vitro on NCI-N87 cells. Figure 4.3 shows 
the representative flow cytometry plots and the final flow cytometry results for the normalized 
ratio of signal of DDAO to IRDye for each probe over 48 hours. To measure the normalized 
ratio, the cells were analyzed on flow cytometry and the median fluorescent intensity for each 
channel (DDAO and IRDye) was measured at different times. Then each channel was 
normalized to the initial time point, and the DDAO to IRDye ratio was calculated. This value 
yields the approximate ratio of intact protein to cumulative uptake. As protein is degraded, the 
DDAO/IRDye ratio decreases as the intact signal approaches zero. EGF showed a rapid drop in 
the ratio while A33 maintained strong signal over several days, validating the approach in vitro. 
Cetuximab and T-DM1 decreased at a moderate rate as expected in vitro (124,138). Imaging the 
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cell lysate with fluorescence SDS-PAGE shows the formation of low molecular weight IRDye 
products, while the non-residualizing DDAO does not (Figure 4.6). 
 
Figure 4.3 In vitro flow cellular metabolism.  
(a) Representative flow cytometry plots of dually labeled T-DM1 and EGF gated on cells. Intact 
protein appears in the DDAO(+)/IRDye(+) quadrant. Over time as the biologic is degraded, there 
is a gradual shift towards DDAO(-)/IRDye(+). (b) Fraction of intact protein for four agents over 
time. EGF shows rapid internalization and degradation, while A33 maintains signal over several 
days. Cetuximab and T-DM1 decrease at a moderate rate as expected. (c) Model system for 
validation of dual channel technique. For each model protein the molecular weight and plasma 
clearance is listed. The associated cell line used for xenografts, receptor density, and 
internalization half-life are also listed.  
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Figure 4.4 Plasma clearance for each agent over 24 hours.  
Biexponential fits were performed using PRISM and the fitted alpha, beta, and fraction alpha 
parameters are listed. 
 
To visualize the change in ratio, cells were imaged using a confocal microscope at similar 
time points. Figure 4.5 shows separate DDAO (red) and IRDye (green) channels for each agent. 
All four agents showed similar behavior but on different time scales. IRDye800CW initially 
labels the surface receptors but is internalized, degraded, and trapped in punctate endosomes and 
lysosomes. DDAO predominately labels the surface. As it is degraded, the dye leaks out of the 
cells as seen by a drop in signal. Although the DDAO does lose some fluorescence due to pH 
effects (pKa = 5)(23), lysed cells show very low levels of DDAO indicating that loss of signal 
dominates over pH effects (113). 
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Figure 4.5 In vitro confocal microscopy of dually labeled proteins.  
 (a), A33 (b), cetuximab (c), and T-DM1 (d). For each agent DDAO (red) shows cellular labeling 
and loss of signal over time, while IRDye (green) also shows cellular labeling initially and then 
the formation of punctate spots as it is trapped in endosomes and lysosomes. The degradation 
kinetics of each agent is consistent with flow cytometry. Scale bar = 10 µm. 
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Figure 4.6 NIR Fluorescence SDS-PAGE of dual labeled T-DM1.  
Similar to Figure 4.3 and Figure 4.5, NCI-N87 cells were pulsed for 30 minutes with dual 
labeled T-DM1 at the corresponding time points. Cell lysate was run on a reducing SDS-PAGE 
gel and scanned using the NIR Odyssey CLx Scanner. At later times the residualizing IRDye 
shows formation of lysine-dye adducts (left arrow), while the non-residualizing DDAO does not 
(right arrow).   
 
The promising in vitro results needed to be verified in vivo, since many imaging 
techniques behave well in cell culture but do not provide robust results in the heterogeneous in 
vivo environment. In particular, the DDAO fluorophore has lower brightness relative to many 
cyanine-based dyes, so the detection above autofluorescence in tissue needed to be verified.  
Figure 4.7 shows stitched whole organ histology images of an A431 tumor and kidney for 
cetuximab and EGF doses, respectively. Figure 4.7 shows fresh frozen section following a 
subsaturating (~4 mg/kg) dose of cetuximab 24 hours post injection. Further ex vivo staining of 
the vasculature using CD31-AF555 is shown in cyan. The subsaturating dose results in a 
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characteristic perivascular staining (shown in the high resolution inset) where the antibody signal 
is concentrated around blood vessels but does not diffuse homogeneously throughout the tumor 
(41,43,54). CD31 staining shows the degree of vascularization of the tumor and can be used to 
quantify the penetration distance (41). Figure 4.7 also shows stitched whole kidney images for 
EGF 24 hours post injection. EGF is below the molecular weight cut off for renal filtration; it is 
filtered by the glomerulus, degraded in the proximal tubule, and the peptide/amino acids are 
taken up by cells in the renal cortex (142,143). High-resolution images shown in the inset give 
further detail at the cellular scale, where the NIR dyes are seen in individual tubules. 
 
 
Figure 4.7 Whole organ immunofluorescence histology.  
(a) High resolution images of A431 xenograft frozen sections 24 hours post injection of 100 µg 
(~4 mg/kg) of dual labeled cetuximab (DDAO, red). Sections were stained with anti-CD31-
AF488 (cyan) ex vivo. Left scale bar is 1 mm and right is 100 µm. (b) High resolution images of 
kidney frozen sections 24 hours post injection of EGF-DDAO (red) and EGF-IRDye (green). 
Sections were stained with Hoechst 33342 (blue) ex vivo. Left scale bar is 2 mm and right is 100 
µm. 
 
Applying the dual NIR labeling technique to EGF, T-DM1, and cetuximab in vivo 
yielded insight into the single-cell and tissue distribution of these proteins in vivo (Figure 4.8). 
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For example, the clinical dose of T-DM1 (3.6 mg/kg) does not fully penetrate the tumor tissue 
(46,106,137) and only targets approximately 10% of cells by flow cytometry (Figure 4.8). This 
penetration depth did not change after 7 days (137) indicating that the therapeutic drug likely 
never reaches all the tumor cells. However, T-DM1 is clinically approved and effective in breast 
cancer, indicating that despite this heterogeneity, it still shows a clinical response. Examining the 
DDAO/IRDye ratio in vivo through flow cytometry shows how the systemic delivery of the 
protein plays an important role in the intact versus aggregate degraded probe. EGF, which is 
cleared rapidly from the blood (Figure 4.4) and internalized rapidly in vitro, shows little intact 
protein at 24 hours post-injection (Figure 4.8). However, the slowly clearing antibodies 
cetuximab and T-DM1 show mostly intact protein (a ratio of ~1) at 24 hours post-injection from 
having a constant intact supply from the blood and an initial time to accumulate in the tumor, 
even though in vitro the fraction intact decreased significantly after 24 hours (Figure 4.3). Only 
at 3 days, once the plasma concentration is lower and after maximum tumor uptake, is the 
majority of the ADC degraded and the payload released (Figure 4.8). Understanding degradation 
kinetics is crucial for many ADCs since they only release their toxic payload after degradation, 
and cell trafficking is a potential mechanism of resistance (144). In addition to organ 
biodistributions, the lower autofluorescence in the NIR region of light allows for direct whole 
animal imaging to see protein localization. In Figure 4.9, the three antibodies showed primarily 
tumor localization while the smaller EGF showed some tumor targeting with high kidney uptake.  
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Figure 4.8 In vivo cellular metabolism and distribution.  
(a) Representative flow cytometry plots of single cell suspension from NCI-N87 tumors at 24, 
48, and 72 hours post-injection of 3.6 mg/kg of dually labeled T-DM1. Intact dually labeled T-
DM1 appears in DDAO(+)/IRDye(+) quadrant. Over time as ADC is degraded there is a gradual 
shift towards DDAO(-)/IRDye(+). (b) T-DM1, EGF, and cetuximab degradation in tumor cells. 
At 24 hours EGF (a rapidly clearing protein), is mostly degraded in the tumor. However, the 
slowly clearing cetuximab and T-DM1 show mostly intact protein. Over 48-72 hours, after 
maximum uptake is reached, T-DM1 is increasingly degraded. Data plotted as mean ± standard 
deviation. (c) Molecules of DM1 payload released per target cell in vivo for the targeted cells 
calculated using the total cell uptake and fraction intact. Data plotted as mean ± standard 
deviation. (d) Fluorescence biodistribution of EGF, cetuximab, and A33 at 24 hours and T-DM1 
at 24, 48, and 72 hours. Some data is duplicated in Figure 6.16 for ease of viewing.   
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Figure 4.9 Whole animal imaging 24 hours post injection for each agent using the 
PerkinElmer In Vivo Imaging System (IVIS).  
The low autofluorescence in the near-infrared and residualizing properties of IRDye make it 
suitable for whole animal imaging. In agreement with the organ biodistribution from Figure 4.8, 
the three antibodies show high tumor uptake, while the EGF shows high renal uptake and limited 
tumor uptake.  
 
 
4.4 Discussion 
In this study, a novel dual channel near-infrared fluorescence ratio technique to quantify 
the metabolism and distribution of therapeutic proteins from subcellular to whole animal scales 
is presented and validated for several biologics. We apply this technique to three well-
characterized proteins, EGF, cetuximab, and A33, as a proof-of-concept (Figure 4.3) and then 
show how this technique can give important pharmacokinetic data for a clinically relevant ADC, 
T-DM1. Using NIR fluorescence provides much higher spatial resolution than conventional 
techniques, such as nuclear imaging, particularly in the preclinical setting. NIR fluorescence also 
provides a safe and facile method for tracking biologics that is more widely available and less 
expensive than radiolabeling. It can provide multiplexed information from the subcellular 
(Figure 4.5) to tissue and whole organ (Figure 4.7) distribution. In comparison to previous 
visible light approaches (85), using the NIR region of light provides less background 
autofluorescence and better tissue penetration, up to 1-2 cm, allowing for live imaging in vivo 
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and absolute biodistribution (%ID/g, Figure 4.8). Importantly, this technique provides 
distribution information across multiple length scales down to the single cell level using flow 
cytometry to measure millions of cells and subcellular distribution using confocal microscopy; 
both techniques can easily be integrated with visible light fluorescence approaches to examine 
pharmacodynamics, the impact of the tumor microenvironment, and single cell variability. 
 
For proof of concept we chose three well-characterized proteins, EGF, cetuximab, and 
A33, with varying internalization rates to show how this technique can be used to gather both 
metabolism and distribution data at several length scales. In vitro metabolism studies compared 
the DDAO to IRDye normalized ratio over time using flow cytometry and confocal microscopy. 
These results were as expected where the rate of decrease in the DDAO/IRDye ratio was 
proportional to internalization time (Figure 4.3).   
 
Examining the DDAO/IRDye ratio in vivo through flow cytometry (Figure 4.8) shows 
how the systemic delivery of the protein plays an important role in the intact versus aggregate 
degraded probe. EGF, which is cleared rapidly from the blood (Figure 4.4) and internalized 
rapidly in vitro, shows little intact protein at 24 hours post-injection. However, the slowly 
clearing antibodies cetuximab and T-DM1 show mostly intact protein (a ratio of ~1) at 24 hours 
post-injection from having a constant intact supply from the blood, even though in vitro the ratio 
decreased significantly after 24 hours. Only after 3 days, once the tumor has reached post-
maximal uptake and plasma concentrations are lower, does it appear that most of the antibody 
has been degraded. Understanding this kinetics is crucial for many ADCs since they only release 
 70 
their toxic payload after degradation, and cell trafficking is a potential mechanism of resistance 
(144).  
 
Another major advantage of this technique over conventional nuclear imaging is the 
ability to easily quantify cellular uptake for millions of cells in vivo with flow cytometry. 
Although techniques with radiolabeled probes are approaching the single cell level (98), the 
resolution is intrinsically limited by the path length of the positron and/or imaging equipment. 
Because the fluorescent residualizing dye gets trapped in the lysosomes, it approximates the 
cumulative uptake in each cell. For ADCs this provides the aggregate number of small-molecule 
drugs internalized per cell, and the method can be used to quantify the single cell variability in 
the number of antibody molecules required to achieve a therapeutic outcome in vivo in 
preclinical models. Also, with therapeutic proteins and antibodies, the in vivo rate of 
internalization is a critical design characteristic (145). Although this method does not directly 
measure the internalization rate, it measures the rate at which the protein is degraded in vitro and 
in vivo. This is a more relevant rate for many drugs because it determines either how long the 
active intact protein can achieve its therapeutic effect on the cell surface and in endosomes (146), 
or, in the case of ADCs, how long until the small molecule is released.  
 
This technique also allows for a multi-scale understanding of distribution in the same 
mouse. Antibodies are known to distribute heterogeneously throughout the tumor (147). 
Combined with tumor microenvironment heterogeneity (e.g. differences in vascularization, 
macrophage infiltration, and necrosis) and animal-to-animal variability, this makes comparisons 
between animals especially difficult. In tumors that have differing vascular density, the overall 
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delivery of the antibody will change and could significantly influence the clinical outcome. 
Using this technique, in vivo metabolism at the cellular scale and distribution at the cellular, 
tissue, organ, and whole animal scales is done in the same animal, allowing for a more direct 
analysis of impact at the site of action with macroscopic response. Immunofluorescence staining 
shows how the specific tissue microenvironment for each animal affects delivery. The 
combination of flow cytometry data for single cell metabolism and uptake with the tissue 
distribution better informs how novel protein therapeutics acting at the microscopic scale affect 
the tissue distribution (normalization or vascular collapse) and ultimate response. 
 
We chose to study the distribution and metabolism of T-DM1 given the dose limitations 
from small molecule toxicity, which could result in heterogeneous distribution, and the 
importance of protein metabolism to release the small molecule payload. Applying this dual NIR 
labeling technique to T-DM1 yielded several important results. First, the clinical dose of T-DM1 
(3.6mg/kg) does not fully penetrate the tumor tissue and only reaches several cell layers. This 
penetration depth did not change after 3 or more days (137) indicating that the therapeutic drug 
likely never reaches all the tumor cells. However, T-DM1 is clinically approved and effective in 
breast cancer, indicating that despite this heterogeneity, it still shows a clinical response. 
Although the mechanism of cell death from the small molecule DM1 is well understood (148), 
understanding how T-DM1 is therapeutically effective in the tumor is more complicated. It could 
act by killing cells layer after layer with each successive treatment until it reaches farther into the 
tumor. Alternatively, killing the cells immediately surrounding a blood vessel could cause 
collapse of the vessel resulting in poor delivery of oxygen and indirect cell death. Also, 
trastuzumab has been shown to exhibit vasculature normalization properties, meaning that 
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consecutive therapy with T-DM1 may increase the overall delivery to the tumor (149) if the 
increase in vessel density outweighs a reduction in macromolecular permeability. However, 
others have reported that vascular normalization decreases uptake of trastuzumab (150). 
Understanding the complex interplay of pharmacokinetics and pharmacodynamics (PK/PD) of 
both the antibody and small molecule requires understanding distribution from subcellular to the 
entire tumor and facile integration with pharmacodynamic measurements across these same size 
ranges (tumor growth curves, tissue level vascular effects, and single cell efficacy). The method 
presented here provides the tools to make these measurements in a cost-effective manner with 
unprecedented cellular resolution. As T-DM1 remains the only FDA approved drug for treating 
solid tumors, understanding the tissue and cellular effects is important for developing new ADCs 
directed against other targets and cancers (55), particularly in light of recent failed clinical trials 
of ADCs. 
 
While this method has several advantages over alternate technologies (radiolabeling, 
mass spectrometry, ELISA, conventional fluorescence, etc.), it is important to understand the 
limitations. First, similar to radiolabeling, it is important to note that the NIR fluorescence 
measures the distribution of the dye and not the protein itself (92). Second, decorating the 
surface with fluorophores can change the physicochemical properties of the protein, thereby 
changing the plasma clearance and/or distribution (76,104). Although significant differences in 
plasma clearance do not occur at early times (Figure 4.1, Figure 4.4, (151)), following the 
antibodies over days to weeks can result in faster clearance rates. Therefore, this technique is 
better suited for shorter studies. The same phenomenon can be observed with some negatively 
charged and/or radiolabeled antibodies (95,126), and care must be taken to not over-label the 
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protein. In this study, the degree of labeling was kept very low, around 0.3 for IRDye and 0.7-1 
for DDAO to minimize the impact of the dyes and better approximate the true protein 
distribution (137). Assuming a Poisson distribution, an average degree of labeling of 0.2 may be 
ideal to limit signal to antibodies labeled with 1 dye per protein. In the preclinical development 
of ADCs this is especially important because the degree of small molecule drug loading can also 
affect clearance (152). Similar to radiolabeled antibodies, basic quality control measures must be 
performed to ensure the labeling efficiency, lack of free dye, and no loss in binding affinity. 
Finally, the fluorescence intensity of DDAO was not large enough to measure the bulk organ 
digest signal accurately. DDAO was selected based on its rapid washout rate from cells 
following degradation (113). However, its optical properties are lower than the cyanine-based 
dyes. The IRDye800CW signal is much higher than the background at this wavelength, but for 
DDAO, the higher 650 nm autofluorescence and lower dye brightness results in a similar signal. 
Specifically, the trends behaved as expected (e.g. the ratio of DDAO to IRDye was very low in 
the kidney of mice injected with dual labeled EGF), but the error bars were too large for useful 
measurements (low contrast to noise ratio). Fortunately, the signal is bright enough for both 
confocal microscopy and flow cytometry measurements, thereby only limiting the type of 
technique and not the dual label method.  
 
4.5 Conclusions 
In conclusion, here we present a facile method for investigating the tissue and cellular 
distribution of therapeutic proteins using dual label NIR fluorescence imaging. Tracking protein 
distribution from the subcellular and cellular scales to organ and whole animal level was 
demonstrated using four different biologics along with measurements of protein metabolism at 
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the cellular scale both in vitro and in vivo. Using this technique we can investigate the complex 
interactions of heterogeneous delivery to the tumor and cellular metabolism of therapeutics, and 
begin to relate the tissue and cellular distribution to therapeutic efficacy. In particular, we show 
that the FDA approved drug Kadcyla only reaches a small fraction of tumor cells in mice over 
several days. Applying this technology to novel biologics in the preclinical setting will allow for 
quick and effective characterization of the microscale pharmacokinetics using a limited numbers 
of animals.  
 
4.6 Experimental Methods 
A detailed protocol of the dual label technique can be found in Appendix A. The methods 
outlined in this protocol are listed in brief below.  
 
Imaging agents and Cell lines  
Cetuximab (Bristol-Myers Squibb, Princeton, New Jersey), A33 (R&D systems, 
Minneapolis, Minnesota), and Kadcyla® (T-DM1)(Genentech USA, San Francisco, California) 
were conjugated with CellTraceTM Far Red DDAO-SE (DDAO)(Life Technologies, Eugene, 
Oregon) and IRDye® 800CW NHS Ester (IRDye)(LI-COR, Lincoln, Nebraska) according to 
manufacturer’s instructions as previously described (113). The final degree of labeling was 
determined to be between 0.7-1.0 and 0.2-0.4 for DDAO and IRDye, respectively. The DOL for 
IRDye was chosen to be below 0.5 to minimize any physicochemical effects (size and -3 net 
charge) of the dye on the antibody (SI). All conjugates were run on SDS-PAGE and scanned on 
an Odyssey CLx Scanner (LI-COR, Lincoln, Nebraska) to ensure all free dye was removed.  
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IRDye 800CW EGF Optical Probe (EGF-IRDye) was purchased from LI-COR. EGF-
DDAO was synthesized by reacting DDAO-SE with EGF (R&D Systems) at a molar ratio of 6, 
concentrating/purifying with a 3kDa cutoff Amicon filter, and polishing using reverse phase 
HPLC. MALDI-TOF was performed on the product to ensure the desired product was at a DOL 
of 1.0 or below.  
 
A431, LS-174T, NCI-N87 cells were obtained from ATCC (Manassas, Virginia). A431 
and LS-174T lines were grown in DMEM containing 10 % (v/v) FBS, 50 U/ml penicillin, 50 
µg/ml streptomycin, and 1.5 g/l sodium bicarbonate (A-431 only). NCI-N87 lines were grown in 
RPMI-1640 containing 10 % (v/v) FBS, 50 U/ml penicillin, and 50 µg/ml streptomycin. 
 
Animal Models 
All animal studies were approved and conducted in compliance with the University of 
Michigan University Committee on Use and Care of Animals (UCUCA). Tumor xenograft 
studies were done using A-431, LS-174T, and NCI-N87 cell lines. 2x106 cells (A-431 and LS-
174T) or 5x106 cells (NCI-N87) were inoculated into the rear flanks of nude mice. Tail vein 
injections were done when the longest axis of the tumor was approximately 10 mm, 
approximately 2 (A-431 and LS-174T) or 4 (NCI-N87) weeks after inoculation. Unless 
otherwise specified, tail-vein injections consisted of 100 µg (~4 mg/kg) for A33, cetuximab, and 
T-DM1, and 3 nmol EGF-DDAO and 1 nmol EGF-IRDye for EGF. All experimental conditions 
were repeated in at least three mice. 
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In Vitro Cellular Clearance and Confocal Imaging 
The rates of cellular dye loss were measured over a period of 72 hours similar to previous 
reports (113). Briefly, cells were plated in 96-well plates overnight at 80-90% confluency. Then 
cells were labeled with cetuximab, EGF, A33, or T-DM1, washed, and incubated at 37°C at 
different times up to 72 hours. Cells were washed twice daily to remove any dye from solution, 
and the signal was quantified on a per cell basis using an Attune Acoustic Focusing Cytometer 
(Life Technologies, Eugene, Oregon). 
 
Confocal Imaging 
Slides were imaged with an upright Olympus FV1200 confocal microscope using 405, 
542, 635, and 750 nm lasers. In vitro experiments were done using Falcon™ Culture Slides 
(Fisher Scientific, Pittsburgh, Pennsylvania). Incubation conditions and times are the same as 
described above for the three probes. After 72 hours, cells were incubated with Hoechst 33342 
for 5 min at room temperature, washed twice with 400µL of cell media, and imaged using a 60x 
objective. Histology slices of tissue were imaged using a 20x objective and high-resolution 
images of organs were obtained using a series of stitched smaller images and the Olympus 
software. Immunofluorescence staining was done using MAC3 (BD Biosciences, San Jose, CA) 
and CD31 (Biolegend, San Diego, CA) conjugated with Alexa Fluor 555 (Life Technologies, 
Eugene, Oregon). The conjugation and characterization protocol follows the one listed above. 
All confocal images were exported and analyzed using ImageJ image analysis software. 
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Biodistribution protocol for %ID/g 
Biodistribution was measured using a previously published protocol (53,122). Briefly, 
after the animals were euthanized, organs were resected, weighed, and homogenized. 
Homogenization consisted of incubating with a RIPA buffer/PBS mixture supplemented with 
6mg/mL collagenase IV solution, cell disruption using FB-120 Sonic Dismembrator, and further 
incubation with a RIPA buffer/0.05% trypsin-EDTA solution, as previously described (122). 
After homogenization, each sample was serially diluted in a 96 well plate and scanned using the 
Odyssey CLx scanner. The percent injected dose per gram (%ID/g) was determined by 
comparing signal from the Odyssey CLx scanner to a calibration curve and then normalizing by 
organ weight and homogenate volume. A density of 1 g/mL was assumed for each tissue. 
 
Plasma clearance 
Each agent was administered to the tumor xenograft nude mice via tail-vein injection. 
Blood samples were obtained via retroorbital sampling, mixed with 15 µL of 10mM EDTA in 
PBS per 10 µL of whole blood, centrifuged (1 min, 3000xg), and scanned in a 384 well plate 
with the Odyssey CLx. Signal intensity was converted to absolute concentration using calibration 
curves of known concentrations of each agent in plasma and fit using a biexponential decay in 
PRISM.  
 
Whole animal imaging 
Whole animal images were obtained 24 hours post injection for each agent after 
sacrificing and before biodistribution using IVIS® Series Pre-Clinical In Vivo Imaging System 
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(PerkinElmer). Animals were scanned using 750/800nm excitation/emission filters and images 
were processed using ImageJ image analysis software.  
 
In Vivo Tumor Protein Metabolism 
To study the ratio of DDAO to IRDye, tumor xenografts were resected, digested, and 
analyzed on flow cytometry (similar to the in vitro assay). For EGF, 3 nmol EGF-DDAO and 1 
nmol EGF-IRDye was injected vial the tail-vein and animals were sacrificed 24 hours post 
injection. For cetuximab and T-DM1, 100µg of dually labeled antibody was injected via tail-vein 
and animals were sacrificed at 24 and 72 (T-DM1 only) hours. After sacrifice, tumors were 
resected and sliced before being placed in a collagenase IV solution (5mg/mL). The tissue was 
digested for 25 min before centrifugation (5 min, 300xg). The cell pellet was resuspended in 
media and filtered through an 80µm filter. The cell suspension was then stained with a non-
competitive anti-EGFR-AF488 (EGF and cetuximab) or cetuximab-488 (T-DM1) for 30 min at 
room temperature, followed by two washes. Cells were then analyzed on flow cytometry and 
gated by size and AF488 signal to determine intact tumor cells. The ratio of DDAO and IRDye 
was examined in these cells by taking the ratio of the background subtracted signals and 
normalizing to the initial ratio. The initial ratio was determined by labeling tumor cells from an 
un-injected mouse ex vivo and in vitro cells on ice. Flow cytometer settings were kept constant 
for tumor types and imaging agents.  
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Chapter 5 
Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular 
Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy 
 
5.1 Publication Information 
Cilliers, C., H. Guo, J. Liao, N. Christodolu, and G. M. Thurber. Multiscale Modeling of 
Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal 
Pharmacokinetics and Potential Implications for Efficacy. The AAPS Journal. 2016; 18(5): 
1117-30. 
  
Khera, E., C. Cilliers, S. Bhatnagar, and G. M. Thurber. Computational transport 
analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: 
implications for therapy. Mol Syst Des Eng. 2018; 3(1): 73-88. 
 
Modifications have been made to the published documents to adapt the content to this 
text. Previous chapters demonstrate experimental techniques to quantify the distribution of 
antibodies in tumors. This chapter complements the experimental approaches by providing a 
modeling framework to simulate the multiscale distribution of antibodies and antibody-drug 
conjugates from the cellular scale in the tumor to the whole animal. 
 
5.2 Abstract 
Antibody drug conjugates exhibit complex pharmacokinetics due to their combination of 
macromolecular and small molecule properties. These issues range from systemic concerns, such 
as deconjugation of the small molecule drug during the long antibody circulation time or rapid 
clearance from non-specific interactions, to local tumor tissue heterogeneity, cell bystander 
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effects, and endosomal escape. Mathematical models can be used to study the impact of these 
processes on overall distribution in an efficient manner, and several types of models have been 
used to analyze varying aspects of antibody distribution including physiologically based 
pharmacokinetic (PBPK) models and tissue-level simulations. However, these processes are 
quantitative in nature and cannot be handled qualitatively in isolation. For example, free 
antibody from deconjugation of the small molecule will impact the distribution of conjugated 
antibodies within the tumor. To incorporate these effects into a unified framework, we have 
coupled the systemic and organ-level distribution of a PBPK model with the tissue-level detail of 
a distributed parameter tumor model. We used this mathematical model to analyze new 
experimental results on the distribution of the clinical antibody drug conjugate Kadcyla in HER2 
positive mouse xenografts. This model is able to capture the impact of the drug antibody ratio 
(DAR) on tumor penetration, the net result of drug deconjugation, and the effect of using 
unconjugated antibody to drive ADC penetration deeper into the tumor tissue. This modeling 
approach will provide quantitative and mechanistic support to experimental studies trying to 
parse the impact of multiple mechanisms of action for these complex drugs. 
 
5.3 Background 
Antibody-drug conjugates (ADCs) provide a powerful method to selectively deliver toxic 
small molecules to cancer cells while reducing non-specific uptake in healthy tissue. Significant 
effort has gone into designing the multiple aspects of these complex prodrugs, including the 
target selection, antibody structure and conjugation site, small molecule drug, linker design, and 
ratio of small molecule to antibody (drug antibody ratio, DAR) (9,13,20,23,153). Currently there 
are two FDA approved ADCs, with Kadcyla (ado-trastuzumab emtansine, T-DM1) being the 
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only ADC approved for solid tumors, and there are over 30 ADCs in various stages of the 
clinical pipeline (17,154). Although the mechanism of individual cell death by the cytotoxic 
small molecule is well documented, the multiple and complex steps in delivery involving both 
tumor uptake of the macromolecule, local metabolism, and distribution of the small molecule 
effector make it challenging to design an optimal drug. Mathematical simulations provide an 
efficient method for exploring the vast parameter space and selecting agents with an increased 
likelihood of success, reducing the thousands of possible combinations of these complex drugs to 
a few testable approaches.  
 
Physiologically based pharmacokinetic (PBPK) models have become ubiquitous in 
translational research for evaluating the behavior of lead compounds in dosing regimens and 
providing valuable information into reaction kinetics and transport phenomena in vivo. PBPK 
models have been used extensively to data fit dosing curves for more accurate interspecies dose 
scaling (155–161) and in predictive methods for first in animal studies (42,162–165). Because 
these models are arranged anatomically they often provide better dosing estimations than simple 
one- or two-compartment models or allometric scaling. Also, these models provide a framework 
to estimate unknown parameters or rates that might be difficult to measure accurately in vivo. 
However, there is strong motivation within this framework to develop more predictive models 
(versus data fitting) so that the pharmacokinetic behavior of lead compounds can be simulated 
and used to streamline preclinical and clinical studies. 
 
Current PBPK models for antibodies vary in how the organ compartments are structured. 
For example, a model by Baxter uses two-pore formalism to estimate the extravasation of the 
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antibody into the surrounding tissues (156). Models by Ferl and Davda also used two-pore 
formalism but added FcRn recycling into select organ compartments to capture this important 
antibody metabolism pathway (157,166). Another model from Garg et al. incorporated FcRn 
recycling into all tissues and used one-pore formalism to model antibody extravasation (158). 
Recently, Shah et al. developed a platform PBPK model that incorporates up to 18 
compartments, each with detailed mechanistic behavior that subdivides each organ into plasma, 
blood cell, endothelial, interstitial, and cellular sub-compartments and uses FcRn interactions 
(161). While all these models share a similar framework, there is not a general consensus on the 
optimal way to describe the organ compartments (167). This likely results from the trade-offs of 
more detailed models being able to capture more complex behavior at the cost of additional 
parameters that could result in an underspecified system or one where it is difficult to 
independently measure values for predictions.  
 
Although organ-level PBPK models can simulate systemic and individual organ 
concentrations over time, they lack detailed tissue level distribution and do not provide a 
framework for predicting the heterogeneous tumor distribution associated with antibodies. The 
most common method for capturing these tissue scale dynamics is through a Krogh cylinder or 
tumor cord geometry (168–172). Using this geometry along with mixed boundary conditions to 
capture permeability limitations, explicit blood flow and axial gradients to measure blood flow 
limitations, and diffusion with non-linear binding kinetics to quantify diffusion limitations, tissue 
level models are useful for determining the uptake and distribution of a diverse range of drugs, 
including small molecules, therapeutic proteins, and antibodies (43,90,173–175). For antibodies, 
the tumor cord geometry has been validated by multiple groups and has been used to estimate 
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whole organ distribution and uptake (81,90,176–179). The lack of functional lymphatics in 
tumors (180) also lends itself to this geometry focused on transcapillary exchange and 
distribution. However, the Krogh geometry requires the systemic (plasma) concentration as an 
input, therefore limiting its ability for purely predictive studies. Combining the Krogh cylinder to 
describe the tumor compartment with a general PBPK model for systemic distribution would 
give an accurate, multi-scale depiction of antibody distribution. Additionally, since self-
consistent therapeutic parameters are available for a wide range of molecules including 
antibodies and small molecule drugs (42,81,181), the Krogh cylinder simulations are able to 
simultaneously capture multiple different species within the tumor.  
 
Here we present a multi-scale model integrating two previously published and validated 
models: a PBPK model for organ and whole body distribution and a tumor tissue Krogh cylinder 
to simulate the distribution of the clinically used ADC T-DM1. This model combines the 
strength of PBPK models by simulating the systemic distribution while accurately capturing the 
heterogeneous antibody distribution in the tumor. To highlight the importance of systemic and 
tumor concentrations, we use two clinically relevant therapeutics: the monoclonal antibody 
Herceptin (trastuzumab) and the ADC T-DM1. Through simulation and experiment we show that 
at the clinical dose of T-DM1 (3.6 mg/kg) the tumor distribution is highly heterogeneous, 
resulting in a typical perivascular tumor distribution. Additionally we show that co-
administration of trastuzumab with a constant T-DM1 dose results in a significantly more 
homogeneous tumor distribution, thereby targeting more tumor cells with the potent cytotoxic 
small molecule drug. Importantly, the total tumor uptake of the ADC does not change 
significantly, but in vivo experimental data shows a drastically different tumor distribution. The 
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combined PBPK-Krogh cylinder model accurately captures the systemic organ concentrations 
and the considerably different tumor distribution, something that neither model can do alone. 
The interplay between systemic level pharmacokinetics and tumor distribution is important for 
ADCs, and several literature examples are shown in the context of tissue penetration. The impact 
of dose, DAR, deconjugation, receptor expression, and trafficking all strongly impact the 
distribution. This model is therefore useful in accurately capturing the complex distribution 
resulting from varying the DAR, linker stability, and antibody distribution on tumor efficacy. 
 
5.4 Results 
A graphic depiction of the combined PBPK and Krogh cylinder model is shown in Figure 
5.1. This multi-scale model captures the systemic and organ level concentrations (PBPK model, 
Figure 5.1) along with the heterogeneous tissue distribution in the tumor and cellular metabolism 
of the ADC (Krogh cylinder model, Figure 5.1). Currently, the endosomal processing and escape 
of the metabolite are not included but could be added to the modeling framework as others have 
done (177,182). The higher vascular density in healthy tissue (resulting in shorter diffusion 
distances between vessels) and lack of specific binding in most tissue results in a homogeneous 
antibody distribution (37). Therefore, only the tumor compartment is represented explicitly with 
a Krogh cylinder model. The small molecule metabolite for T-DM1 is relatively hydrophilic, 
resulting in little bystander effect within the tissue (13), so the diffusion of the metabolite was 
not simulated. The metabolite is represented by the green arrows.  
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Figure 5.1 Multi-scale PBPK-Krogh cylinder model diagram.  
A, PBPK model tracks systemic distribution of both antibody and ADC. Solid black lines 
correspond to antibody/ADC flow and green dotted lines correspond to metabolite flow. B, 
representative organ compartment model. All organs except the tumor and carcass are divided 
into vascular, interstitial, and metabolite compartments. The endothelial compartment is added in 
the carcass to account for FcRn recycling. C, the tumor compartment is modeled by a 1-D Krogh 
cylinder tissue model with permeability (P) across the endothelium (extravasation) and diffusion 
(D) through the surrounding tissue. D, cellular-scale model showing binding, internalization, and 
degradation rates of both antibody and ADC.  
 
The tumor distribution of antibody and small molecule drug is a function of the dose, 
DAR, systemic clearance, and in vivo kinetics (such as deconjugation depending on the 
linker(183,184)). To capture the impact of the antibody dose relative to small molecule delivery, 
a constant dose of T-DM1-AF680 was given with increasing doses of trastuzumab. This could 
represent a constant small molecule dose while decreasing the DAR (assuming both free 
antibody and ADC behave similarly as seen with T-DM1 (184)), the impact of deconjugation 
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and free antibody accumulation in the plasma, or an intentional effort to increase antibody tissue 
penetration by competing for available antigen. Figure 5.2 shows that the clinical dose of T-
DM1-AF680 (3.6 mg/kg) is highly heterogeneous in NCI-N87 tumor xenografts. Figure 5.3 and 
Figure 5.4 show that the plasma clearance and tumor distribution of unlabeled T-DM1 and T-
DM1-AF680 are similar. Co-administration of trastuzumab at a 3:1 or 8:1 ratio dramatically 
increases penetration of T-DM1 by competing for receptor sites within the tissue. These results 
also agree with literature reports where increasing the antibody dose results in more 
homogeneous distribution throughout the tumor (36,41,178). 
 
Figure 5.2 Heterogeneous ADC distribution.  
A, graphic depiction of T-DM1 tumor distribution with co-administration of trastuzumab. 
Without a carrier dose of trastuzumab, tumor distribution of T-DM1 is perivascular. Co-
administration of T-DM1 with ‘carrier’ doses of trastuzumab (at constant T-DM1 doses) results 
in significantly more T-DM1 tumor penetration. B, immunofluorescence imaging following co-
administration of 3.6 mg/kg of AlexaFluor 680 tagged T-DM1 (green) with trastuzumab at 0:1, 
3:1, and 8:1 ratios (0 mg/kg, 10.8 mg/kg, and 28.8 mg/kg unlabeled trastuzumab, respectively). 
Immunofluorescence staining with CD31-AF555 (red) shows tumor vasculature. Window 
leveling of images is different. Scale bar = 200 µm. 
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Figure 5.3 Normalized plasma clearance of trastuzumab and trastuzumab-AF680.  
Conjugation of AF680 to trastuzumab at a low degree of labeling (0.3 dyes per antibody) does 
not significantly alter the plasma clearance of trastuzumab over 16 days. 500 µg of unlabeled 
trastuzumab and 50µg of trastuzumab-AF680 were administered via tail-vein injection to N=3 
mice. Blood samples were processed as described in Materials and Methods section. Samples 
were first scanned on the Odyssey NIR Imaging System and then used with a Human IgG1 
ELISA kit (eBioscience, Cat. No. 88-50560-22).  
Figure S7: ELISA Data
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Figure 5.4 Distribution of unlabeled T-DM1.  
Immunofluorescence imaging 24 hour post injection of unlabeled T-DM1 (green) shows 
perivascular distribution, similar to Figure 5.2, Figure 5.7, and Figure 5.8. Ex vivo staining was 
first done with anti-human-Fc-AF680 (green), washed, then stained with trastuzumab-AF488 
(red) to show free HER2 receptor. Scale bar 500 µm. 
 
A PBPK model using a compartmental model for the tumor can accurately capture the 
average tissue concentration (64), but does not describe the tumoral distribution. The increasing 
doses of trastuzumab do not significantly impact the average concentration of T-DM1 in the 
tumor or other organs prior to saturation (Figure 5.5), but it dramatically changes the ADC tissue 
distribution (Figure 5.2). The increased penetration lowered the concentration of T-DM1 on each 
cell (resulting in lower fluorescence intensity per cell) but did not lower the total tumor uptake. 
The lack of significant binding in other organs results in a minor difference in non-specific 
distribution (Figure 5.5). The molecules co-exist in these tissues but do not interact/compete for 
binding sites. Because the PBPK portion of the simulation was adapted from a previously 
published model, the organ concentrations were fit to biodistribution data and plasma clearance 
(Figure 5.5 and Figure 5.6) using a minimal number of fitted agent-specific parameters for n = 3 
mice per dose level, and the fitted parameters are shown in Table 5.1. For parameter estimates, 
the 24-hour time point was used for biodistribution studies because this is the approximate time 
for maximum uptake of trastuzumab and other antibodies (36,60,64) along with plasma clearance 
data out to 72 hours.  
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Table 5.1 Fitted PBPK model parameters. 
Parameter Value Units %CV 95% C.I. Description 
kdeg,liver 7.4 x 10-6 mL/s 34.5 3.1 x 10
-6 to 
1.2 x 10-5 
Liver degradation 
rate 
kdeg,organ 3.2 x 10-7 mL/s 72.1 0* to 7.0 x 10-7 Organ degradation rate 
U 6.9 x 10-4 s-1 65.8 0* to 1.5 x 10-3 Metabolite urinary excretion rate 
kloss 5.2 x 10-5 s-1 20.9 3.4 x 10
-5 to 
7.1 x 10-5 Metabolite loss rate 
*Confidence interval was constrained to zero because lower bound was negative. 
 
Figure 5.5 PBPK model results and experimental biodistribution data.  
PBPK model shows systemic distribution of 3.6 mg/kg T-DM1 with trastuzumab at 0:1 (black), 
3:1 (red), and 8:1 (blue) ratios (trastuzumab:T-DM1, N=3 mice for each). 0:1 and 3:1 
distributions overlap since the tumor is below saturation at these dosing levels. At 8:1 ratio, the 
dose is slightly above tumor saturation resulting in lower tumor %ID/g and slower clearance. 
Experimental data shows T-DM1 distribution at 24 hours for the respective ratios; data points 
were shifted slightly for visibility. The PBPK results are similar despite widely differing 
distribution seen within the tumors in Figure 5.2. 
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Figure 5.6 T-DM1 Plasma clearance.  
Plasma clearance of 3.6 mg/kg T-DM1 with co-administration of trastuzumab at 0:1, 3:1, and 8:1 
ratios (0 mg/kg, 10.8 mg/kg, and 28.8 mg/kg unlabeled trastuzumab, respectively). The addition 
of a carrier dose had a negligible impact on clearance. 
 
 
The Krogh cylinder portion of the model was used to predict the tumor tissue distribution 
following co-administration of trastuzumab and T-DM1 at 0:1, 3:1, and 8:1 ratios (0 mg/kg, 10.8 
mg/kg, and 28.8 mg/kg unlabeled trastuzumab, and 3.6 mg/kg T-DM1, respectively)(Figure 5.7). 
It should be noted that none of the parameters used in this portion of the model were fit to new 
experimental data but were all taken from literature. The penetration distance increases from 
strongly perivascular distribution with the 0:1 ratio to homogeneous distribution with the 8:1 
ratio while the T-DM1 concentration per cell is reduced. These results agree favorably with all 
tumors tested (Figure 5.8, Figure 5.9, Figure 5.10). Macroscopic images of a larger tumor region 
are shown (Figure 5.7) along with a higher magnification of the boxed region. The Krogh 
cylinder parameters used for all simulations are shown in Table 5.2. 
Figure S6: Plasma clearance
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Figure 5.7 Quantitative Krogh cylinder simulation results and immunofluorescence 
imaging results.  
A, model predictions of bound T-DM1 with co-administration of trastuzumab at 0:1, 3:1, and 8:1 
ratios 24 hours post injection. B, experimental validation of model predictions. Whole tumor 
(bottom) and inset (top) T-DM1 (green) distribution following injection of 3.6mg/kg T-DM1 
with trastuzumab at 0:1, 3:1, and 8:1 ratios. Immunofluorescence staining with CD31-AF555 
(red) shows tumor vasculature. I and M show regions of inflammatory cells and muscle, 
respectively. Window leveling between different carrier dose images is different. Scale bar = 50 
µm (top) and 1 mm (bottom). 
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Figure 5.8 T-DM1 distribution at 0:1 dosing ratio (only 3.6 mg/kg T-DM1). 
Immunofluorescence imaging 24 hour post injection of T-DM1 (green) shows perivascular 
distribution. 30 min prior to sacrifice Hoechst 33342 (blue) was injected at 15 mg/kg to highlight 
functional vasculature. Ex vivo staining was done with CD31 (red) to further show tumor 
vasculature. Window leveling different than Figure 5.9 and Figure 5.10. Scale bar 200 µm. 
 93 
 
Figure 5.9 T-DM1 distribution at 3:1 dosing ratio (3.6 mg/kg T-DM1 + 10.8 mg/kg 
unlabeled trastuzumab).  
Immunofluorescence imaging 24 hour post injection of T-DM1 (green) shows further penetration 
into tumor. 30 min prior to sacrifice Hoechst 33342 (blue) was injected at 15 mg/kg to highlight 
functional vasculature. Ex vivo staining was done with CD31 (red) to further show tumor 
vasculature. Window leveling different than Figure 5.8 and Figure 5.10. Scale bar 200 µm. 
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Figure 5.10 T-DM1 distribution at 8:1 dosing ratio (3.6 mg/kg T-DM1 + 28.8 mg/kg 
unlabeled trastuzumab).  
Immunofluorescence imaging 24 hour post injection of T-DM1 (green) shows homogeneous 
distribution throughout tumor. 30 min prior to sacrifice Hoechst 33342 (blue) was injected at 15 
mg/kg to highlight functional vasculature. Ex vivo staining was done with CD31 (red) to further 
show tumor vasculature. Window leveling different than Figure 5.8 and Figure 5.9. Scale bar 200 
µm. 
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Table 5.2 Krogh cylinder simulation parameters from literature. 
Parameter Value Units Reference Description 
D 10 µm2/s (90) Antibody diffusivity 
P 3 x 10-9 m/s (185) Antibody permeability 
kon 7.1 x 105 M-1 s-1 (186) Trastuzumab binding rate 
Kd 0.5 nM (186) Trastuzumab dissociation constant 
koff 3.5 x 10-4 s-1 (186) Trastuzumab dissociation rate 
RKrogh 75 µm (36,187) Krogh cylinder radius 
Rcapillary 8 µm (188) Capillary radius 
[Ag]0 0.83 µM (43,189,190) Initial Antigen concentration (106 HER2/cell, 5x108 cells/mL) 
ε 0.24 Dimensionless (42) void fraction 
H 0.45 Dimensionless (90) Hematocrit 
ke 3.3 x 10-5 s-1 (124) Trastuzumab internalization rate 
Q 0.0015 mL/g/s (60) Blood flow rate to tumor 
Rs 3.3 x 10-5 s-1 (124) Antigen recycle rate 
 
The penetration depth of antibodies is a complex function of dose, receptor expression 
and trafficking, and tumor physiology (permeability, vascular density, etc.). Figure 5.11 shows 
the predicted T-DM1 radial distribution as the competitor trastuzumab “carrier” dose is 
increased. When no carrier dose is added (only T-DM1 from 0 to 3.6 mg/kg total ADC dose), T-
DM1 exhibits a perivascular distribution where cells immediately outside the blood vessel are 
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saturated and cells farther away receive almost no ADC. As carrier trastuzumab is added, 
however, it competes for receptors, allowing T-DM1 to penetrate farther into the tumor, albeit 
with lower T-DM1 concentration per cell. (Note that higher doses of T-DM1 would also achieve 
additional penetration, but TDM-1 is limited by toxicity at 4.8 mg/kg (48).) As more carrier dose 
is added, the carrier dose continues to spread out the ADC distribution until all the binding sites 
are occupied by trastuzumab or TDM-1. At the theoretical receptor saturating concentration for 
total antibody, T-DM1 (and trastuzumab) penetrates evenly throughout the tumor. Above this 
total antibody saturating concentration, the T-DM1 concentration remains homogeneous 
throughout the tumor. However, the average intra-tumoral T-DM1 concentration starts to drop 
because the increasing amount of trastuzumab competes for receptors, and there are no additional 
binding sites deeper in the tissue once saturation is achieved. Importantly, receptor expression 
(and therefore the saturation dose) can vary significantly between patients and within 
tumors/metastases. To highlight the relationship between receptor expression, penetration depth, 
and total antibody dose (ADC plus free antibody), three-dimensional plots of radial 
concentration versus total dose with different receptor expression are shown in Figure 5.11. 
These simulations were done using a high (1x106 receptors per cell) and moderate (3x105 
receptors per cell) HER2 expression level (Figure 5.11 and Figure 5.12), which roughly 
corresponds to 3+ and 2+ IHC staining (191). 
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Figure 5.11 Prediction of T-DM1 distribution versus trastuzumab carrier dose.  
Predicted perivascular tumor distribution following dosage with T-DM1 and trastuzumab for 
tumor cells expressing 1 x 106 receptors per cell, A, and 3 x 105 receptors per cell, B, 
corresponding to ~3+ and ~2+ IHC staining, respectively. From 0 to 3.6 mg/kg total dose only T-
DM1 is dosed. After 3.6 mg/kg the T-DM1 dose is kept constant (3.6 mg/kg) and trastuzumab 
carrier dose is increased. 
 
 
Figure 5.12 Prediction of T-DM1 distribution versus trastuzumab carrier dose.  
Predicted tumor distribution following dosage with T-DM1 and trastuzumab for tumor cells 
expressing 1 x 106 receptors per cell and 3 x 105 receptors per cell, corresponding to 3+ and 2+ 
IHC staining, respectively. From 0 to 3.6 mg/kg total dose only T-DM1 is dosed. After 3.6 
mg/kg the T-DM1 dose is kept constant (3.6 mg/kg) and trastuzumab carrier dose is increased. 
Axis corresponds to total dose (T-DM1 + trastuzumab). Graph is identical to Figure 5.11 but at 
alternate viewing angle. 
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The antibody penetration depth is also a function of time. Figure 5.13 shows the radial 
profile of 3.6 mg/kg T-DM1 along with a 3:1 and 8:1 trastuzumab co-administration. The 
penetration depth quickly reaches the maximum distance at 24 hours and then stalls. This is 
caused by continuous internalization preventing further penetration even as the antibodies 
continue to extravasate. The longer circulation time of antibodies does not increase the 
penetration depth due to this constant internalization, making Cmax a critical factor in determining 
tissue penetration depth (37,43).  
 
 
Figure 5.13 Antibody tumor penetration over time.  
Penetration depth reaches a maximum at approximately 24 hours, and continuous internalization 
prevents further penetration as additional antibody continues to extravasate.  
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Co-administration of trastuzumab with T-DM1 lowers the average effective DAR since 
the same amount of small molecule payload is administered with more antibodies. Multiple 
groups have examined the impact of DAR on plasma clearance and efficacy. Figure 5.14 
highlights the results of several groups (using different ADCs against different targets) where the 
overall small molecule dose was similar but the DAR and ADC dose was varied. For clarity, 
only tumor growth curves where there is an equivalent small molecule dose spread over a 
different ADC dose (and different DAR) are shown. Previous work by several groups has 
demonstrated the importance of DAR on systemic clearance (24). Two important mechanisms 
include DAR-dependent clearance and DAR-dependent deconjugation. In DAR-dependent 
clearance, a high number of small molecule drugs per antibody can increase systemic clearance 
of the entire antibody-drug conjugate. With DAR-dependent deconjugation, a larger number of 
small molecule drugs can result in faster loss of the small molecule while the antibody (with a 
lower DAR or without a payload, i.e. DAR0) remains in circulation. Only a few informative 
studies have measured the dynamic change of individual DAR species in vivo. Using these 
studies, we modeled the effective difference in small molecule AUC and divided the results into 
cases where the antibody exposure, and therefore penetration distance into the tumor, was much 
higher than the difference in payload exposure (Figure 5.14), and cases where DAR-dependent 
clearance and/or deconjugation dominated over differences in antibody AUC. Vertical red lines 
and boxes show the approximate percentage difference between the small molecule payload 
AUC, typically chosen at a time point when the tumor growth curves begin to diverge. The 
results in Figure 5.14 highlight the fact that at a similar small molecule exposure,/AUC a higher 
antibody concentration (corresponding to increased tumor penetration) generally has higher 
efficacy. Individual cells receive less small molecule drug, but the IC50 is lower than the Kd for 
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these agents, so cells within the saturated perivascular region still receive a toxic dose. The lone 
exception is a paper using a less toxic small molecule, and this is also the only paper where the 
IC50 is greater than the Kd. These studies provide preliminary (but indirect) evidence that a more 
homogeneous distribution may result in better ADC efficacy. The studies shown in Figure 5.14 
highlight the importance of DAR-dependent clearance. In Lyon et al. the linker was varied, and 
significant differences in the clearance were seen with the DAR8 conjugates. The faster 
clearance ultimately resulted in worse efficacy. Similarly, in Hamblett et al. the higher small 
molecule exposure resulted in better efficacy; however, the higher antibody dose at the time of 
maximum uptake in the tumor (predicted to occur approximately 1 day after the ADC was 
dosed) would result in higher tumor penetration, thereby complicating the interpretation.  
 
To examine the role of the bystander effect, the tumor growth studies were grouped by 
payloads that are not capable of diffusing into neighboring cells (non-bystander payloads) in 
Figure 5.15, and payloads that are (bystander payloads) in Figure 5.16 (192). Several of the 
tumor growth studies in Figure 5.15, Figure 5.16, and Figure 5.17, are taken from Figure 5.14, 
but are arranged by payload properties for clarity. Expectedly, for non-bystander payloads at 
constant payload dose, the high ADC dose/low DAR strategy consistently resulted in greater 
tumor shrinkage and better efficacy (Figure 5.15). Bystander payloads like MMAE are able to 
efflux from the cell and diffuse into and target adjacent cells to exert their cytotoxic effects. 
While an important role for these payloads is killing antigen negative cells, they also have the 
ability to penetrate farther into the tumor beyond ADC-saturated perivascular cells, and 
potentially improve ADC efficacy. In contrast to non-bystander payloads, bystander payloads 
that are delivered at a higher dose than needed for cell killing (‘overkill’) can diffuse deeper into 
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the tissue, thus improving the penetration distance of the payload and killing additional cells. 
Literature review of cases using a constant payload dose with different ADC doses/DAR 
revealed that improved tissue penetration still improves efficacy (Figure 5.16). Importantly, this 
shows that direct targeting by the ADC is more efficient at delivering the payload to the tumor 
cell than the bystander effect. Finally, we examined the effect of keep the antibody dose constant 
and increasing the payload dose for both bystander payloads and non-bystander payloads (Figure 
5.17). Literature review of cases using a constant bystander ADC dose with increasing DAR 
revealed that for an equivalent dose of bystander ADC, higher DAR consistently improves 
efficacy. However, increasing the DAR for non-bystander payloads (at a constant ADC dose) 
may only further concentrate payload in perivascular tumor cells, exacerbating the ‘overkill’ of 
these cells but not necessarily altering the overall efficacy. Despite delivering twice the payload 
dose, Junutula et al. showed comparable efficacy and Jackson et al. showed less efficacy with the 
higher DAR ADCs. However, Pillow et al. showed improved efficacy with the higher DAR, 
indicating tissue distribution is one factor of many properties impacting ADC efficacy. We 
hypothesize that additional factors (DAR-dependent clearance and/or tissue-level effects in 
vascularization) may be responsible for these deviations when similar efficacy is predicted due to 
equivalent tissue penetration. 
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Figure 5.14 Literature review of efficacy with constant small molecule dose but differing 
DAR and antibody doses.  
A, at a constant small molecule dose, ADCs with a higher DAR and lower antibody dose (black) 
are generally less efficacious than ADCs with a lower DAR and higher antibody dose (gray). 
Blue arrows correspond to six cases where a constant small molecule dose delivered with a 
higher antibody dose improved efficacy and is predicted to have increased tissue penetration. In 
one case the reverse was true (green arrow); however, here the small molecule had an IC50 
reported to be greater than the KD of the antibody due to a less toxic payload. This would require 
saturation of cells with a high DAR antibody for efficacy. Red lines and boxes correspond to the 
estimated difference in small molecule AUC between different DAR/antibody doses using 
literature reports of DAR-dependent deconjugation and clearance rates in a pharmacokinetic 
model. B, DAR-dependent clearance can significantly affect the efficacy, making it difficult to 
parse tumor penetration effects from small molecule AUC.   
 
The increasing trastuzumab doses do not appreciably lower the tumor uptake of T-DM1 
(Figure 5.18). Because extravasation is the rate-limiting step in antibody uptake (37), T-DM1 
molecules that extravasate but are blocked from binding perivascular cells will continue to 
diffuse deeper in the tissue rather than intravasate and wash out. Eventually they bind to a cell 
with free receptor. Similar to radiolabeled antibodies (193), only after the tumor is saturated will 
the %ID/g start to decrease (Figure 5.18).  
 
 
 103 
 
Figure 5.15 Distribution and efficacy of non-bystander payloads.  
(a) Graphic depiction of the same payload dose for non-bystander ADCs with a high and low 
DAR (top and bottom, respectively). Higher antibody doses result in better tumor penetration 
(bottom) but the lower DAR results in a lower average number of payloads per cell. This is still 
sufficient for cell death with high potency payloads. (b) Literature review of cases using a non-
bystander ADC at the same payload dose but with different DARs/ADC doses. In all these cases 
the higher antibody dose (lower DAR) improved efficacy despite the same payload dose. Blue 
arrows indicate cases where the lower DAR improved efficacy at a constant payload dose. 
 
 
Figure 5.16 Distribution and efficacy of bystander ADCs given at constant payload dose 
with different DAR/antibody doses.  
(a) Graphic depiction of the same payload dose for ADCs with a high and low DAR (top and 
bottom, respectively). Higher ADC doses target more cells, but the lower DAR results in a lower 
average number of payloads per cell.. (b) Literature review of cases using a bystander payload at 
the same payload dose. Although bystander payloads are able to diffuse farther into the tumor, in 
almost all cases the lower DAR ADC had improved efficacy, indicating direct cell targeting by 
the ADC may improve payload distribution more than bystander effects. Blue arrows indicate 
cases where the lower DAR (or higher ADC dose) improved efficacy despite a constant payload 
dose. Red double-sided arrows indicate similar efficacy. Tumor growth data taken from 
references8, 9, 44, 82. Tras, trastuzumab; Steap, anti-Steap. 
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Figure 5.17 Distribution and efficacy of a constant dose of antibody with increasing DAR 
for both bystander and non-bystander payloads.  
(a) Graphic depiction of the same ADC dose given with increasing DAR. The same ADC dose 
targets the same number of cells; however, bystander payloads are able to diffuse farther into the 
tumor, reaching more cells than initially targeted. (b) Literature review of cases using a constant 
bystander ADC dose with increasing DAR. Higher DAR bystander ADCs at the same ADC dose 
gave improved efficacy in ten cases (blue arrows). Two cases showed similar efficacy (red 
double-sided arrows). (c) Graphic depiction of the same ADC dose given with increasing DAR. 
Non-bystander payloads are unable to diffuse farther into the tumor and an equivalent ADC dose 
targets the same number of cells resulting in similar efficacy between high and low DAR non-
bystander ADCs. (d) Literature review of cases using a constant non-bystander ADC dose with 
increasing DAR. Red double-sided arrows indicate negligible change in efficacy. Single-sided 
arrows indicate opposing differences in efficacy. 
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Figure 5.18 Predicted and experimental impact of carrier dose on total tumor uptake.  
A, bound and internalized uptake of T-DM1 in tumor with increasing trastuzumab carrier dose. 
Prior to saturation, the addition of a carrier dose (or equivalently, delivering a constant small 
molecule dose while lowering the DAR) does not lower total tumor uptake of a constant T-DM1 
dose (3.6 mg/kg). It only changes the distribution. B, experimentally measured %ID/g of T-DM1 
at respective ratios. Differences of %ID/g were not statistically significant between the 0:1 to 
8:1. 
 
In addition to the tumor site, some antigens are expressed in healthy tissue, and this is an 
important aspect of target-mediated toxicity. The higher vascular density results in homogeneous 
ADC distribution that can be accurately represented with a compartmental model. If the healthy 
tissue is saturated with ADC (which is likely given higher vascularization and often lower 
receptor expression), the co-administration of free antibody will lower the ADC uptake in this 
healthy tissue (Figure 5.19) while having insignificant (p = 0.06) impact on tumor uptake (Figure 
5.18). This could potentially increase the therapeutic window provided the carrier dose has a 
neutral or positive impact on tumor efficacy due to increased drug penetration. 
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Figure 5.19 Impact of carrier dose/DAR on healthy tissue targeting.  
A, graphic depiction of specific binding added to the heart organ compartment. A bound 
compartment was added to represent the low levels of HER2 antigen expressed in the heart. B, 
Bound and internalized T-DM1 (constant 3.6 mg/kg dose) in heart compartment with increasing 
trastuzumab carrier dose shows lower healthy tissue uptake with a carrier dose or lower DAR. 
The y-axis is normalized to initial unbound antigen in heart. 
 
 
 
5.5 Discussion 
Antibody drug conjugates display complex pharmacokinetics at multiple scales: systemic 
clearance as a function of DAR and deconjugation, organ heterogeneity from specific and non-
specific processes, tumor tissue heterogeneity due to target binding, and cellular/subcellular 
kinetics of endosomal escape and bystander effects. Here we present a novel pharmacokinetic 
model for antibody biodistribution where a mechanistic Krogh cylinder geometry tissue based 
model is integrated into a PBPK framework (Figure 5.1). We show theoretically and 
experimentally that the tumor distribution of T-DM1 in NCI-N87 xenografts at clinical doses is 
highly heterogeneous, and that co-administration of trastuzumab effectively spreads out T-DM1 
homogeneously throughout the tumor (Figure 5.2, Figure 5.7). Importantly, a compartmental 
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treatment of the tumor would show similar average uptake of the ADC with and without the co-
administration of trastuzumab but would not be able to discern any impact on distribution. The 
combined model accurately captures the similar average organ uptake but drastic differences in 
tumor heterogeneity (Figure 5.2, Figure 5.5, Figure 5.7).  
 
To highlight the importance of the integrated tissue distribution model, we showed how 
co-administration of T-DM1 with trastuzumab results in a significantly different tumor 
distribution with a similar systemic distribution. At the clinical dosage level of T-DM1 (3.6 
mg/kg), the tumor distribution was perivascular with limited penetration, similar to trastuzumab 
(36). Adding a carrier dose of trastuzumab at a 3:1 ratio considerably increased the tumor 
penetration with limited changes in the overall uptake. The total ADC per cell is lower, but more 
tumor cells are receiving the therapeutic. Similarly with the 8:1 ratio, although the overall 
concentration received by the cells is less than the 3:1 ratio, the distribution in the tumor is even 
more homogeneous. Since the 8:1 dose is close to the theoretical receptor-saturating dose, this 
resulted in a slight (but not statistically significant, p = 0.06) reduction in total uptake.  
 
Compartmental PBPK models do not take into account the tissue-scale distribution of 
antibodies or ADCs. The integrated tissue model based on the Krogh cylinder, however, uses a 
systems approach based on the physicochemical properties of the ADC to predict tissue 
distribution. Although the combined model presented here is not purely predictive because 
several agent-specific PBPK parameters were fit to experimental data, the Krogh cylinder 
portion of the model only requires the systemic concentration as input since published parameter 
correlations are available for the other values (42,81,90). Importantly, the mechanistic tissue 
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model gives the ability to easily change simulation parameters based on the specific therapeutic 
or target (Figure 5.11). These simulations were based on literature parameters for trastuzumab/T-
DM1 binding affinity, antibody diffusivity/permeability, NCI-N87 receptor expression, and 
HER2 receptor kinetics. However, these parameters are often measured for other therapeutics 
and targets, giving the model broad applicability. 
 
It has been known for some time that antibody distribution in tumors is heterogeneous 
(194), saturating doses are required to obtain even distribution (178), and very high doses are 
required to saturate tumors in the clinic (195,196). Many monoclonal antibodies for solid tumors 
are given frequently (often weekly) at relatively high doses (2-15 mg/kg), making it possible to 
approach tumor saturation. However, the potency of the small molecule payload often limits the 
dose and frequency of administration with ADCs. This limitation on dose and frequency, 
combined with current ADCs that often use high affinity antibodies, potent payloads, and highly 
expressed targets, can result in subsaturating (and therefore heterogeneous) distribution as we 
have shown when dosing T-DM1 at the clinical dosage (Figure 5.2, Figure 5.7, Figure 5.8). The 
importance of heterogeneity on therapeutic efficacy of antibodies and ADCs is still debated. The 
choice of model could implicitly bias the data interpretation (popularly phrased by Maslov’s 
hammer). Examining the systemic clearance or deconjugation will focus on the impact these 
mechanisms have on efficacy. Likewise, measuring the tissue level heterogeneity will center the 
discussion on the impact of tumor distribution. By including both systemic and tissue level 
effects, the relative contribution of each can be quantified with this model and corresponding 
experiments.  
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We conducted an extensive literature search to determine if there is potential evidence of 
heterogeneity impacting ADC efficacy. Importantly, it depends on the toxicity of the payload. If 
receptor saturation with an ADC is required for cell death, then spreading out the ADC using a 
carrier dose may lower efficacy due to a subsaturating number of ADCs delivered per cell (a 
potency limitation). Conversely, if the ADC is toxic to cells at subsaturating concentrations, then 
heterogeneous delivery results in more drug being delivered to perivascular cells (“overkill”) 
while other cells receive no treatment (a delivery limitation). In this case, a more uniform 
distribution would benefit efficacy by using the ‘excess’ ADC to reach and kill more cells. This 
is counter-intuitive, where the most potent drug is often pursued during development, but 
considering the tumor heterogeneity and high toxicity of the payloads, is possible. Looking at in 
vitro cell killing curves, the toxic payloads, high expression levels, and efficient internalization 
often result in IC50 values well below the antibody Kd, indicating they are toxic at subsaturating 
concentrations (148,190). To demonstrate that heterogeneity is having an impact on efficacy, the 
same payload must be delivered with varying heterogeneity to isolate and quantify the influence 
of heterogeneity on efficacy. One set of data available for this analysis are studies manipulating 
the DAR and dose. For example, an antibody with half the DAR but twice the antibody dose will 
deliver approximately the same small molecule payload to the tumor but spread out over twice 
the number of cells (assuming the plasma clearance and/or deconjugation of different DAR 
ADCs are similar). Several studies were identified that fit these criteria. 
 
In the study by Hamblett et al. the effects of differing DAR and ADC dose to tumor 
killing was examined (28). When keeping the overall small molecule dosage the same (e.g. 
antibodies with a DAR of 2, and 4 dosed at 1, and 0.5 mg/kg, respectively), they found the best 
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clinical response with the highest antibody dose, or the dosage that would penetrate into the 
tumor the farthest. Similarly, Junutula et al. examined the efficacy of ADCs with DARs of 1.6 
and 3.1 (19) and found the same pattern. They also showed that for the same antibody dose (but 
different DAR) the outcome was not significantly different, despite having different small 
molecule exposure. (Simulations show that this would deliver more small molecule to cells that 
are already receiving a toxic dose.) In another study with a different ADC and target Junutula 
and colleagues again showed that when keeping the small molecule dose the same, a 
significantly better outcome was seen with higher antibody doses (197). Jackson et al. did not 
find a difference in efficacy between DAR2 and DAR3.8 when the antibody dose was the same 
(which would reach the same number of cells) but observed much higher efficacy when the same 
small molecule dose was delivered with a higher antibody dose (190). A recent study by Pillow 
et al. (198) examined the efficacy of different DARs of THIOMAB conjugates, and they found 
that DAR2 conjugates dosed at 10 mg/kg were more efficacious than DAR4 conjugates dosed at 
5mg/kg. In other words, having higher drug loading per antibody did not improve efficacy, and 
correspondingly, when injecting the same dose of small molecule, the drug spread out over more 
antibodies is more efficacious. In contrast to these other 6 examples (blue arrows, Figure 5.14), 
Goldenberg et al. found that with a low potency payload, a high DAR was needed. 
 
To summarize the above results, we identified 6 publications with data suitable for 
analysis (19,28,190,197–199). Intriguingly, 5 of the 6 results showed higher efficacy with a 
lower DAR, where the same small molecule drug delivered with a larger antibody dose (due to 
lower DAR) resulted in reduced tumor growth (Figure 5.14). Most of the cell lines used in these 
studies were also resistant to the free antibody therapy, indicating the higher antibody dose alone 
 111 
is not responsible for the effect. Upon closer inspection, the sole exception (Goldenberg et al. 
(199)) used a lower potency drug (SN-38 versus maytansinoids) with moderately lower 
expression (~105 receptors/cell versus ~106). Notably, the IC50 values for this ADC (range 1-33 
nM, median 2 nM) were higher than the Kd of the antibody (0.564 nM). This is also consistent 
with the "overkill” hypothesis, where agents that require saturation for cell killing would not 
significantly benefit from a more even distribution, as this lowers the efficacy of all targeted 
cells. From a tissue penetration standpoint, matching the IC50 to the Kd of the ADC by lowering 
the DAR would be ideal. If the small molecule drug is dose-limiting, this maximizes the 
antibody dose to achieve maximum penetration while maintaining a toxic dose for the targeted 
cells. This also maximizes other mechanisms of action, such as cell-signaling disruption (200) 
and Fc-effector functions (201) compared to other strategies for increased penetration (such as 
lower affinity (54,202,203)). The model described here can help design experiments to determine 
if this strategy is effective in preclinical models. 
 
DAR-dependent clearance and/or DAR-dependent deconjugation that significantly 
lowered the payload AUC/delivery could potentially explain the higher efficacy of lower DAR 
molecules. To quantify any impact of DAR-dependent clearance or DAR-dependent 
deconjugation, we modeled the small molecule exposure for each case. Pharmacokinetic 
measurements from each study were used to estimate the small molecule exposure (small 
molecule AUC). Since a detailed study of deconjugation or DAR-dependent clearance was not 
performed in all cases, we combined data from related studies to model the impact on small 
molecule AUC from deconjugation (unless data were presented showing deconjugation was 
negligible) or DAR-dependent clearance. The studies in Figure 5.14 had a small difference in 
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small molecule AUC (<25% and in most cases, <10%) relative to the large difference in 
antibody exposure (~100% or greater). On the contrary, the results in 6B showed a much larger 
difference in small molecule AUC (200-300%) relative to antibody exposure. Compared to the 
Lyon et al. paper, the studies in Figure 5.14 showed a larger difference in tumor efficacy despite 
drastically lower differences in payload AUC, indicating systemic clearance is unlikely to 
explain the differences in efficacy in Figure 5.14. It is also worth noting that the Goldenberg et 
al. paper shows the exact opposite trend that one would expect if DAR-dependent clearance or 
deconjugation were playing a role but is consistent with a potency-limited (versus a distribution-
limited) ADC. 
 
This analysis is not proof that antibody penetration is the only element (or even a 
dominant factor) in determining efficacy. For example, the relative contribution between more 
efficient small molecule distribution versus higher tumor antibody levels is unknown, although 
most cell lines were resistant to unconjugated antibody. However, the lack of quantitative models 
in the literature between DAR-dependent clearance/deconjugation versus tumor tissue 
heterogeneity makes it difficult to draw strong conclusions about the relative contributions of 
these phenomena. Clearly, DAR-dependent clearance and deconjugation are important, both for 
tumor exposure and potential toxicity. Lyon et al. showed ADCs having the same DAR but 
different clearance rates have proven the importance of plasma clearance on efficacy (24). While 
not proof, these 6 papers are consistent with heterogeneity impacting efficacy. The effect of 
individual tumor cell death on the eradication of the tumor is complex (149,150,204). The model 
developed here, by accounting for both systemic factors (like plasma clearance and linker 
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stability) and tumor tissue heterogeneity, will be able to quantitatively examine the impact of 
both to design more efficient clinical agents.  
 
Besides ADC distribution, the PBPK model can help track secondary tissue toxicity. 
Because ADCs have higher toxicity caused by the small molecule drug, it is important to track 
their accumulation in healthy tissue. For example, trastuzumab and T-DM1 are both known to 
exhibit some cardiac toxicity because of low HER2 expression in the heart (205). By increasing 
the trastuzumab carrier dose in these simulations the overall cardiac uptake of the ADC is 
lowered. In this case both the antibody and ADC show toxicity but for other possible targets, co-
dosing with the unconjugated antibody could result in less overall toxicity to healthy tissue. 
Similarly, Boswell et al. showed that the intestines were acting as an antigen sink when dosing 
the ADC anti-TENB2-MMAE; however, co-administration of an anti-TENB2 antibody with the 
anti-TENB2-MMAE ADC significantly reduced ADC uptake in the intestines (206). These 
approaches are analogous to ‘cold’ dosing prior to radiolabeled antibody distribution (207). 
Although some unconjugated antibodies in the clinic are given at high doses, such as 
bevacizumab (15 mg/kg) or IVIG (multiple grams per kg), it is important to consider that co-
administration of the naked antibody at 3 to 8 times the ADC dose could reach dose-limiting 
toxicities in the clinic. However, antibodies such as trastuzumab are well-tolerated even when 
delivering 18 mg/kg over a 3 week period (49). 
 
There are a couple important model limitations. First, the pharmacodynamics of the 
therapeutic can affect the pharmacokinetics of delivery in the tumor. This coupling of PK and PD 
makes simulations of efficacy very challenging. For example, it has been reported that 
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trastuzumab may result in vascular normalization (149), which can increase the functional 
vascular density in the tumor and lower the permeability of the vessels by making them less 
‘leaky.’ Increasing the vascular density would result in a smaller Krogh cylinder radius in the 
model resulting in less carrier antibody needed for saturation. Since antibodies are 
extravasation/permeability limited, a decrease in the membrane permeability would result in less 
antibody extravasating out of the vessel (150). Additionally, vascular collapse and/or 
revascularization of areas (particularly during the 3 weeks between clinical treatment with T-
DM1, for example) are difficult to predict. The second limitation is the impact of bystander 
effects. For T-DM1, the more hydrophilic nature of the metabolite results in few bystander 
effects (relative to more lipophilic conjugates that can diffuse out of the original targeted cell 
(25) or from the interstitium (208) and into a local cell (13)). Cytosolic access of hydrophilic 
metabolites may even require transporters within the target cell for toxicity (209). Bystander 
effects from more lipophilic payloads such as MMAE may explain why higher DAR can 
improve efficacy with the same antibody dose (e.g. (210)), while in the examples above with a 
hydrophilic payload, it had little benefit. The diffusion of the metabolite in the tissue could be 
incorporated into this model to predict the additional penetration of the metabolite into tumor 
tissue as a function of lipophilicity (81) and whether this reaches therapeutic concentrations far 
from the original site of antibody degradation. Finally, a recent study by Müller et al. showed 
that effector functions of T-DM1 (and not trastuzumab) could activate the immune system, 
where T-DM1 increased tumor vulnerability to immune attack (211). Modeling these complex 
immune interactions is difficult, but the simulations can help design experiments to test the 
overall impact on efficacy.  
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5.6 Conclusion 
In conclusion, the multi-scale PBPK-Krogh cylinder model is able to track both the 
systemic and tissue scale distributions of antibodies and ADCs. We show that at clinical doses T-
DM1 exhibits a heterogeneous perivascular distribution and through co-administration of 
trastuzumab the effective DAR is lowered and a homogeneous distribution is achieved. 
Modeling both the systemic and tissue level distribution can provide a facile method to facilitate 
ADC development by quantitatively combining complex factors such as target, linker stability, 
DAR, small molecule, and antibody backbone and their impact on efficacy.   
 
5.7 Experimental Methods 
In Vivo Experimental Work 
T-DM1 and trastuzumab were obtained through the University of Michigan Pharmacy. 
Alexa Fluor 680 (AF680) was conjugated to T-DM1 following the manufacturer's instructions 
and as previously described (113). For reactions, a molar ratio of 0.7 was used that resulted in an 
overall degree of labeling of 0.3 to mitigate any potential physicochemical effects from the dye 
on the antibody. Conjugates were run on SDS-PAGE and scanned on an Odyssey CLx NIR 
scanner to ensure free dye was removed. 
 
Animal studies were approved and conducted in accordance with University of Michigan 
University Committee on Use and Care of Animals (UCUCA). NCI-N87 cells were obtained 
from ATCC and were grown in RPMI-1640 containing 10 % (v/v) FBS, 50 U/ml penicillin, and 
50 µg/ml streptomycin. Tumor xenograft studies consisted of 5x106 NCI-N87 cells inoculated in 
the rear flanks of nude mice. Tail vein injections were done approximately 4 weeks after 
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inoculation when the longest axis of the tumor was approximately 10-12mm. Tail vein injections 
consisted of 3.6 mg/kg of T-DM1-AF680 and either 0, 10.8, or 28.8 mg/kg of unlabeled 
trastuzumab.  
 
Plasma clearance was measured via retroorbital sampling, mixed with 15 µL of 10mM 
EDTA in PBS per 10 µL of whole blood, centrifuged (1 min, 3000xg), and scanned in a 384 well 
plate with the Odyssey CLx. Signal intensity was converted to absolute concentration using 
calibration curves of known concentrations of each agent in plasma and fit using a biexponential 
decay in PRISM. Animals were euthanized after 24 hours (the time of maximum tumor uptake, 
data not shown and (36)) for biodistribution and histology measurements. 
 
The biodistribution protocol was adapted from previously published protocols (53,122). 
Briefly, after the animals were euthanized, organs were resected, weighed, and homogenized. 
Homogenization consisted of incubating with a RIPA buffer/PBS mixture supplemented with 
6mg/mL collagenase IV solution, cell disruption using FB-120 Sonic Dismembrator, and further 
incubation with a RIPA buffer/0.05% trypsin-EDTA solution. After homogenization, each organ 
was serially diluted in a 96 well plate and scanned using the Odyssey CLx scanner. The percent-
injected dose per gram (%ID/g) was determined by comparing signal from the Odyssey CLx 
scanner to a calibration curve and then normalizing by organ weight and homogenate volume. A 
density of 1g/mL was assumed for each tissue. 
 
To quantify the tumor distribution of the antibodies, nude mice bearing NCI-N87 
xenografts were euthanized 24 hours after tail vein injection of antibody, and the tumors were 
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resected and flash frozen in OCT using isopentane chilled on dry ice. Histology slices (16 
micron) were imaged with an upright Olympus FV1200 confocal microscope using 405, 542, 
and 635 lasers, and a 20x objective. Sixteen micron sections were used relative to the more 
typical 5 micron slices to improve signal-to-noise from the NIR fluorescence imaging.  High-
resolution images of organs were obtained using a series of stitched smaller images and the 
Olympus software. Immunofluorescence staining was done using CD31 conjugated with Alexa 
Fluor 555. All confocal images were exported and analyzed using ImageJ image analysis 
software. 
 
PBPK Model 
For this study, the PBPK model was adapted from Ferl et al. (60). A graphical depiction 
of the model is shown in Figure 5.1. Changes from this previously published and validated 
model were as follows. Heart and lung compartments were added and follow the general 
structure of the other organ compartments. Physiologic parameters for the heart and lung were 
taken from Baxter et al. (155). The PBPK tumor compartment was removed and instead 
represented using a distributed parameter model with Krogh cylinder geometry (described 
below). Each organ compartment was divided into vascular, interstitial, and metabolite 
subcompartments, and the carcass contained an endothelial subcompartment for FcRn kinetics 
(Figure 5.1). All parameter values can be found in Appendix B and model equations can found in 
Appendix C. Other changes from the original PBPK model include changing the permeability 
surface area product for large and small pores to values for intact IgG. The model was 
constructed for both unconjugated antibodies and ADCs to simulate the distribution of each 
individually.  
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Robust predictions of the whole animal distribution of biologics are not yet possible, so 
several agent specific parameters not found in the literature were fit to experimental data using 
Matlab as shown in Table 1. These parameters are the degradation rates for the liver (kdeg,liver), 
degradation rate in all other organs (kdeg,organ), the metabolite urinary excretion rate (U) and 
metabolite loss rate (kloss). Percent coefficient of variation (%CV) values and 95% confidence 
intervals (95% C.I.) for these fitted parameters are listed in Table 5.1.  
 
Tissue Disposition Model 
A tissue distribution model based on previously published work (43,81,90) was 
incorporated into the PBPK model (Figure 5.1). This modeling approach has been validated for 
the tissue distribution of antibodies and ADCs by our group and others (43,90,176,177,179). 
Briefly, this model is based on the Krogh cylinder geometry of tumor blood vessels. Because 
antibodies are permeability limited, a one-dimensional model with only radial gradients was 
used. The model consisted of free antibody, free ADC, free target, bound antibody, bound ADC, 
internalized antibody, and internalized ADC. Detailed equations and parameter values can be 
found Appendix B and C, and Table 5.2, but briefly, trastuzumab and T-DM1 extravasate from a 
blood vessel and are free to diffuse and bind to HER2 receptor in the tissue, upon which they are 
internalized and degraded. These molecules compete for the same pool of HER2, and after 
internalization, HER2 recycles back to the cell surface, consistent with experimental studies 
(124). The tissue disposition model is connected to the PBPK model by the entering and exiting 
plasma concentrations adjusted by the efflux into the tumor to capture any target-mediated drug 
disposition effects (212–214). Importantly, all parameters in the Krogh cylinder were taken from 
the literature and were not changed or fit to data.   
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Chapter 6      
Improved Tumor Penetration and Single-Cell Targeting of Antibody Drug Conjugates 
Increases Anticancer Efficacy and Host Survival 
 
6.1 Publication Information 
Cilliers, C., B. Menezes, I. Nessler, J. Linderman, and G. M. Thurber. Improved Tumor 
Penetration and Single-Cell Targeting of Antibody Drug Conjugates Increases Anticancer 
Efficacy and Host Survival. Cancer Research. 2018; 78(3): 758-68. 
 
Modifications have been made to the published document to adapt the content to this text. 
The previous chapter outlined a dosing strategy of coadministering trastuzumab with a constant 
dose of T-DM1 to improve T-DM1 tumor penetration. In this chapter, the dosing strategy is 
tested in vivo and, for the first time, is shown to result in significantly improved efficacy in a 
trastuzumab resistant mouse model. 
  
6.2 Abstract 
Current antibody-drug conjugates (ADC) have made advances in engineering the 
antibody, linker, conjugation site, small molecule payload and drug-to-antibody ratio (DAR). 
However, the relationship between heterogeneous intratumoral distribution and efficacy of ADC 
is poorly understood. Here we compared trastuzumab and ado-trastuzumab emtansine (T-DM1) 
to study the impact of ADC tumor distribution on efficacy. In a mouse xenograft model 
insensitive to trastuzumab, co-administration of trastuzumab with a fixed dose of T-DM1 at 3:1 
and 8:1 ratios dramatically improved ADC tumor penetration and resulted in twice the 
improvement in median survival compared to T-DM1 alone. In this setting, the effective DAR 
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was lowered, decreasing the amount of payload delivered to each targeted cell but increasing the 
number of cells that received payload. This result is counterintuitive because trastuzumab acts as 
an antagonist in vitro and has no single-agent efficacy in vivo, yet improves the effectiveness of 
T-DM1 in vivo. Novel dual-channel fluorescence ratios quantified single-cell ADC uptake and 
metabolism and confirmed that the in vivo cellular dose of T-DM1 alone exceeded the minimum 
required for efficacy in this model. Additionally, this technique characterized cellular 
pharmacokinetics with heterogeneous delivery after one day, degradation and payload release by 
two days, and in vitro cell killing and in vivo tumor shrinkage 2-3 days later. This work 
demonstrates that the intratumoral distribution of ADC - independent of payload dose or plasma 
clearance - plays a major role in ADC efficacy. 
 
6.3 Background 
Antibodies and antibody-drug conjugates (ADCs) make up the largest portion of the 
growing biologics market. Currently, there are over 50 FDA approved antibodies, and nearly 500 
in the various stages of the clinical pipeline (91). Although there are currently over 70 ADCs in 
the clinical pipeline (50,215) only four, Adcetris, Besponsa, Mylotarg, and Kadcyla (T-DM1), 
are currently approved by the FDA. While these ADCs have had clinical success, the factorial 
optimization of the antibody, linker, conjugation site, small molecule payload, drug loading, and 
target selection make development of each ADC a unique challenge. Although there have been 
advances in engineering the biophysical characteristics to improve safety, stability, and develop 
more homogeneous products, ADCs continue to be limited by toxicity, which is typically driven 
by the toxicity of the small molecule payload (19,47). In particular, several of the recent ADC 
failures may have been prevented by marginal gains in tolerability (215).  
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It is widely known that antibodies/ADCs exhibit heterogeneous distribution in solid 
tumors (36,37,41,54,81,178); however, it is not well understood how the heterogeneous tissue 
distribution of ADCs impacts their overall efficacy. ADC efficacy requires a multi-step process, 
which includes the distribution of intact ADC in the tumor, cellular uptake and degradation of 
the antibody, release of the small molecule payload, induction of apoptosis by the cytotoxin, and 
potentially bystander effects on neighboring cells (25,216,217). Therefore, there is a need to 
understand the ADC’s effects from the subcellular scale (e.g. how many ADCs are required to 
achieve cell death in vivo) to the tissue level (e.g. how many cells in the tumor are receiving a 
therapeutic dose) to whole organ biodistribution (e.g. what is the healthy tissue exposure and 
resulting toxicity) in order to develop effective therapeutics.  
 
Previously we developed a combined tissue and physiologically-based pharmacokinetic 
(PBPK) model to describe both the tumor and systemic distribution of T-DM1 (106). We found 
that co-administration of trastuzumab with T-DM1 (trastuzumab linked to the payload DM1, 
which therefore competes for the same binding epitope of HER2) dramatically improved tumor 
penetration, but total tumor uptake of ADC was unchanged. Co-administration of trastuzumab 
with T-DM1 lowers the effective drug to antibody ratio (DAR) while competing with T-DM1 for 
HER2 receptors and driving penetration deeper into the tissue. The higher the trastuzumab dose, 
the farther the ADC will penetrate into the tumor; however, the average DM1 payload 
concentration in each targeted cell will be lower. Several studies in the literature demonstrate 
that cohorts of mice treated with ADCs having different DAR but the same overall payload dose 
(i.e. DAR2 given at 2 mg/kg vs. DAR4 given at 1 mg/kg) had better outcomes with the lower 
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DAR (and therefore higher antibody dose which correlates with better tumor penetration) (106). 
These results are consistent with tumor penetration playing a major role in efficacy independent 
of the target antigen, antibody, linker, payload, or bystander effects. However, these were not 
prospective studies, and although certain mechanisms, such as DAR-dependent clearance, did 
not appear to play a role in the analysis, they could have affected the data interpretation. 
Therefore, we wanted to design an experimental study to isolate the impact of distribution on 
efficacy. 
 
Here, we demonstrate that co-administration of trastuzumab with T-DM1 improves 
efficacy (tumor growth reduction and overall survival as measured by tumor volume endpoint) in 
a trastuzumab-insensitive mouse xenograft model. Against trastuzumab-insensitive cell lines the 
addition of trastuzumab was antagonistic in vitro (i.e. lowered efficacy by blocking T-DM1 
uptake), as expected. Counterintuitively, co-administration of trastuzumab (which acts as an 
antagonist in vitro and has no single-agent efficacy in this animal model in vivo) with T-DM1 
showed a significant improvement in efficacy in a mouse xenograft model despite the same small 
molecule dose and tumor uptake as T-DM1 alone. In fact, the combination of trastuzumab, 
which had no single agent efficacy, and T-DM1 was synergistic, meaning the net improvement 
was greater than additive (since trastuzumab alone had no impact on efficacy in the absence of 
T-DM1). Histological imaging showed a significant increase in T-DM1 tumor penetration with 
the co-administered trastuzumab. Additionally, we present a novel near-infrared (NIR) 
fluorescence ratio technique with dually labeled ADCs to track the metabolism and distribution 
of ADCs at the single-cell level. Applying this technique to single agent T-DM1 therapy showed 
the delivery of ADC to cells within the targeted population in vivo was higher than the threshold 
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required for cell death, while the majority of tumor cells did not receive any ADC. These results 
demonstrate that the intratumoral distribution of ADCs in tumor tissue plays a major role in 
determining their efficacy independent of the amount of total tumor payload delivered. To our 
knowledge, this is the first time that the distribution itself, independent of the other parameters 
that affect efficacy and tumor penetration such as dose, plasma clearance, and molecular weight, 
significantly impacted survival. 
 
6.4 Results 
Co-Administration of Trastuzumab with T-DM1 Improves T-DM1 Tumor Penetration 
ADC tumor distribution is dependent on many parameters including dose, DAR, systemic 
clearance, antigen expression and internalization rate in tumor (and healthy tissue), and the 
surface to volume (S/V) ratio of the vasculature. The clinical dose of T-DM1-AF680 (3.6 mg/kg) 
shows a heterogeneous, perivascular distribution in NCI-N87 tumor xenografts (Figure 6.1, 
Figure 6.2) consistent with high affinity antibodies that target highly expressed receptors and are 
dosed at subsaturating levels (41,202,218). Co-administration of unlabeled trastuzumab at 10.8 
or 28.8 mg/kg (3:1 or 8:1, respectively) dramatically increases tumor penetration of a constant T-
DM1 dose (Figure 6.1), allowing more cells to receive the cytotoxic payload. However, adding 
trastuzumab lowers the effective DAR, increasing the number of targeted cells while reducing 
the average number of payload molecules delivered per cell. Immunofluorescence staining with 
antihuman IgG Fc-488 shows antibody distribution is more homogeneous with increasing doses 
of trastuzumab (Figure 6.1). Similarly, increasing the dose of T-DM1 alone also improved tumor 
penetration (Figure 6.3), but this exceeds the maximum tolerated dose in humans. HER2 was 
stained ex vivo with trastuzumab-AF750 to ensure the heterogeneous distribution is not from 
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lack of available antigen (Figure 6.4). T-DM1 binding affinity was unchanged by fluorophore 
conjugation (Figure 6.5). 
 
 
Figure 6.1 Improving T-DM1 tumor distribution through co-administration of 
trastuzumab.  
Administration of T-DM1 at 3.6 mg/kg (single agent) results in a heterogeneous, perivascular 
distribution due to rapid binding relative to transport in the tissue (A). The tumor penetration of a 
constant dose of T-DM1 is improved when co-administered with a subsaturating (B) or 
saturating (C) dose of trastuzumab.  Trastuzumab competes for binding sites, increasing T-DM1 
penetration. The middle column shows distribution of AF680-labeled T-DM1 (green) at 3.6 
mg/kg with unlabeled trastuzumab at 0:1, 3:1, and 8:1 trastuzumab:T-DM1 ratios (0, 10.8, and 
28.8 mg/kg, respectively). Immunofluorescence staining with CD31-AF488 (red) shows the 
tumor vasculature. The right column shows immunofluorescence staining with antihuman IgG 
Fc-AF555 (gray). The window leveling between images is different since the intensity of the T-
DM1 decreases with an increasing ratio while the anti-Fc staining labels both trastuzumab and T-
DM1 thereby maintaining a constant intensity while the penetration increases (see Figure 6.2). 
Scale bar is 200 µm. 
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Figure 6.2 Improving T-DM1 tumor distribution through co-administration of 
trastuzumab. 
 Similar to Figure 6.1, administration of T-DM1 at 3.6 mg/kg (single agent) results in a 
heterogeneous, perivascular distribution due to rapid binding relative to transport in the tissue 
(top row). T-DM1 distribution is improved when co-administered with a subsaturating (middle 
row) or saturating (bottom row) dose of trastuzumab. The left and middle column shows 
distribution of AF680 labeled T-DM1 (green) at 3.6 mg/kg with unlabeled trastuzumab at 0:1, 
3:1, and 8:1 trastuzumab:T-DM1 ratios (0, 10.8, and 28.8 mg/kg, respectively). Microscope 
settings and window leveling are identical for the top row, middle row, and bottom row images 
in the middle column to show differences in intensity (less ADC per targeted cell), while the 
images of the top, middle, and bottom rows of the left column are window leveled to highlight 
the better tumor penetration of ADC. Immunofluorescence staining with CD31-AF488 (red) 
shows the tumor vasculature. The right column shows immunofluorescence staining with 
antihuman IgG Fc-AF555 (gray). All tumors were resected 24 hours after injection. Scale bar is 
200 µm. 
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Figure 6.3 Immunofluorescence histology of T-DM1-800 (green) dosed at 14.4 mg/kg (same 
total antibody dose as 3:1 trastuzumab:T-DM1 ratio).  
Hoechst 33342 (blue) was injected prior to sacrifice to stain functional vasculature as outlined in 
Materials and Methods. CD31-555 (red) and trastuzumab-AF488 (cyan) were stained ex vivo. 
Trastuzumab only binds free receptors in regions not targeted by T-DM1 at this time point. 
Similar to increasing the dose of trastuzumab, tumor penetration is improved with higher doses 
of single agent T-DM1. Although tumor penetration is improved with higher ADC doses, ADC 
toxicity limits the maximum tolerated dose. Top left, all stains; top right, T-DM1 (green), 
Hoecsht 33342 (blue), and CD31 (red); bottom left, free HER2 antigen (trastuzumab ex vivo, 
cyan); bottom right, Hoechst and CD31.  Scale bar is 200 µm.  
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Figure 6.4 Immunofluorescence histology of HER2 antigen.  
Slices were stained with trastuzumab-AF750 to ensure the perivascular distribution of T-DM1-
AF680 was not from a lack of available antigen farther from the vessels. The left column shows 
a merge of T-DM1-680 (green), trastuzumab-750 (cyan), and CD31-555 (red). The middle and 
right columns show unmerged images of trastuzumab-750 and T-DM1-680 with CD31, 
respectively. Tras, trastuzumab; G, green; C, cyan; R, red.  
 
 
 
Figure 6.5 T-DM1 dye conjugate binding affinity.  
Conjugation of fluorophores to T-DM1 at a dye-to-protein ratio of 0.3 or less did not affect T-
DM1 binding affinity. Binding affinity was performed as previously described (93,137). Briefly, 
concentrations of unlabeled antibody and antibody−dye conjugates were incubated with 50,000 
HCC1954 cells on ice for 3 hours and washed with PBS. After the primary incubation, cells were 
further incubated with antihuman IgG Fc-AlexaFluor488 at 40 nM for 30 minutes on ice, then 
washed with PBS, and subsequently analyzed on an Attune Focusing Cytometer (Applied 
Biosystems). Kd was calculated using PRISM and is reported as Kd ± standard error. DL, dual-
label (both IRDye and DDAO); 680, AlexaFluor680. 
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T-DM1 is Effective In Vitro When Occupying Only a Fraction of HER2 Receptors Even Under 
Saturating Antibody Conditions 
The increasing doses of trastuzumab improve T-DM1 penetration into tumor tissue but 
lower the DM1 payload delivery by competing with HER2 receptors. To determine if the lower 
payload delivery was still sufficient to kill cells in vitro, we measured efficacy with T-DM1 
alone or a saturating combination of total antibody (T-DM1 + trastuzumab) while varying the T-
DM1 to trastuzumab ratio. Toxicity assays with trastuzumab alone showed only slight growth 
inhibition at the highest concentrations (Figure 6.6), consistent with literature reports that the 
NCI-N87 cell line is sensitive to T-DM1, while trastuzumab has a slight growth inhibitory effect 
in vitro (219). We measured the toxicity of T-DM1 in vitro with the NCI-N87 and HCC1954 cell 
lines and we found IC50 values of 82 and 33 pM for NCI-N87 and HCC1954 (Figure 6.7), 
respectively, consistent with other reports (148,190). Next, we performed toxicity assays with 
fluorescently tagged T-DM1-AF680 and examined cellular uptake of T-DM1 by flow cytometry. 
The IC50 for each cell line was much less than the concentration needed for half of the 
normalized uptake, indicating that complete surface receptor saturation is not needed for T-DM1 
cytotoxicity in vitro. Additionally, we found that fluorophore conjugation had no impact on T-
DM1 cytotoxicity in vitro (Figure 6.8). The maximum cellular uptake occurred at concentrations 
below the Kd (1.8 nM (137)), indicating treatment likely impacts uptake over this time scale. To 
mimic the effect of co-administering trastuzumab in vivo, we performed toxicity assays where 
the T-DM1 concentration was varied, but the total antibody concentration was kept constant at 
10 nM (saturating) to see how competition for receptors would affect toxicity (Figure 6.7). T-
DM1 still showed toxicity below the antibody Kd against both cells lines with the addition of 
trastuzumab, although the IC50 was higher likely due to competition from the trastuzumab. 
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Using a simple competitive inhibition binding model, we found that T-DM1 cytotoxicity was 
similar when adjusting for the fraction of receptors bound by T-DM1 (Figure 6.9). Additionally, 
a similar number of molecules of T-DM1 were required to achieve 50% cell death in both cases 
(Figure 6.10). Because trastuzumab increases the penetration (while lowering the single-cell 
delivery) of T-DM1 and T-DM1 remains toxic at sub-saturating conditions, we tested the 
efficacy of this combination in a trastuzumab-insensitive mouse xenograft model. 
 
 
Figure 6.6 In vitro toxicity of trastuzumab alone.  
NCI-N87 and HCC1954 cells were incubated with trastuzumab titrations over 6 days. Consistent 
with literature reports that these cell lines are resistant to trastuzumab, both cell lines showed 
only limited growth inhibition at the highest concentrations.  
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Figure 6.7 In Vitro Cytotoxicity.  
(A, B) in vitro cytotoxicity of T-DM1 against NCI-N87 (A) and HCC1954 (B) cell lines. Assays 
were performed in triplicate and average IC50’s were 82 ± 10 pM and 33 ± 20 pM for NCI-N87 
and HCC1954 cell lines, respectively. The number of DM1 molecules per cell (gray) was 
estimated by measuring T-DM1-680 uptake with flow cytometry and quantitative beads. (C, D) 
in vitro cytotoxicity varying the T-DM1 concentration, while keeping total antibody 
concentration (T-DM1 + trastuzumab) constant at 10 nM. Cells were incubated with T-DM1 
and/or trastuzumab in media for 6 days and media was replaced daily for all in vitro cytotoxicity 
assays. Data plotted as mean ± standard deviation.  
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Figure 6.8 Dye conjugation to T-DM1 does not affect in vitro cytotoxicity.  
Similar to Figure 6.7, NCI-N87 (left) and HCC1954 (right) cells were incubated with varying 
concentrations of T-DM1 or T-DM1 dye conjugates for six days, replacing the media daily. IC50 
and 95% confidence interval was estimated using PRISM and is reported below each plot. DL, 
dual-label (both IRDye and DDAO); 680, AlexaFluor680. 
 
 
 
Figure 6.9 NCI-N87 cell viability data fit with a competitive binding model.  
Using the affinity data from Figure 6.5 and our previous work with trastuzumab (137), we 
estimated the fraction bound of T-DM1 alone and T-DM1 with trastuzumab (Figure 6.7) using a 
simple competitive inhibition binding model. Although adding trastuzumab increased the IC50 in 
Figure 6.7, cell viability was similar when adjusting to the fraction of receptors bound by T-
DM1.  
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Figure 6.10 NCI-N87 cell uptake and viability.  
Similar to other cytotoxicity assays, NCI-N87 cells were incubated with varying concentrations 
of T-DM1-680 for six days. Viability was measured using the PrestoBlue assay (Materials and 
Methods) and then cells were analyzed by flow cytometry to determine AF680 fluorescence 
signal. Quantitative beads were used to convert fluorescence signal to absolute number of 
molecules (and adjusting for the drug antibody ratio (DAR) and fluorophore degree of labeling 
(DoL). In both the T-DM1 alone and T-DM1 plus trastuzumab (constant 10 nM total antibody) 
cases, approximately 3.5 million molecules of DM1 are needed to achieve 50% cell killing. This 
agrees with Figure 6.9, where cell killing is determined by the amount of internalized T-DM1 
and the amount of payload needed for cell death is not impacted by the presence or absence of 
trastuzumab.  
 
Addition of Trastuzumab (an In Vitro Antagonist) to T-DM1 Therapy Improves In Vivo Efficacy 
in a Trastuzumab Resistant Xenograft Model 
To examine the impact of ADC tumor distribution on efficacy, we administered a fixed 
dose (3.6 mg/kg) of T-DM1 with varying ratios of trastuzumab in an NCI-N87 tumor xenograft 
mouse model. Non-fluorescently labeled (clinical) T-DM1 and trastuzumab were used for in 
vivo efficacy studies. We selected the NCI-N87 cell line because a) it was less sensitive than the 
HCC1954 cell line to T-DM1 in vitro (Figure 6.7) and in vivo (190) providing more room to 
detect improvements in efficacy, and b) other groups have shown that at moderate doses, like the 
ones used in this study, trastuzumab treatment did not significantly alter tumor growth from 
control (219,220). Trastuzumab treatment results in modest (but statistically significant) growth 
inhibition at higher dosages (>60 mg/kg total dose) but does not result in tumor reduction even at 
highest doses of 280 mg/kg total dose over several weeks (220–222). Additionally, we chose to 
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use large established tumors that were 250 mm3 or greater. Others have shown antibody-
dependent cell-mediated cytotoxicity (ADCC) is reduced in larger established tumors, albeit with 
a different HER2 expressing cell line (223). Expectedly, the clinically approved T-DM1 therapy 
alone showed significant improvement over control (Figure 6.11). Although others have shown 
complete tumor regression using T-DM1 (148), the larger tumors and single administration 
prevented consistent cures. Addition of trastuzumab to T-DM1 resulted in slower tumor growth 
than T-DM1 alone for all dosage levels (Figure 6.11), with 3:1 and 8:1 (T:T-DM1) ratios having 
a statistically significant effect. The 3:1 and 8:1 dosing levels had several more partial responses 
and exhibited a statistically significant increase in survival with increasing trastuzumab doses 
(Figure 6.11).  Kaplan-Meier survival plots with 95% confidence intervals calculated by PRISM 
and individual tumor growth curves are shown in Figure 6.12 and Figure 6.13, respectively. 
Animals receiving trastuzumab only were similar to saline control demonstrating that 
trastuzumab has no direct effect on efficacy at these doses. Additionally, mice receiving 
treatment were weighed over the course of the study and showed comparable tolerability (Figure 
6.14), consistent with the payload and not the antibody dose driving toxicity. Since trastuzumab 
is tolerated at much higher doses than T-DM1 (49) and the same T-DM1 dose was given, all 
treatments were consistently well tolerated.  
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Figure 6.11 KEY FIGURE: Co-administration of trastuzumab with T-DM1 results in a 
significant reduction in tumor growth compared to T-DM1 alone.  
(A) Tumor growth curves for mice bearing NCI-N87 tumor xenografts following treatment with 
a single administration of saline, single-agent trastuzumab (10.8 mg/kg), single-agent T-DM1 
(3.6 mg/kg), or co-administration of trastuzumab and T-DM1 at 1:1, 3:1, and 8:1 dosage levels 
(T-DM1 constant at 3.6 mg/kg, trastuzumab varied at 3.6, 10.8, and 28.8 mg/kg). Non-
fluorescently labeled T-DM1 and trastuzumab were used for tumor growth experiments. Data 
plotted as mean ± standard error. The number of partial responses, complete responses, and 
durable complete responses is tabulated. (B) Kaplan-Meier survival curves of time to progression 
to 1000 mm3. Survival curves were analyzed by log-rank test (significance level of p ≤ 0.05). All 
treatments except single-agent trastuzumab resulted in statistically significant improvements in 
survival (p = 0.0442, 0.0021, 0.0006, 0.001 for 0:1, 1:1, 3:1, 8:1, respectively). The 3:1 and 8:1 
treatments significantly improved survival over the single-agent T-DM1 (p = 0.0486, 0.0484 for 
3:1 and 8:1, respectively). N = 10 for each treatment. T, trastuzumab; PR, partial response; CR, 
complete response; DCR, durable complete response. 
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Figure 6.12 Individual Kaplan-Meier curves with 95% confidence interval generated using 
PRISM software.  
 
 
 
 
 
Figure 6.13 Individual tumor growth curves for all animals.  
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Figure 6.14 Percent weight change during treatment.  
All treatments were well tolerated and no significant differences in mouse weight were 
encountered between treatments. 
 
Single-Cell T-DM1 Uptake and Metabolism In Vivo Highlights a Fraction of Cells with Higher 
Delivery than Needed for Cell Killing While Other Cells Receive Negligible T-DM1 
The fluorescence histology images (Figure 6.1) qualitatively show better penetration, but 
they cannot be used to quantify payload delivery. We utilized a novel NIR fluorescence ratio 
technique to determine the absolute uptake and payload delivery per cell in vivo. In particular, 
we applied the technique to single agent T-DM1 therapy to confirm that targeted tumor cells 
were receiving more payload than necessary to achieve cell death and the lack of tumor 
penetration was limiting efficacy in vivo. Figure 6.15 shows a graphic depiction of the technique. 
Two NIR fluorescent dyes, DDAO and IRDye, were chosen because of their widely differing 
residualization rates (113). The non-residualizing dye rapidly leaks out of the cell upon 
degradation, thereby approximating intact protein, while the residualizing dye is trapped in the 
cell, approximating cumulative ADC uptake. This approach is analogous to radiolabeling with 
125I as the non-residualizing probe and 111In as the residualizing probe (60).  
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To visualize the change in fluorescence ratio and validate the method in vitro, cells were 
imaged using a confocal microscope after pulsing with labeled ADC for 30 minutes at different 
times over 48 hours. Figure 6.15 shows separate and merged channels for DDAO (red) and 
IRDye (green) for dually labeled T-DM1. Initially, DDAO and IRDye are only seen on the 
surface. As ADC is internalized and degraded, however, the DDAO signal gradually decreases, 
while IRDye forms punctate spots in lysosomes. Figure 6.15 shows the fraction intact of T-DM1 
for HCC1954 (black) and NCI-N87 (grey) cell lines over time. Although both express the same 
antigen, the HCC1954 cell line degraded T-DM1 slightly faster than the NCI-N87 cell line. To 
quantify the kinetics of cell death following cell targeting, we measured the viability of both cell 
lines over six days (Figure 6.15). Consistent with the faster T-DM1 degradation of HCC1954 
cells and published link between intracellular payload concentration and toxicity (25), their 
viability decreased more quickly than NCI-N87 cells. We used flow cytometry to quantitatively 
measure the cellular signal for DDAO and IRDye over time at the single-cell level (Figure 6.15). 
Initially the ADC is intact and the cell population is positive for DDAO and IRDye. Over time 
there is a gradual shift to DDAO(-)/IRDye(+), indicating that the ADC is degraded and DDAO 
has washed out. 
 
After demonstrating the NIR fluorescence ratio technique in vitro, we applied the 
technique in vivo. Mice were injected via tail-vein with 100 µg (~4 mg/kg) of dually labeled T-
DM1 and euthanized at 24, 48, and 72 hours. Then tumors were resected and digested into a 
single cell suspension and analyzed by flow cytometry (Figure 6.16). Representative flow 
cytometry plots of single cell tumor digests are shown in Figure 6.16. 24 hours post injection, 
targeted cells (IRDye(+)) show mostly intact protein (DDAO(+)/IRDye(+)) because there is a 
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constant supply of intact ADC from the blood. However, by 48 and 72 hours there is a shift from 
DDAO(+)/IRDye(+) to DDAO(-)/IRDye(+) for the targeted cells, indicating that much of the 
surface bound ADC was internalized and degraded. Additionally, consistent with the tumor 
histology (Figure 6.1), only a small fraction of cells in the tumor (around 10% according to flow 
cytometry and consistent with histology and a ~10-fold higher dose for saturation) are targeted 
with ADC, despite administering the clinical dose. Because IRDye is a residualizing dye and 
approximates the cumulative uptake of ADC (113), we used quantitative beads to convert the 
IRDye signal from targeted cells into the number of ADCs per cell. Combining the number of 
ADCs targeted per cell with the percent intact, we estimated the number of DM1 payload 
molecules released in targeted cells (Figure 6.16). Consequently, the amount of DM1 released 
increased dramatically between 24 and 48 hours and started to plateau by 72 hours.  
 
In addition to single cell tumor metabolism from flow cytometry, the NIR fluorescence 
ratio technique was used to measure the biodistribution of ADC in the same animals (Figure 
6.16) to verify the normal systemic distribution of the antibodies. The reduced autofluorescence 
in the near infrared window makes IRDye an appropriate dye for biodistribution studies 
(53,107,137). We have previously shown that at a dye to protein ratio of 0.3 or less there is no 
impact on protein pharmacokinetics over the first 3-4 days (137). The plasma clearance of dually 
labeled trastuzumab was similar to trastuzumab-IRDye, indicating the addition of the DDAO 
fluorophore did not impact clearance (Figure 4.1). The biodistribution of dually labeled T-DM1 
shows primarily liver and tumor uptake and is similar to radiolabeling studies of trastuzumab, 
albeit with lower tumor uptake in this model (224). Consistent with the single cell flow 
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cytometry data, the maximum tumor uptake was reached 24 hours after injection and there was a 
gradual decrease at 48 and 72 hours (Figure 6.16).  
 
Figure 6.15 In vitro T-DM1 metabolism and pharmacodynamics.  
(A) A graphic depiction of the NIR fluorescence ratio technique. The dually labeled antibody 
binds the target, is internalized, and degraded. The non-residualizing DDAO (red star) leaks out 
of the cell, while the residualizing IRDye800CW (green star) is trapped within in the cell. (B) 
Representative confocal images of dually labeled T-DM1. DDAO (red) shows cell surface 
labeling with a loss of signal over time. IRDye (green) shows initial cell surface labeling 
followed by the formation of punctate spots as it is trapped in the lysosomes. Scale bar is 10 µm. 
(C) T-DM1 metabolism. Fraction of intact ADC following pulse of dually labeled T-DM1 for 
HCC1954 (black) and NCI-N87 (gray) cells. Data plotted as mean ± standard deviation. (D) 
Timing of T-DM1 pharmacodynamics. The fraction of viable cells over time for HCC1954 
(black) and NCI-N87 (gray) cells when treated with a constant 5 nM T-DM1. Non-fluorescently 
labeled (clinical) T-DM1 was used for this assay. Data plotted as mean ± standard deviation. (E) 
Representative flow cytometry plots of dually labeled T-DM1 gated on cells. Intact dually 
labeled T-DM1 appears in DDAO(+)/IRDye(+) quadrant. Over time as ADC is degraded there is 
a gradual shift towards DDAO(-)/IRDye(+).  
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Figure 6.16 In vivo T-DM1 metabolism in tumor.  
(A) Representative flow cytometry plots of single cell suspension from NCI-N87 tumors at 24, 
48, and 72 hours post-injection of 3.6 mg/kg of dually labeled T-DM1. Intact dually labeled T-
DM1 appears in DDAO(+)/IRDye(+) quadrant. Over time as ADC is degraded there is a gradual 
shift towards DDAO(-)/IRDye(+). Cells targeted with T-DM1 (IRDye+) were used to calculate 
percent intact as described in Materials and Methods. (B) T-DM1 degradation in tumor cells. The 
fraction of intact ADC (for the fraction of cells that are targeted by T-DM1 at this dose). Data 
plotted as mean ± standard deviation. (C) Molecules of DM1 payload released per target cell in 
vivo for the targeted cells calculated using the total cell uptake and fraction intact. Data plotted as 
mean ± standard deviation. (D) T-DM1 biodistribution. T-DM1 shows maximum uptake 24 
hours post injection  
 
Untargeted Tumor Cells Can Sustain Tumor Growth Through Newly Functional Tumor Vessels 
To better understand the relationship between the heterogeneous T-DM1 distribution and 
efficacy, we imaged the distribution of T-DM1 and trastuzumab at maximum uptake and during 
treatment. The NIR fluorescence ratio technique showed that the maximum uptake was reached 
24 hours post injection and payload release appeared to plateau around 3 days. From the tumor 
growth curves it appeared that the maximum shrinkage was occurring several days after payload 
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release, around 5 days after initial injection for T-DM1. Once tumor cells are killed, they are no 
longer able to internalize and degrade the drug, potentially allowing ADCs to penetrate deeper 
into the tissue. However, the tumor distribution of T-DM1-680 and trastuzumab-680 (3.6 mg/kg) 
at one and five days post-injection remained heterogeneous and perivascular with a significant 
fraction of the tumor untargeted (Figure 6.17). 15 minutes prior to sacrifice we injected Hoechst 
33342 to stain functional tumor vasculature and then stained histology slices with antimouse 
CD31 ex vivo to show all (functional and nonfunctional) vasculature. Using an automated image 
analysis algorithm, we calculated the absolute vessel surface area to tumor volume ratio (S/V) 
along with the fraction of these vessels that had Hoechst and/or T-DM1 signal around them 
(Figure 6.17). 24 hours after injection, T-DM1 distribution was localized to functional vessels 
(Figure 6.17, arrows). By five days after injection there were several regions of the tumor that 
had functional vessels but no perivascular ADC (Figure 6.17, arrowheads), and the image 
analysis indicated a significant increase (Student’s t test, p < 0.0001) in the fraction of functional 
vessels (Hoechst and CD31) lacking ADC, consistent with angiogenesis and/or opening of 
collapsed vessels. Collapsed vessels (CD31 vessels stained with ADC but not Hoechst, 
indicating they are no longer functional) were also present. These phenomena were present in 
both T-DM1 and trastuzumab treated tumors, indicating that they are not necessarily a result of 
T-DM1 efficacy. However, the formation of newly functional vessels in regions untargeted by T-
DM1 could play a role in rescuing the tumor, further supporting the importance of ADC 
distribution on efficacy. 
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Figure 6.17 Immunofluorescence histology after treatment.  
(A) Tumor distribution of 3.6 mg/kg of T-DM1-680 (top, green) or trastuzumab-680 (bottom, 
green) at 24 hours (left) or 5 days (right) after tail-vein injection. 15 minutes prior to sacrifice 15 
mg/kg Hoechst 33342 (blue) was administered via tail-vein to label functional vasculature. 
CD31-555 (red) was stained ex vivo to label all vasculature (functional and nonfunctional). 
Arrows highlight examples of functional vessels that contain perivascular T-DM1 labeling, 
which dominate at early times after treatment. By 5 days, a significant fraction of functional 
vessels (CD31 and Hoechst labeled) lack perivascular T-DM1 (arrowheads). Since some vessels 
still contain perivascular T-DM1 at this time point, presumably these vessels are newly formed 
(or became functional) once a significant fraction of T-DM1 cleared. The window leveling is 
different for each image (qualitative distribution only).  Scale bar is 200 µm. (B) Image analysis 
of histological samples. The fraction of functional vessels (Hoechst and CD31) containing 
perivascular T-DM1 at 5 days after treatment was significantly less than at 1 day (p < 0.0001), 
indicating angiogenesis and/or opening of collapsed vessels. 
  
 
 
6.5 Discussion 
The efficacy of ADCs is determined by a complex interplay between tumor uptake, 
distribution, cellular targeting, internalization, antibody degradation, and release of the small 
molecule payload. Here, we show that improving tumor penetration by co-administering 
trastuzumab enhances the efficacy of T-DM1 in a trastuzumab-insensitive mouse xenograft 
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model. These results have significant implications for the development of ADCs. Although 
substantial efforts have been made in optimizing the drug itself (high affinity antibodies, stable 
linkers, and highly potent small molecules), these data demonstrate the intratumoral distribution 
(independent of the payload dose) plays a major role in determining efficacy. Given that the 
ADC dose is often limited by the small molecule payload dose and not the amount of antibody, 
matching the potency of the ADC with delivery (rather than trying to maximize potency) may 
provide a way to improve the efficacy of ADCs while maintaining tolerability (47).  
 
The rapid binding of antibodies relative to their tissue penetration results in receptor 
saturation of perivascular cells (37,54). To penetrate deeper into the tissue, additional antibody 
must enter the tissue, but the toxicity of ADCs generally prevents the administration of higher 
ADC doses. Although there are other strategies to improve tumor penetration, such as decreasing 
protein size (i.e. F(ab) or F(ab’)2 fragments) or lowering affinity, increasing the antibody dose 
has the potential to improve multiple mechanisms of action. The co-administration of 
unconjugated antibody improves penetration (Figure 6.1) and is generally well tolerated relative 
to the cytotoxic payload. For example, trastuzumab is well tolerated even at high doses, such as 
an intensive loading schedule totaling 18 mg/kg given over 15 days (49). This does not increase 
(or decrease) the amount of ADC uptake in the tumor; it only changes the distribution as long as 
the dose remains sub-saturating (106). (In the clinic, saturating doses can require multiple grams 
of antibody for highly expressed and/or rapidly internalized antigens (225), possibly higher with 
heavy tumor burdens due to target mediated binding (226).) More uniformly delivering the ADC 
could potentially lower efficacy on the perivascular cells that typically receive a high 
concentration of ADC. However, ADCs tend to have low IC50’s, often over an order of 
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magnitude below the Kd (Figure 6.7) (19,28,227), indicating sub-saturating concentrations can 
result in cell death. Therefore, the heterogeneous delivery of ADC in the tumor can result in 
“overkill” of perivascular cells, where they receive more therapeutic than what is needed, while 
other cells receive none. When co-administering trastuzumab with T-DM1, the perivascular cells 
receive a smaller payload dose; however, more cells overall receive therapeutic levels of 
payload. At super-saturating doses (e.g. 60-120 mg/kg in this high expression model), it is 
anticipated efficacy would decrease since there would be no increase in penetration for a 
saturated tumor and payload uptake would decrease. Likewise, administering a saturating 
antibody dose a day before the ADC (e.g. (228)) can decrease efficacy. 
 
These data show that the addition of an antagonist (trastuzumab, which antagonizes T-
DM1 at high concentrations in vitro, Figure 6.7) with no single-agent efficacy (Figure 6.11) can 
improve in vivo efficacy and survival. The converse of this concept must also be considered. 
Newer and more potent payloads may be required for targets with low to moderate receptor 
expression and/or slow internalization rates (229). However, an ADC with higher in vitro 
potency may actually be less efficacious in vivo for some targets that are highly expressed. The 
increased potency (whether from higher DAR or a more toxic payload) could lower the 
maximum tolerated dose. This lower dose reduces the number of cells that can be targeted, 
thereby lowering the overall efficacy. When developing new ADCs, these results indicate that 
neither the maximum cellular potency nor the maximum antibody dose is optimal. Rather, this 
work emphasizes the need to match the single-cell potency with single-cell delivery to maximize 
efficacy. 
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In previous work (106), we identified studies that used a constant small molecule dose 
with different DAR/antibody doses and demonstrated the higher antibody dose (and 
correspondingly lower DAR) exhibited better efficacy. These studies included multiple targets, 
antibodies, linkers, and payloads (with and without bystander effects, e.g.(25,197)) indicating 
that the impact of tissue penetration is important across all ADCs studied to date. Since this 
publication (106) two other studies reported the same result – keeping the small molecule dose 
the same and increasing the antibody dose improved efficacy (29,227). However, a potentially 
confounding factor in these studies was that higher DAR ADCs tend to have faster clearance 
(DAR-dependent clearance), although the difference in payload AUC was less than 25% for 
these cases (24,29). The current work avoids potential DAR-dependent clearance by only using 
T-DM1. Another possible explanation could be that adding trastuzumab resulted in a dose 
dependent slower clearance of T-DM1 (230). However, the plasma clearance rates are similar 
with or without trastuzumab (106).  
 
Using the NIR fluorescence ratio technique, the fraction of tumor cells targeted by ADC, 
the number of ADC molecules delivered per cell, and the fraction of intact ADC versus degraded 
were measured (Figure 6.16). The slowly clearing T-DM1 showed mostly intact protein (~85%) 
at 24 hours post-injection due to continuous delivery from the blood during this period with the 
highest plasma concentrations. Conversely, over half of the ADC was degraded by 24 hours in 
vitro when the ADC was pulsed (Figure 6.15). After 3 days, once the tumor had surpassed 
maximal uptake and plasma concentrations decreased, the majority of the ADC in the tumor was 
degraded (Figure 6.16). Consistent with the histology images, only ~10% of the tumor cells are 
targeted by a 3.6 mg/kg dose of T-DM1 at maximum uptake. This is also in agreement with the 
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9-fold higher antibody dose required for saturation of the tumor (Figure 6.1). The number of 
DM1 molecules delivered per targeted cell is estimated at 1.7 +/- 0.3 million. Given the 2-3 day 
residualization half-life of IRDye (113), this measurement at 3 days is likely lower than the 
actual payload delivery but significantly higher than the uptake at the IC50 in vitro (Figure 6.7). 
These results are consistent with a rapid targeting of ADC (~1 day) in perivascular cells at a 
higher concentration than needed for cell death. A large fraction of cells within the tumor 
(~90%) are not exposed to T-DM1 even after 48-72 hours when maximum payload delivery is 
achieved within the tumor. Therefore, a significant fraction of cells receives more drug than 
needed for cell killing, while a large fraction of cells completely escape therapy, lowering the 
overall tumor efficacy despite efficient targeting (15% ID/g in these 300-400 mm3 tumors).  
 
The fluorescently tagged ADC was used to image distribution during tumor response (the 
nadir in the tumor growth curves occurs around 5-7 days, Figure 6.11). The tumor distribution of 
both trastuzumab and T-DM1 5 days after injection shows both functional (CD31 vessels labeled 
with intravenous Hoechst) and nonfunctional vessels with signal. Additionally, there are 
functional vessels that do not have detectable ADC signal, indicating that after maximum uptake 
in the tumor is reached there may be new vessels that form, which won’t receive significant 
payload until a high plasma concentration is achieved with the next dose (every 3 weeks in the 
case of T-DM1). The irregular, dynamic vasculature has important implications for ADC 
treatment when a significant fraction of cells are untargeted by ADC (Figure 6.17). New vessels 
deliver both oxygen/nutrients for survival and drugs for cell killing. However, the ADC requires 
approximately 1 day for uptake, 1 day for complete metabolism, and several days for cell killing, 
while oxygen and nutrients can rescue the cells more quickly. Therefore, the dynamic 
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vasculature within the tumor has the potential to repeatedly rescue untreated regions of the tumor 
even with continuous ADC in the plasma, which may stymie attempts to kill cells layer by layer 
with successive treatments. 
 
Despite distribution limitations, ADCs and antibodies have had great success in the clinic 
and further insight into mechanisms of how a heterogeneous tissue distribution is able to result in 
complete tumor eradication is needed. The NIR fluorescence ratio technique provides a 
convenient way to monitor the multiple stages of ADC delivery with single-cell resolution and 
absolute quantification of delivery (molecules/cell). The heterogeneous tissue delivery can be 
imaged through microscopy, the fraction of targeted cells can be quantified through flow 
cytometry (Figure 6.1, Figure 6.16, Figure 6.17), and the kinetics of ADC degradation measured 
by ratio measurement on flow cytometry (Figure 6.16). Differences in target expression, antigen 
processing, possible target shedding, competition with endogenous ligands, accessibility (such as 
mucin blocking binding), and other mechanisms make the tumor distribution and development of 
each ADC uniquely challenging. Understanding these kinetics is crucial for developing ADCs 
since the majority release their toxic payload after degradation, and cell trafficking is a potential 
mechanism of resistance (231).   
 
Similarly, the impact of payloads with bystander effects, which are not present in the T-
DM1/trastuzumab model, is not completely defined. Intuitively, bystander effects would improve 
efficacy because therapeutic payload would reach cells beyond the penetration distance of the 
ADC (in addition to the benefit of targeting antigen negative cells). For example, tumor 
penetration issues may explain why similar antibody doses but higher DAR (and therefore a 
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higher toxic payload dose) did not improve efficacy in several animal models (29,190,197) using 
agents without bystander effects. The higher DAR delivers more payload to cells that are already 
receiving a toxic dose, resulting in “overkill” of these cells. However, this same scenario with a 
payload that exhibits bystander effects shows improved efficacy (25,28,227). Although the 
payload is delivered to the same cells, it has the ability to diffuse into adjacent cells to improve 
overall cell killing. Consistent with our results, several groups (19,28,227) have shown greater 
efficacy with increased antibody-driven penetration (greater total antibody dose but same 
payload dose) even with payloads that exhibit bystander effects. For these payloads, it appears 
that the dilution and washout of the free payload may prevent the same efficacy as antibody-
driven penetration to reach cells far from vessels. 
 
Although our results demonstrate that ADC tumor distribution has a significant role in 
efficacy, there remain several challenges to clinical implementation. First, matching the single-
cell potency to single-cell delivery is challenging given that many targets are measured using 
immunohistochemistry rather than a more quantitative method capable of reporting 
receptors/cell. Second, selecting the optimum potency could be challenging given intra- and 
inter-patient variability where one could perfectly ‘match’ potency and delivery of an ADC to a 
primary tumor but not a metastasis with much higher or lower expression. It is unknown whether 
it is better to err on the side of higher potency (targeting fewer cells with a higher dose than 
necessary for cell killing which could help avoid mechanisms of drug resistance (231)) or higher 
delivery (increased tumor penetration at a sub-toxic dose). In this model system, higher 
penetration appears to be more beneficial. The use of higher antibody doses to increase ADC 
penetration has additional potential benefits, such as maximizing other mechanisms of action, 
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including receptor signaling blockade and/or immune cell interactions (211). Sacituzumab 
govitecan, an ADC that has received Breakthrough Therapy designation from the FDA, takes 
this approach using a lower potency payload with much higher antibody doses (8-10 mg/kg, 
Clinical Trial: NCT01631552) (232). Additionally, our modeling work shows that healthy tissue 
with low target expression would have less uptake when ADC and antibody are administered 
together compared to ADC alone (106). Finally, imaging may play a useful role in identifying 
optimal treatment regimens (233). The ZEPHIR trial looks to combine pretreatment and early 
metabolic response molecular imaging to select patients that respond best to T-DM1 therapy 
(234). Combining molecular imaging and pharmacokinetic models (137) to determine the 
optimum antibody/ADC dosage could provide an individualized treatment with potentially better 
outcome. Nonetheless, some patients that are HER2 positive may not have trastuzumab uptake 
(234), while other patients that have HER2 negative primary cancers may have metastases that 
are HER positive (235), making individualized treatment challenging.  
 
6.6 Conclusion 
In conclusion, we have shown that improving tumor penetration of a constant dose of T-
DM1 by co-administration of trastuzumab (in a trastuzumab-insensitive xenograft model) results 
in significantly better efficacy than T-DM1 alone. Maximizing tumor penetration of ADCs in 
addition to optimizing the antibody, linker, and payload during development may help improve 
the efficacy of future ADCs in the clinic. 
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6.7 Experimental Methods 
Antibodies and NIR Imaging Agents for Ratio Measurements 
Herceptin (trastuzumab, Roche) and Kadcyla (T-DM1, Roche) were obtained from the 
University of Michigan Pharmacy. Alexa Fluor 680 NHS Ester (AF680, ThermoFisher 
Scientific, A37567), IRDye 800CW NHS Ester (IRDye, LI-COR, 929-70020), and CellTraceTM 
Far Red DDAO-SE (DDAO, ThermoFisher Scientific, C34553) were conjugated to the 
antibodies following the manufacturer’s instructions as previously described (106,113). 
Antibody/ADC at 2 mg/mL supplemented with 10% sodium bicarbonate (v/v) was reacted with 
dye at molar ratios of 0.5 (AF680, IRDye) and 1.5 (DDAO) for 2 hours at room temperature and 
purified using P6 Biogel (1g gel/10mL PBS) resulting in dye to protein ratios of approximately 
0.3 (AF680, IRDye) and 0.7 (DDAO). Our previous work has shown that the distribution of T-
DM1 is unchanged after labeling with AF680 at dye to protein ratio of 0.3 or less (137). 
Antibody/ADC dye conjugates were run on SDS-PAGE and scanned on the Odyssey CLx 
Scanner (LI-COR) to ensure free dye was removed. For fluorescence histology, antimouse CD31 
(BioLegend, 102402) was conjugated with Alexa Fluor 555 (ThermoFisher Scientific, A37571), 
mouse antihuman IgG Fc antibody (BioLegend, 409302) was conjugated with Alexa Fluor 488 
(ThermoFisher Scientific, A20000), and trastuzumab was conjugated with Alexa Fluor 750 
(ThermoFisher Scientific, A20011) at dye to protein ratios of 1.5.  
 
Cell Lines and In Vitro Toxicity 
NCI-N87 and HCC1954 cells were purchased from ATCC in May 2015 and June 2016, 
respectively. Cell line authentication was performed by ATCC. Cells were grown at 37°C with 
5% CO2 in RPMI 1640 growth medium supplemented with 10% (v/v) FBS, 50 U/ml penicillin, 
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and 50 µg/ml streptomycin. Mycoplasma testing was performed yearly using the Mycoalert 
testing kit (ThermoFisher Scientific, NC9719283). Cells were cultured 2-3 times per week up to 
passage number 50 (approximately 3-4 months). For cell viability assays, 5,000 cells were plated 
in 96 well plates. Titrations of T-DM1 or T-DM1 and trastuzumab were replaced daily for 6 days 
and viability was measured using the PrestoBlue Cell Viability Reagent (ThermoFisher 
Scientific, A13261). Briefly, cells were washed twice with media and a 1:10 dilution of 
PrestoBlue in media was incubated for 25 minutes at 37°C. After incubation, the fluorescence 
(560/590, Ex/Em) of each well was measured using a Biotek Synergy plate reader. Background 
signal from wells without cells was subtracted from all samples and then viability was 
normalized to untreated cells.  
 
In Vitro NIR Fluorescence Ratio Measurements and Fluorescence Microscopy 
ADC metabolism was studied by dually labeling T-DM1 with DDAO and IRDye as 
described above. As the labeled ADC binds to the cell surface receptor, gets internalized, and 
subsequently degraded, the low molecular weight and more lipophilic DDAO diffuses out of the 
cell while the IRDye remains trapped (113). DDAO therefore approximates the intact protein 
(since it is cleared upon degradation), while IRDye approximates the cumulative uptake in the 
cell (63). Unlike pH effects (136) or quenching/FRET, this provides an irreversible measurement 
of both intact protein and payload delivery without requiring a high degree of labeling (self-
quenching approach) or larger dye-quencher conjugates. NCI-N87 and HCC1954 cells were 
plate in 96 well plates. Cells were labeled for 30 minutes at 37°C at different times over a 48 
hour period. After each labeling cells were washed twice to remove excess media. After 48 hours 
cells were washed three times, then harvested using Cellstripper (Corning, 25-056-CI), a non-
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enzymatic cell dissociation solution, and fluorescence intensity was quantified using an Attune 
Acoustic Focusing Cytometer (Life Technologies). The signal for each dye was normalized to 
the initial time point, and the normalized ratio of DDAO divided by IRDye was plotted to show 
the ratio of intact ADC to cumulative uptake. Alternatively, cells were imaged using 
fluorescence confocal microscopy (Olympus) with a 635 nm laser for DDAO and a 748 nm laser 
for IRDye.  
 
Tumor Growth Studies  
All animal studies were conducted in accordance with the University of Michigan 
Institutional Animal Care and Use Committee (IACUC). For all tumor xenografts studies, 5 x 
106 NCI-N87 cells were inoculated in the rear flanks of mice (one flank for tumor growth 
studies, both flanks for all others). For tumor growth studies, tumor volume was measured using 
calipers every other day using the formula volume = 0.5*length*width2. Trastuzumab, T-DM1, 
both trastuzumab and T-DM1 (all unlabeled), or saline were injected via tail vein once tumors 
reached 250 mm3. For tumor growth studies 10 animals were used for all treated and untreated 
cohorts. Kaplan-Meier survival curves were generated in PRISM and were analyzed by log-rank 
test at significance level of p ≤ 0.05.   
 
In Vivo NIR Fluorescence Ratio Measurements and Fluorescence Histology 
To study the cellular uptake and metabolism kinetics in vivo, tumor xenografts were 
treated with DDAO and IRDye labeled T-DM1, and the tumors were resected, digested into a 
single cell suspension, and analyzed on flow cytometry (similar to the in vitro assay). Once the 
longest axis of the tumor reached 9-10 mm, 100 µg of dually labeled T-DM1 was injected via 
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tail-vein and animals were sacrificed at 24, 48, and 72 hours. After sacrifice, tumors were 
resected and sliced before being placed in a collagenase IV solution (5 mg/mL). The tissue was 
digested for 25 minutes before centrifugation (5 min, 300 g). The cell pellet was resuspended in 
media, washed twice, and filtered through a 40 µm filter. Cells were then analyzed by flow 
cytometry. Uninjected negative control tumor digests were used to establish gates for DDAO and 
IRDye fluorescence. To determine the percent intact (from the DDAO/IRDye ratio) we 
examined cells that were targeted with T-DM1 (IRDye+). The background mean fluorescence 
intensity in RL1 and RL2 from negative control tumors was subtracted from the mean 
fluorescence intensity of DDAO (RL1) and IRDye (RL2) to get fluorescence per targeted cell. 
Then the DDAO signal was divided by IRDye to get the DDAO/IRDye ratio. To get the percent 
intact, this ratio was normalized to the initial intact ratio, which was determined by harvesting in 
vitro cells, labeling on ice for 25 minutes, washing twice, and analyzing by flow cytometry. In 
addition to running tumor cells on flow cytometry, part of the tumor was used for fluorescence 
biodistribution. The low autofluorescence in the near-IR makes IRDye a suitable fluorophore to 
determine organ uptake (53,107,137), and fluorescence biodistribution was performed as 
previously described (106,122,137). Fluorescence histology was performed as previously 
described (106,137).  
 
Immunofluorescence Histology 
Trastuzumab and Alexa Fluor 680 labeled T-DM1 (T-DM1-680) were administered via 
tail-vein at 0:1, 3:1, and 8:1 ratios (0, 10.8, and 28.8 mg/kg unlabeled trastuzumab with a 
constant 3.6 mg/kg T-DM1-680). Additionally, 15 minutes prior to sacrifice Hoechst 33342 
(ThermoFisher Scientific, H3570) was injected via tail-vein at 15 mg/kg to labeled functional 
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vasculature (236). 24 hours post-injection animals were euthanized, tumors were resected, flash 
frozen in OCT, and cut into 16 µm slices for histology. Before imaging, slides were stained for 
25 minutes with antimouse CD31-AF555 and antihuman IgG Fc-AF488, or trastuzumab-AF750. 
The CD31 stain was used to calculate the total vessel surface area, and an automated image 
analysis program identified which CD31 stained vessels were adjacent to Hoechst stained cells 
(functional vessels), ADC-stained cells, or both to calculate the fraction of functional vessels that 
delivered ADC. 
 
Image Analysis 
Imaging tumors following treatment can provide insight into tumor relapse and regrowth 
between therapies (once every 3 weeks for T-DM1). The residualizing nature of the IRDye 
800CW and AF680 labels on T-DM1 provide a history of which cells received the payload. Co-
injection of Hoechst 33342 labels the functional vessels at the time of tumor resection. To 
determine impacts of the tumor vasculature (which both supplies oxygen and nutrients for tumor 
growth but also drugs for cell killing), we imaged tumors 1 and 5 days after treatment with 3.6 
mg/kg of T-DM1. Significant mismatch between the functional vessels (Hoechst labeled) and 
treated regions (perivascular T-DM1) appeared at 5 days. To quantify these results, we used an 
automated image analysis algorithm to calculate the absolute vessel surface area to tumor 
volume ratio (S/V) along with the fraction of these vessels that had Hoechst and/or T-DM1 
signal around them. 
In order to find the surface-volume ratio, standard stereology methods were used on 
tumor xenograft images (237). Briefly, random ‘lines’ were placed on histological images (5 
images per tumor and 4 (day 5) or 5 (day 1) tumors per condition) and the number of ‘cuts’ of 
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the vessels was counted to yield the surface of the blood vessels- tumor volume ratio (S/V) as 
determined from the equation below (188,238). 
 
!" = 	 %&'(	        
Where: c: cuts, L: length of lines (𝜇m), n: number of lines. 
 
A MATLAB code to automate this counting was created. Briefly, the three image 
channels representing the vessels, the intravenously delivered Hoechst signal (for functional 
vessels), and the antibodies were uploaded to the MATLAB script. A binary mask was generated 
to identify signal from background, and noise was removed. 10,000 lines were randomly placed 
on the image (to increase accuracy (238)), and the function checks for the number of ‘cuts’ from 
these lines across a vessel. The length of the line was also chosen to be small (71µm, equivalent 
to 50 pixels). The S/V for select images was calculated manually using 300 lines to ensure the 
code was accurate. Each cut is categorized as either cut from a vessel (total vascular density), a 
cut from a functional vessel (proximity to intravenously delivered Hoechst), a cut from a vessel 
that delivered ADC (proximity to intravenously delivered ADC), or cut from a functional vessel 
that delivered ADC (proximity to both intravenously delivered Hoechst and ADC). With all the 
cuts estimated, the respective S/V is calculated. 
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Chapter 7      
Concluding Remarks and Future Directions 
 
7.1 Summary of Work 
In this dissertation, I developed computational and experimental techniques to study the 
distribution of antibody and ADC therapeutics in tumor at several length scales in order to design 
therapeutic agents with improved efficacy. In order to study the tumor distribution of antibodies 
with high sensitivity and subcellular resolution, I used near-infrared (NIR) fluorescently labeled 
antibodies. In Chapter 2, I characterized the residualization properties of NIR fluorophores to 
elucidate the relationship between fluorescence signal and intact vs. degraded protein. This also 
enabled fluorophore selection for optimal molecular imaging agent design. In Chapter 3, to 
ensure the pharmacokinetics (PK) and tumor distribution of NIR fluorescently labeled antibodies 
is indistinguishable from unlabeled antibodies, I determined the optimal degree of labeling 
(DOL) before further experimentation. I labeled two FDA approved antibodies with two 
commonly used NIR fluorophores, AlexaFluor680 (AF680) and IRDye800CW (800CW), 
measured the PK, biodistribution, and affinity and compared it to unlabeled. Unexpectedly, even 
an average degree of labeling of 1 dye per antibody was too high due to the Poisson distribution. 
I determined that AF680 labeled antibodies show nearly identical PK to unlabeled at a DOL of 
0.3 or less, even out to nearly 3 weeks. IRDye showed similar PK over the first few days, and 
then gradual faster clearance at this DOL in agreement with other literature reports.  
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Building on the labeling guidelines, in Chapter 4, I developed a dual channel NIR 
labeling technique, which involves labeling an antibody with a non-residualizing dye (DDAO) 
and a residualizing dye (IRDye). As the dually labeled antibody binds the cells, internalized, and 
degraded, the non-residualizing dye permeates out of the cell, while the residualizing dye is 
trapped in the cell. In other words, the non-residualizing dye approximates the intact antibody, 
since it leaks out after antibody degradation, while the residualizing dye approximates the 
cumulative cellular uptake of antibody, since it is trapped in the cell and accumulates. I selected 
several model proteins and found that the dual label technique was able to capture their widely 
differing internalization half-lives, both in vitro and in vivo. I applied the dual label technique to 
T-DM1, and, using the single-cell resolution of flow cytometry, I found that the clinical dose of 
T-DM1 only targeted about 10% of cells in the tumor, and that targeted cells were receiving 
more ADC than necessary to achieve cell death. Importantly, this technique is the first to 
measure both protein metabolism and distribution in vivo with single-cell resolution. 
 
In Chapter 5, I modeled both the systemic and tumor distribution of antibodies/ADCs 
using a novel, mechanistic, multi-scale model combining a PBPK model with the Krogh cylinder 
tumor model. Using this model, I predicted and experimentally verified the tumor distribution of 
a T-DM1 with and without the coadministration of the unconjugated antibody (trastuzumab). 
The unconjugated antibody binds and competes for the same receptor and drives T-DM1 further 
into the tumor, increasing the total number of cells targeted. Using the model as a theoretical 
framework, I imaged the tumor distribution of a constant 3.6 mg/kg T-DM1 as a single agent and 
with 10.8 mg/kg and 28.8 mg/kg trastuzumab (3:1 and 8:1 ratios, respectively) in a mouse tumor 
xenograft model. As a single agent, T-DM1 was highly heterogeneous, even at the dosage given 
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to patients in the clinic. Adding trastuzumab significantly improved the ADC tumor penetration, 
which resulted in a near homogeneous distribution at the 8:1 dosing level.  
 
Encouraged by the modeling results in Chapter 5, I tested the efficacy of T-DM1 with 
and without trastuzumab in a trastuzumab resistant xenograft mouse model in Chapter 6. 
Expectedly, the administration of T-DM1 alone showed a significant improvement in efficacy 
and survival, while trastuzumab alone had no impact. However, despite trastuzumab having no 
efficacy by itself (and lowering the efficacy of T-DM1 in vitro), I demonstrated a clear trend 
where coadministration of trastuzumab at 1:1, 3:1, and 8:1 trastuzumab:T-DM1 ratios 
dramatically improved efficacy over T-DM1 alone. In fact, the 3:1 and 8:1 ratios showed a 
statistically significant improvement in survival over T-DM1 alone. These striking results are 
counterintuitive to the current dogma of the ADC field. Most pharmaceutical companies 
developing ADCs focus on engineering the ADC itself (making antibody bind better, making 
more stable linker, etc.) and do not consider the distribution of the molecule. Our results stand in 
contrast to this approach and clearly shows ADC distribution plays a major role in efficacy.  
 
This dissertation provides unique tools to study antibody and ADC distribution and 
metabolism, quantitative computational tools to simulate in vivo distribution, and concrete 
guidance on how to improve efficacy of ADC therapeutics. Specifically, Chapters 2 and 3 offer 
guidelines for labeling antibodies with NIR fluorophores to study distribution with high spatial 
and temporal resolution. Chapter 4 presents a novel dual label technique that can quantify 
antibody distribution and metabolism in vivo with unprecedented single cell resolution. Chapter 
present a modeling framework to simulate both the systemic and tumoral distribution of 
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antibodies and ADCs. Finally, in Chapter 6 I present the first study to show antibody distribution 
itself plays a major role in efficacy and improve the efficacy of an FDA-approved ADC. 
Together, this dissertation will advance the growing field of ADCs and improve patient 
treatment. 
 
7.2 Future Work and Directions 
The work in this dissertation opens several new avenues of research, and, in this section, I 
briefly outline additional work to continue building our understanding of the relationship 
between ADC distribution and efficacy. 
 
Applying the unconjugated antibody and ADC coadministration strategy in tumor models with 
low or heterogeneous antigen expression.  
In Chapter 6, the efficacy study using a dosing strategy of ADC with unconjugated 
antibody was the first to show that ADC tumor distribution plays a major role in overall efficacy. 
Although testing ADC efficacy in mouse xenografts is the industry standard for ADC 
development, in the clinic there is significant intra- and interpatient tumor heterogeneity. Testing 
the coadministration dosing strategy in more realistic tumor models, such as patient-derived 
xenografts (PDX) or mosaic tumor models with mixed antigen positive and negative cells, may 
better mimic the clinical scenario where there is heterogeneous antigen expression. In these 
tumor models, we could apply several of the techniques outlined in this dissertation to, ideally, 
match the potency of the ADC to its distribution in the tumor. First, the tumor distribution of 
fluorescently labeled ADC at several doses can be imaged through fluorescence microscopy. 
Then, using flow cytometry, the fraction of cells targeted in the tumor and the absolute uptake of 
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ADC can be quantified. Using microscopy to visualize the tumor distribution and flow cytometry 
to quantitate ADC uptake will help enable the selection of dosing levels to optimize tumor 
distribution.  
 
Testing the dosing strategy in a cell line with lower antigen expression may help 
determine if it is better to err on the side of higher potency (i.e. lower ratios of antibody to ADC) 
or better distribution (i.e. higher ratio of antibody to ADC). In our study, we used the NCI-N87 
cell line because of its high HER2 expression (~one million receptors per cell) and selected a 
subsaturating (3:1) and saturating (8:1) dosing levels. In our case the saturating dose of 8:1 was 
the most effective treatment; however, there is likely an upper limit to the amount of antibody 
that can be coadministered with the ADC. In a tumor model with lower antigen expression, the 
tumor will reach saturation with much lower doses, and too high a ratio of antibody to ADC may 
decrease efficacy. To apply the coadministration strategy in the clinic, where antigen expression 
in the tumor is often highly variable, it will be critical to determine if there is an upper limit of 
the amount of antibody that can be coadministered with ADC to maximize efficacy.  
 
Quantifying payload bystander effects through pharmacodynamic marker imaging 
 Payload cytotoxicity is one of the central drivers of ADC efficacy; however, relatively 
little imaging data are available of the payload distribution in tumors. In particular with 
bystander payloads, it is unclear how far they can diffuse from cells targeted with ADC. 
Although our group has modeled the bystander effect and predicted payload tumor distributions 
based on the physicochemical properties of the payload, more imaging data is required to 
confirm, or refute, these predictions. One potential method of quantify the bystander effect is 
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through imaging pharmacodynamic markers from the payload engaging its target. For example, 
in the case of PBD-based ADCs, after the PBD payload is released and it binds DNA, an anti-
phospho-histone H2A.X antibody will bind the payload-DNA complex. The payload and 
antibody distribution can be compared by administering an antibody with a residualizing 
fluorophore in vivo, and then ex vivo staining of the pharmacodynamic marker with a different 
fluorophore. Theoretically, since PBD is a bystander payload capable of diffusing into 
neighboring cells, the payload would reach more cells than the antibody alone. Using image 
analysis tools similar to those in Chapter 6, the distance the payload traverses into the tumor can 
be quantified. Visualization of the payload distribution in tumors coupled with computational 
models will give further insight into the relationship between payload distribution and efficacy. 
 
ADC therapy and the immune system.  
When developing ADCs, it is common to test efficacy in immunodeficient mouse 
models, such as NOD/SCID or nude mice; however, several groups have shown that ADC 
therapy results in immune cell activation in immunocompetent mouse models. Since ADCs 
distribute heterogeneously in the tumor and may leave much of the tumor untargeted, it is 
possible that, in the clinic, ADCs activate immune cells, which are then able to kill tumor cells 
untargeted by the ADC. Müller et al. showed in a preclinical mouse model that T-DM1 does 
result in T cell activation; however, this study used very high doses of T-DM1 (15 mg/kg) (211). 
Studying immune cell activation in immunocompetent animal models following ADC therapy at 
more clinically tolerable doses would help determine the relative impact from immune cells 
versus the ADC payload on overall efficacy. Additionally, since most ADC research is 
conducted in immunodeficient mouse models, it is unclear how ADC therapy may synergize 
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with other immune-oncology agents, such as checkpoint inhibitors. For example, if ADC therapy 
is in fact stimulating the immune system, then combining ADC therapy with an anti-PD1 
checkpoint inhibitor provides both tumor cell killing capabilities and immune stimulation from 
the ADC, while preventing immune cell suppression by disrupting the PD1-PDL1 
immunosuppresive interaction.  
 
7.3 Concluding Remarks 
The current dogma for ADC development involves developing a humanized antibody 
against a tumor antigen of interest and attaching the most potent payload to it with a stable linker 
chemistry. Usually several variants are made and characterized before conducting in vitro 
testing. Then, the in vitro characterization of the ADC normally consists of cell viability assays 
against multiple cell lines, cell binding, and potentially fluorescence microscopy to visualize 
surface staining of the antigen. Often the most toxic agent in vitro is selected to move forward 
for in vivo testing, where it is used in tumor growth studies, biodistribution with radiolabels, and 
plasma clearance. Based on the work in this thesis, I believe that the assumption that the most 
toxic agent in vitro will be the best candidate in vivo oversimplifies the ADC as simply a vehicle 
for the payload to the tumor and neglects much of the dynamics of antibody therapy. 
 
One of the critical findings in this thesis is that the distribution of ADCs plays an 
important role in the overall efficacy of these agents, and this is one of the major hurdles in 
developing ADCs against solid tumors. ADCs have shown great promise against blood cancers 
where there are fewer delivery limitations; however, they have struggled against solid tumors. 
The lack of available imaging data, from both preclinical and especially clinical samples, makes 
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it difficult to conclude with great certainty that distribution is the primary cause for failure of 
ADCs; however, the literature reviews and efficacy study outlined in this thesis make a 
compelling case that it has been significantly underappreciated. My hope is that this work will 
encourage those developing ADCs to make tumor imaging a staple of the ADC development 
process, and directly pair tumor imaging studies at the same doses as efficacy studies. Many 
pharmaceutical companies already use fluorescence imaging as part of the in vitro 
characterization process for ADCs, and it should be relatively facile to extend this imaging to 
histological sections. Although I have outlined labeling conditions and fluorophores for direct 
imaging of the ADC, at minimum, immunofluorescence or immunohistochemical staining should 
be used when the ADC consists of a humanized antibody in a mouse xenograft model because of 
the straightforward detection of the ADC using anti-human Fc secondary antibodies. 
Furthermore, I would encourage those developing ADCs to apply the methods described in this 
thesis to quantitate ADC delivery at the cellular level in the tumor with flow cytometry to allow 
for a direct comparison between in vitro and in vivo studies. I believe it is imperative to couple 
imaging studies examining the tissue and cellular scale distribution of ADCs with conventional 
tumor growth, biodistribution, and plasma clearance studies. This will improve our 
understanding of how ADCs acting at the cellular scale interact with the tumor 
microenvironment at the tissue scale and result in tumor regression at the organ scale. 
 
I anticipate that making tumor imaging a staple of the ADC development will bring 
additional insights into the mechanisms of action of ADCs. Currently, most researchers in the 
ADC field view the payload as the primary driver of ADC efficacy in vivo. While, I believe that 
the payload is certainly one of the central mechanisms of action for ADCs, the fact that many 
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tumor cells remain untargeted by the ADC suggests that other mechanisms of action are playing 
a role in efficacy as well. Some of these may include direct effects, such as immune cell 
recruitment and/or activation, or indirect effects, such as vascular collapse. In Chapter 6, imaging 
the tumor during treatment revealed that additional vessels were forming in regions not targeted 
by the ADC as soon as five days after ADC administration; however, in the clinic, the ADC is 
administered every three weeks. It is possible that administering the ADC more frequently with 
lower doses may target newly formed vessels before the tumor is able regrow further. Rationally 
selecting and testing a more frequent dosing regimen such as this is not possible without directly 
visualizing the antibody distribution in the tumor microenvironment, and likely would not even 
come into consideration with the current dogma of ADC development. I hope that this 
dissertation brings a new perspective to those developing ADCs to continue improving these 
promising therapeutics.  
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Appendix A – Dual Label NIR Fluorescence Ratio Imaging Protocol 
 
MATERIALS 
Reagents 
Cell culture 
• A431 cells (ATCC, cat. no. CRL-1555) 
• LS174T cells (ATCC, cat. no CL-188) 
• NCI-N87 cells (ATCC, cat. no. CRL-5822) 
• RPMI with L-Glutamine (Thermo Fisher Scientific, cat. no. 11875-093) 
• DMEM high glucose, pyruvate (Thermo Fisher Scientific, cat. no. 11995-065) 
• Fetal bovine serum (FBS) (Thermo Fisher Scientific, cat. no. 10437-028) 
• Phosphate buffered saline (PBS) (Thermo Fisher Scientific, cat. no. 10010-023) 
• Penicillin-streptomycin (10,000 U/mL), 100 ml (Thermo Fischer Scientific, cat. no. 15140-
122) 
• Trypsin-EDTA (0.05%) (Gibco, cat. no. 25300054) 
• CellStripper (Corning, cat. no. 25-056-CI) 
• 96 well flat clear bottom black plates (Corning, cat. no. 3603) 
• DMSO (Sigma-Aldrich, cat. no. D2438) 
• Sodium bicarbonate (Thermo Fisher Scientific, cat. no. 25080-094) 
• Quantum™ Simply Cellular® anti-Human IgG Quantitative Beads (Bangs Laboratories, cat. 
no. 816) 
 
Gel Supplies 
• MES Running Buffer (Thermo Fisher Scientific, cat. no. B0002-02) 
• Loading Buffer 
• Odyssey One-Color Protein Molecular Weight Marker (LI-COR, cat. no. 928-40000)  
 
Imaging Agents 
• DDAO-SE (Thermo Fisher Scientific, cat. no. C34553) 
• IRDye 800CW NHS Ester (LI-COR, cat. no. 929-70020) 
• Alexa Fluor 488 (Thermo Fisher Scientific, cat. no. A20000) 
• Alexa Fluor 555 (Thermo Fisher Scientific, cat. no. A37571) 
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Antibody/Proteins 
• IRDye 800CW EGF Optical Probe (LI-COR, cat. no. 926-08446) 
• Human A33 Antibody (R&D Systems, cat. no.  MAB3080) 
• Erbitux (cetuximab), (Eli Lilly and Company) 
• Herceptin (trastuzumab), (Genentech) 
• Kadcyla (ado-trastuzumab emtansine), (Genentech) 
• Antimouse CD31 (BioLegend, cat. no. 102402) 
• Mouse antihuman IgG Fc antibody (BioLegend, cat. no. 409302) 
 
Other 
• NOD/SCID mice, female (Jackson Laboratories, 4–6 weeks) ! CAUTION All animal 
experiments require approval by institutional review board and animal use and care 
committees and must be conducted in accordance with institutional and national regulations. 
 
Equipment 
General Equipment 
• Pipet Tips (1000, 200, 10µL) (Thermo Fisher Scientific, cat. no. 94060716, 94060316, 
94060116) 
• Pipettors (Thermo Fisher Scientific, cat. no. 4700860N) 
• T75 culture flasks (Fisher Scientific, cat. no. 12-556-010) 
• CO2 incubator (Eppendorf, cat. no. CO17301001) 
• Bright-Line Hemacytometer (Hausser Scientific, cat. no. 1483) 
• Thermo Fisher Scientific Sorvall Legend X1R Centrifuge (Thermo Fisher Scientific, cat. no. 
75004261) 
• Labconco Purifier Logic+ Class II Type A2 Biological Safety Cabinet (Labconco, cat. no. 
302310000) 
• Razor blades (Fisher Scientific, cat. no. 12-640) 
• MX35 Premier Disposable Low-Profile Microtome Blades (Thermo Fisher Scientific, cat. no. 
3052835) 
• 40 µm filters  (Corning, cat. no. 352340) 
• Bolt™4-12% Bis-Tris Plus Gels, 15 wells (Thermo Fisher Scientific, cat. no.  
NW04125BOX) 
• Bio-Gel® P-6 Gel (Bio-Rad, cat. no. 150-4134) 
• Costar Spin-X Centrifuge Tube Filter (Fisher Scientific, cat. no. 07-200-388)  
• Nunc™ Lab-Tek™ II Chamber Slide™ System (Thermo Fisher Scientific, cat. no. 154534) 
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• Versa-Orb Digital Orbital Shakers (Chemglass Life Sciences, cat. no. CLS-4021-100) 
• Fisher Scientific Model 120 Sonic Dismembrator (Fisher Scientific, cat. no. FB120110) 
 
Imaging 
• Olympus FV1200 (Olympus) 
• 20× water immersion objective (Olympus, cat. no. UMPLFLN20XW)  
• 60× water immersion objective (Olympus, cat. no. LUMFLN60XW)  
• Odyssey® CLx Imaging System (LI-COR) 
• Leica CM3050S Cryostat 
• TissueTek O.C.T. Compound (VWR, cat. no. 25608-930) 
• MX35 Premier Disposable Low-Profile Microtome Blades (Thermo Fisher Scientific, cat. no. 
3051835) 
• Attune Acoustic Focusing Flow Cytometer (Applied Biosystems) 
• Nanodrop 2000c Spectrophotometer (Thermo Fisher Scientific, cat. no. ND-2000C) 
Software 
• FV10-ASW (Olympus) 
• Image Studio (Odyssey CLx) (LI-COR) 
• Fiji (https://fiji.sc) 
 
Animal Work 
• Fluriso (Isoflurane, USP) (VetOne, cat. no. 501017) 
• AIN-93M Purified Diet (non-fluorescent rodent chow) (Teklad, cat. no. TD.94048)   
 
REAGENT SETUP 
Cell Culture Medium. Supplement RPMI 1640 medium and DMEM medium with 100 
U/mL penicillin, 100 U/mL streptomycin solution and 10% (vol/vol) FBS. Filter-sterilize the 
medium and store the medium at 4 °C for up to 3 months. Use RPMI 1640 medium with the 
NCI-N87 cell line, and DMEM medium with A431 and LS174T cell lines.  
 
P-6 Biogel. Dissolve gel in PBS at 10 mL/g of gel. Hydrate the gel by mixing for at least 
2 hours on a stationary mixer. Store at room temperature for up to six months. 
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Collagenase digest solution #1. Weigh approximately 25 mg of collagenase IV. 
Dissolve in 5 mL PBS. ∆ CRITICAL STEP Prepare digest solution immediately before use. 
Discard excess.   
 
Collagenase digest solution #2. Weigh approximately 25 mg of collagenase IV. 
Dissolve in 2.5 mL of 1x RIPA buffer and 2.5 mL PBS. ∆ CRITICAL STEP Prepare digest 
solution immediately before use. Discard excess.   
 
Trypsin digest solution. Combine 2.5 mL of 1x RIPA buffer and 2.5 mL trypsin. ∆ 
CRITICAL STEP Prepare digest solution immediately before use. Discard excess.   
 
Hoechst 33342. Dilute stock to 0.5 mg/mL in deionized water. Store at 4ºC for 1 year. 
Before labeling cells for microscopy, dilute to 0.1 mg/mL in cell media. Discard immediately 
after use.   
 
PBS-EDTA. Dissolve EDTA in PBS to a concentration of 5 mM. Store at room 
temperature for up to 1 year.   
 
Antimouse CD31-AF488. Pipet at least 100 µg of antimouse CD31 into a 
microcentrifuge tube. Mix with 7.5% sodium bicarbonate solution at 10% (vol/vol). Dissolve 
AF488 NHS Ester in DMSO at 1 µg/µL. Add AF488 NHS Ester at a molar ratio of 4:1 to the 
antimouse CD31 solution. React for 2 hours at room temperature and protect from light. Follow 
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steps 4 and 5 for to purify the antibody-dye conjugate. Quantify antibody concentration and dye 
to protein ratio using a Nanodrop Spectrophotometer. The final concentration should be 
approximately 2-3 mg/mL of antibody and have a dye to protein ratio of approximately 2-3.  
 
PROCEDURE 
Protein Dual Labeling • TIMING 4-5 hours 
1. For antibodies or ADCs adjust concentration to approximately 2 mg/mL in buffer free of 
amines. Mix with a 7.5% sodium bicarbonate solution at 10% (vol/vol). The pH should 
be approximately 8.5.  
2. Dissolve IRDye and DDAO into DMSO at 1-4 µg/µL. ∆ CRITICAL STEP Prevent 
repeated freeze thaw of fluorescent reagents. Store at -20ºC and protect from light. 
3. Combine antibody/sodium bicarbonate solution with IRDye and DDAO at molar ratios of 
0.5 and 1.0, respectively, for 2 hours at room temperature. Protect from light. ? 
Troubleshooting 
4. Purify the antibody/ADC reaction using P-6 Biogel. Add 800µL of P-6 Biogel to spin 
tube. Centrifuge for 1 minute at 3500g. Remove supernatant. 
5. Pipet up to 100 µL of reaction on top of column. Centrifuge for 1 minute at 3500g. 
Transfer antibody-dye conjugate to new microcentrifuge tube. 
6. To ensure free-dye is removed, run the antibody-dye conjugate on SDS-PAGE, and scan 
the gel on the Odyssey CLx or similar NIR scanner. If free dye is still present in the 
solution repeat the purification with P-6 Biogel.  
7. Determine absorbance using Nanodrop Spectrophotometer. Measure absorbance at 
280nm, 650nm, and 778nm. Using the molar extinction coefficients and correction 
factors for the antibody, DDAO, and IRDye, calculate the protein and dye concentrations 
(Figure 4.2).  
8. Calculate degree of labeling for both dyes using equations below. ∆ CRITICAL STEP 
Ensure the degree of labeling is less than 0.3 for IRDye and 0.7 for DDAO. At a degree 
of labeling greater than 0.3, IRDye can impact protein pharmacokinetics. ■ Pause Point 
Antibody-dye conjugate should be used within 3 months. Store at 4ºC and protect from 
light. Aliquot labeled antibody into tubes and store at -80ºC for longer-term storage. 
(Avoid repeated freeze thaws.)  
 
In Vitro Flow Cytometry • TIMING 3-5 days 
9. Harvest cells by removing media, washing twice with PBS, then incubating with 0.05% 
trypsin for 5-10 minutes at 37ºC. Once cells are detached, add media (1:1), and transfer to 
a conical. Count cells with hemacytometer and plate approximately 100,000 cells per 
well in a 24 well plate. Allow cells to adhere to plate for at least 4 hours or overnight. 
Plate enough wells so each time point is run in triplicate. 
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10. Prepare stock of cell media with dually labeled antibody stock in a conical. Dilute dual-
labeled antibody in media at 30 nM (>10 × Kd). Add media without antibody to another 
conical for a negative control. ! CAUTION For steps 10-13 Use proper aseptic technique 
to avoid bacterial contamination. 
11. For each time point, remove cell media and add 300 µL of the dual label antibody in 
media solution for 30 minutes at 37ºC.  
12. After labeling cells for 30 minutes, aspirate dual label antibody media solution, wash 
twice with fresh media and replace media.  
13. Repeat steps 11 and 12 for each time point.   
14. After the final time point, wash all cells once with media and once with PBS to ensure 
any fluorophore that has leaked out of cells is washed away. 
15. Detach the cells for flow cytometry by incubating with CellStripper at 37ºC for 10 
minutes or until cells have detached. 
16. Once cells are detached immediately place the plate on ice. Pipet the cells/CellStripper 
solution forcefully to dislodge cells from the plate and transfer to microcentrifuge tubes 
on ice. ! CAUTION Do not scrape the cells off the plate as this may lyse them. 
17. Wash the cells once by centrifuging cells at 300g for 5 minutes, removing CellStripper 
solution, adding 300µL media, centrifuging the cells at 300g for 5 minutes, and removing 
media. Place resulting cell pellets on ice for flow cytometry. ! CAUTION Carefully 
remove cell media so that the cell pellet is not disturbed. 
18. Immediately before running cells on the Attune Flow Cytometer, resuspend cells in PBS 
and filter through 40 µm filter tubes.   
19. Run all samples on flow cytometer. Ensure the PMT settings for RL1 (DDAO) and RL2 
(IRDye) are adjusted so the background signal is around 1000 to maximize the dynamic 
range for these fluorophores. Export data for analysis in FlowJo. 
20. In FlowJo, gate around the cellular population and export the median intensity for both 
RL1 and RL2.  
21. Background subtract RL1 and RL2 median fluorescence intensity for each channel. 
Divide the background subtracted intensity of each channel by the initial intensity from 
the zero time point. This gives the normalized intensity for RL1 and RL2. To estimate the 
percent intact antibody, divide the normalized intensity of RL1 (DDAO) by the 
normalized intensity of RL2 (IRDye). The ratio of the mean is a simple calculation for 
homogeneous cell populations. For heterogeneous populations, the mean of the ratio and 
full distribution is more descriptive. 
 
In Vitro Microscopy • TIMING 3-5 days 
22. Similar to step 9, harvest cells using trypsin and count cells. Plate approximately 75,000 
cells in each well of a Chamber Slide. 
23. Similar to step 10, prepare dually labeled antibody media solution at approximately 30 
nM.  
24. For each time point, remove cell media and add 300 µL of the dual label antibody media 
solution for 30 minutes at 37ºC. Ensure one well is available for a negative control. ! 
CAUTION For Steps 24 and 25 Use proper aseptic technique to avoid bacterial 
contamination. 
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25. After pulsing cells, remove dual label antibody media solution, wash twice with fresh 
media and replace media.  
26. Repeat steps 24 and 25 for each time point. 
27. After the final time point, wash all cells twice with media to ensure any fluorophore that 
has leaked out of cells is washed away. 
28. Prepare Hoechst/media solution. Add 300 µL to each well and incubate at room 
temperature for five minutes. ∆ CRITICAL STEP The Hoechst/media solution should 
always be prepared fresh and excess should be properly discarded. 
29. Remove Hoechst/media solution and wash twice with media.  
30. Remove well divider using tools provided with Chamber Slide System. ! CAUTION The 
glass culture slide can break if too much force is applied. 
31. Place slide underneath microscope and image each well using a 60× microscope 
objective. Image using 405/635/750 laser lines for Hoechst, DDAO, and IRDye, 
respectively. Save each image as a ‘.oib’ file. 
32. Import images using Fiji. Assign colors to each channel (Hoechst, blue; DDAO, red; 
IRDye, green) and save as a ‘.tiff’.   
 
Ex Vivo Flow Cytometry • TIMING 2-4 weeks  
33. Establish xenograft tumors in both flanks of 4-6 week old female nude athymic mice 
(Jackson Laboratories Foxn1nu). Ensure the appropriate protocol is in accordance with 
institutional review board and animal care and use regulations. Place animals on non-
fluorescent rodent chow at least 4 days before conducting experiments to reduce 
background autofluorescence. Allow subcutaneous tumors to reach 10-12 mm along the 
longest axis (tumor volume should be approximately 300-500 mm3).  
34. Prepare injection of dual label antibody by combining desired amount of antibody with 
USP PBS. ∆ CRITICAL STEP The background signal for flow cytometry, microscopy, 
and biodistribution should be measured using PBS injected negative control mice.  
35. Anesthetize tumor-bearing mouse and perform tail-vein injection of prepared dual label 
antibody.  
36. To obtain plasma clearance data, take blood samples through retroorbital or saphenous 
vein sampling. Mix 10 µL of blood sample with 15 µL PBS-EDTA. Centrifuge at 3000g 
for 1 minute. Remove 15 µL of plasma and place in 384 well plate to scan on Odyssey 
CLx. Repeat at desired time points and ensure that total blood withdrawn does not exceed 
the approved animal protocol limit (e.g. 200 µL). 
37. (Optional) Prepare solution of Hoechst 33342 at 15 mg/kg in USP PBS. To label 
functional vasculature in the tumor, anesthetize tumor-bearing mouse and inject with 
Hoechst/PBS solution 15 minutes prior to euthanasia.  
38. Euthanize mouse in accordance with relevant guidelines and regulations. For example, 
perform cervical dislocation under anesthesia and double pneumothorax to confirm death. 
39. After euthanasia, immediately resect each tumor. Ensure that excess skin and muscle are 
removed from the tumors. Scan both tumors on the Odyssey CLx.  
40. To measure the multi-scale distribution in the same animal, parts of the tumor will be 
used for flow cytometry, histology, and biodistribution. To divide the tumor, gently cut 
tumor along the longest axis with razor blade. Cut 3 mm thick section along the longest 
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axis and place in cryomold with OCT. This part of the tumor will be used for histological 
analysis (Skip to Step 55). Gently cut the rest of the tumor into 1-2 ×1-2 mm pieces. Half 
of the remaining pieces will be used for flow cytometry and the other half for 
biodistribution (Skip to Step 63).  
41. Select the remaining slices of tumor that will be used for flow cytometry. Place tumor 
pieces in collagenase digest solution #1 at 37ºC. ∆ CRITICAL STEP Collagenase 
digest solution #1 should be prepared fresh. 
42. Incubate tumor in digest solution for 25 minutes. ∆ CRITICAL STEP Incubating for 
longer than 25 minutes can damage tumor cells and result in cell lysis and excess cell 
debris. 
43. After incubation, centrifuge tumor suspension/collagenase mixture for 5 minutes at 300g. 
Carefully aspirate the supernatant so as to not disturb the cell/tumor pellet.  
44. Resuspend tumor cell mixture in 8-10 mL of media kept at 4ºC. Keep media on ice or at 
4ºC. Repeatedly pipet to break apart any clumps. Pipet cell mixture through 40 µm filter 
into a 50 mL conical. Repeat this twice 
45. Centrifuge cells at 300g for 5 minutes. Ensure the centrifuge temperature is at 4ºC 
46. Carefully aspirate the supernatant and resuspend in cell medium. Place on ice or at 4ºC. 
Count cells using hemacytometer and divide the tumor cell solution into microcentrifuge 
tubes, transferring approximately 1 x 106 cells to each tube. Place each tube on ice. 
47. (Optional) Since DDAO and IRDye occupy the red and near-IR wavelengths of the 
visible spectrum, the blue and green wavelengths are available for additional fluorophore-
antibody staining. Other stains include, for example, pharmacodynamics markers for 
ADCs, cell lineage markers for immune cells, or other cell surface markers on tumors. As 
with all multicolor flow cytometry, proper controls and/or compensation should be used 
to mitigate any spectral overlap. ? Troubleshooting  
48. Centrifuge the microcentrifuge tubes at 300g for five minutes and remove supernatant. 
Place resulting cell pellets on ice for flow cytometry.  
49. Immediately before running cells on the Attune Flow Cytometer, resuspend cells in PBS 
and filter through 40 µm filter tubes.   
50. Run all samples on Attune Flow Cytometer. Ensure the PMT settings for RL1 (DDAO) 
and RL2 (IRDye) are adjusted so the background signal is around 1000 to maximize the 
dynamic range for these fluorophores. Export experiment for analysis in FlowJo. 
51. Label a positive control. Prepare a positive control by diluting dually labeled antibody to 
30 nM in 1 mL of cell media and then placing the solution on ice. Harvest in vitro cells 
and count using the hemacytomer. Place 100,000 cells in a microcentrifuge tube. Wash 
cells by centrifuging for 5 minutes at 300g, removing supernatant, and resuspending in 
400µL cell media. Centrifuge cells for 5 minutes at 300g and remove supernatant media. 
Resuspend cells with positive control solution and place on ice for 30 minutes. After 
labeling, wash cells twice with media and run on flow cytometer using same settings used 
for tumor digest. The positive control is used to normalize the ratio of cellular events in 
the tumor digest to the ratio of intact dually labeled antibody, similar to the initial time 
point in the in vitro flow cytometry (step 21). ∆ CRITICAL STEP An in vitro positive 
control should be prepared for each tumor digest. 
52. Data analysis in FlowJo. Gate around cell population and plot RL1-H versus RL2-H 
fluorescence signal. Using a negative control mouse set negative gates for positive and 
negative signal for RL1-H (DDAO) and RL2-H (IRDye). Gates should be adjusted so 
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that there are less than 1% of cellular events in the positive quadrants for a negative 
control tumor. Once gates are adjusted, tumor cells that were targeted with antibody 
(RL2+) can be analyzed. 
53. In FlowJo, export the cellular events for targeted cells to a ‘.csv’. Open the .csv in 
Microsoft Excel or import the data into Matlab. For each cellular event, background 
subtract the mean autofluorescence signal (from a negative control mouse) for both the 
RL1-H and RL2-H channels and divide the RL1 signal by the RL2 signal. Repeat this for 
the in vitro positive control. Then normalize the tumor digest ratio by dividing the mean 
DDAO/IRDye ratio by the in vitro positive control ratio. Multiply the normalized ratio by 
100 to get the percent intact antibody. ? Troubleshooting 
54. Quantify absolute fluorescence signal with Quantum Simply Cellular anti-Human IgG 
Quantitative Beads using manufacturer instructions.  
 
Ex Vivo Microscopy • TIMING 4-5 hours 
55. Place the section of tumor set aside for histology in OCT in a cryomold.  Allow the tumor 
to incubate in OCT for 15 minutes. While incubating, cool isopentane using dry ice.  
56. Once isopentane is chilled (dry ice does not bubble when placed in it), add cryomold to 
isopentane and wait 3 minutes. Once the tumor block is completely frozen transfer to an -
80ºC fridge for longer-term storage.  
57. Process the frozen tumor samples by slicing the frozen tissue blocks with a microtome 
cryostat. When slicing the tumor or tissue blocks, set the slice thickness to 16 µm. Mount 
the frozen section on a glass slide and store slides at -80ºC. ■ Pause Point The frozen 
slides can be stored for 1 year at -80ºC. ∆ CRITICAL STEP Using thicker 16 µm 
(instead of the conventional 4 µm) will increase the fluorescence signal for microscopy. 
If using a confocal microscope, fully open the pinhole aperture to ensure maximum 
fluorescence signal.  
58. (Optional) Before imaging, use additional labels of interest to stain the tumor. We 
commonly stain with antimouse CD31-AF488 to show all (functional and non-functional) 
vasculature. For antibody staining, combine antimouse CD31-AF488 with PBS to a 
concentration of 30 nM. Allow section to air dry in opaque container (10-15 minutes). 
Add 100 µL of staining solution on top of frozen section. Protect from light and incubate 
for 30 minutes at room temperature.  
59. Remove antibody and transfer to a clean container and perform two 25mL PBS washes 
(2-3 minutes each).  
60. Dry the slides at room temperature. ■ Pause Point The stained slides can be stored for 2 
weeks at -80ºC. 
61. Image the stained tumor/organ sections using the Olympus FV1200. Secure the slide on 
the microscope stage, lower the objective, and pipet PBS between sample and objective. 
Bring the sample into focus. Once the sample is in focus, open the “Multi-area time 
lapse” function in the microscope software. Outline the tissue slice in the “Zoomed Stage 
Map” area using the “Mosaic Outline” tool. Once the entire sample is outlined and the 
desired settings are selected, apply the settings to the “Registered Point List,” and click 
“Play.” ! CAUTION For extended scans ensure the sample and objective remain 
immersed in PBS. ? Troubleshooting 
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62. Once the scan is complete, use the “Stitch” function in the “Multi Area Time Lapse 
Viewer” to show the large tumor/organ scan. Save the image as a “.oib” file. Open the 
“.oib” file in Fijj to assign the desired colors and adjust the brightness/contrast, then save 
the file as a “.tiff”. 
 
Ex Vivo Biodistribution • TIMING 3-4 hours 
63. Place the section of tumor set aside for biodistribution on a clean cutting surface (we use 
a glass plate). 
64. Fill weight boats with PBS for washing. Resect other organs of interest. For antibodies or 
ADCs, we recommend resecting the liver, tumor, kidney, spleen, heart, lungs, muscle, 
pancreas, small intestine, and skin. Place each organ in a weigh boat with PBS to wash 
the organ for about 30 seconds to 1 minute. After washing, take organ out of PBS and 
dab dry on a kimwipe. Set each organ on the clean cutting surface. ∆ CRITICAL STEP 
The fluorescence intensity will be normalized by the weight of the organ so ensure that 
excess fat or connective tissue is removed from the organ.  
65. Manually disrupt organs using razor blade by repeatedly dicing them. Use a fresh razor 
blade for each organ to avoid cross contamination.  
66. Place each organ into a microcentrifuge tube and record the weight. ! CAUTION For 
large organs (large tumors or the liver) do not exceed 500 mg in the microcentrifuge tube.  
67. Prepare collagenase digest solution #2 and add to each organ. Record the volume of 
solution added to each organ. For organs weighing less than 150 mg, 150 µL should be 
added. For organs that weigh greater than 150 mg and less than 500 mg, approximately 
an equal amount of collagenase digest solution #2 in microliters should be added for the 
organ weight in milligrams (e.g. add 250 µL of solution for an organ weighing 250 mg). 
∆ CRITICAL STEP Collagenase digest solution #2 should be prepared fresh before 
use.  
68. Gently centrifuge each microcentrifuge tube using a tabletop centrifuge (10-20 seconds) 
and vortex (setting 10) for 30 seconds to ensure the organ is suspended in the digest 
mixture. Incubate the organ digest mixture for 1 hour in a 37ºC water bath.  
69. After the incubation, sonicate each sample for one minute using sonic dismembrator with 
amplitude 20% and pulsing every 10 seconds. The sample should appear nearly 
homogeneous. ! CAUTION Sample sonication can result in formation of aerosols. 
Perform sonication in biological safety cabinet according to safety protocols.  
70. Prepare Trypsin digest solution and add the same volume of Trypsin digest solution as 
collagenase digest solution #2 in step 67. ∆ CRITICAL STEP Trypsin digest solution 
should be prepared fresh before use.  
71. Gently centrifuge each microcentrifuge tube using a tabletop centrifuge (10-20 seconds) 
and vortex (setting 10) for 30 seconds to ensure the organ is suspended in the digest 
mixture. Incubate the organ digest mixture for 1 hour in a 37ºC water bath.  
72. After the incubation, sonicate each sample for one minute using sonic dismembrator with 
amplitude 20% and pulsing every 10 seconds. The sample should appear nearly 
homogeneous. ! CAUTION Sample sonication can result in formation of aerosols. 
Perform sonication in biological safety cabinet according to safety protocols. 
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73. Add 200 µL of each homogenized organ to a 96 well plate and serially dilute in 100 µL 
of PBS.   
74. Place the 96 well plate on the Odyssey CLx glass and scan at 3.5mm height, medium 
quality, and 169µm resolution.  
75. To determine the autofluorescence background, perform the biodistribution on saline 
injected negative control mice. Quantify the fluorescence intensity from the same scan 
settings on the Odyssey to fluorescence signal per weight of tissue.   
76. Prepare a calibration curve. Make a known concentration of dually labeled antibody in 
mouse plasma. Add collagenase digest solution #2 and digest as outlined above (step 
67). Add trypsin digest solution and digest as outlined above (step 70). Serially dilute in 
a 96 well plate with PBS and scan on the Odyssey CLx using the same scan settings as 
above (step 74). Make a calibration curve correlating the fluorescence intensity in each 
well to the concentration of dually labeled antibody.  
77. Calculate the percent-injected dose per gram (%ID/g) for each organ. Calculate the 
fluorescence intensity per milligram of tissue. Assume a tissue density of 1 mg/µL for 
most tissues. Calculate the signal from autofluorescence by multiplying the 
autofluorescence signal per milligram by the amount of tissue in the well. Background 
subtract the autofluorescence signal. Using the calibration curve, correlate the 
fluorescence signal intensity to the concentration in the well. Multiply the fluorescence 
concentration in the well by the volume of solution in the well to receive the absolute 
amount of probe in the well. Divide the absolute amount in the well by the absolute 
amount injected and multiply by 100 to get the percent injected dose. Normalize by 
dividing by the organ weight in grams to receive the percent-injected dose per gram 
(%ID/g). 
 
TROUBLESHOOTING 
Step 3, determining optimal molar ratios for antibody labeling. Each protein, antibody, or 
ADC will require optimization of molar ratio for labeling. Increase or decrease the molar ratio 
accordingly; however, ensure the final dye to protein ratio does not exceed 0.3 for IRDye and 0.7 
for DDAO.  
 
Step 47, fixing/permeabilizing cells. Multicolor flow cytometry staining for intracellular 
targets may require permeabilization; however, permeabilization of cells will allow free dye 
(even residualizing dye) to permeate out of cell. Use an unpermeabilized control to calculate 
cumulative protein uptake.   
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Step 53, cell death in the in vitro microscopy or in vitro flow cytometry. Since the 
payload in ADCs may exert a cytotoxic effect on a cell, it can result in cell death before imaging 
or running on flow cytometry. If this occurs, shorten the time course to before the ADC can 
induce cell death. 
 
Step 53, excessive debris on tumor digest. Digest for a shorter amount of time. Do not 
centrifuge at greater than 300g. Avoid selecting clearly necrotic tumor pieces for flow cytometry. 
 
Step 53, variability in intact protein fraction from tumor digest. Perform the histogram 
analysis. 24-48 hours after injection, there may be two populations (intact and degraded). While 
the tumor takes up and degrades some antibody, there is still a constant supply of intact antibody 
from the blood, which can result in a bimodal distribution. The histogram analysis will show a 
more detailed cellular distribution of intact or degraded antibody while the mean shows the 
aggregate distribution.   
 
Step 61, ex vivo fluorescence histology imaging. The radiant sensitivity and quantum 
efficiency of the Olympus FV1200 PMT decreases significantly at wavelengths above 825 nm. 
To maximize fluorescence signal the laser and PMT settings for the 800CW channel may have to 
increase to maximum. Additionally, increasing the pixel dwell time may improve signal; 
however, increasing the pixel dwell time for too long can result in photobleaching. Using 
Kalman filtering of 2-3 is highly recommended to reduce background noise. 
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Appendix B – Table of PBPK-Krogh Cylinder Model Parameters 
 
Table B.1 Table of PBPK-Krogh Cylinder Model Parameters. 
Parameters Units Value Description References 
Q_kidney_sp mL/s/g 0.0403 Flowrates on mass basis (60) 
Q_carcass_sp mL/s/g 0.0017 Flowrates on mass basis (60) 
Q_liver_sp mL/s/g 0.0120 Flowrates on mass basis (60) 
Q_spleen_sp mL/s/g 0.0083 Flowrates on mass basis (60) 
Q_heart_sp mL/s/g 0.0306 Flowrates on mass basis (156) 
Q_lung_sp mL/s/g 0.3570 Flowrates on mass basis (156) 
L_kidney_sp mL/s/g 8.05 x 10-05 Lymph flowrate on mass basis Blood flowrate divided by 500 
L_carcass_sp mL/s/g 3.40 x 10-06 Lymph flowrate on mass basis Blood flowrate divided by 500 
L_liver_sp mL/s/g 2.40 x 10-05 Lymph flowrate on mass basis Blood flowrate divided by 500 
L_spleen_sp mL/s/g 1.67 x 10-05 Lymph flowrate on mass basis Blood flowrate divided by 500 
L_heart_sp mL/s/g 6.12 x 10-05 Lymph flowrate on mass basis Blood flowrate divided by 500 
L_lung_sp mL/s/g 7.14 x 10-04 Lymph flowrate on mass basis Blood flowrate divided by 500 
V_v_kidney_sp mL/g 0.12 Vascular volume on per mass basis (60) 
V_i_kidney_sp mL/g 0.339 Interstitial volume on per mass basis (60) 
V_v_carcass_sp mL/g 0.02 Vascular volume on per mass basis (60) 
V_i_carcass_sp mL/g 0.108 Interstitial volume on per mass basis (60) 
V_v_liver_sp mL/g 0.1 Vascular volume on per mass basis (60) 
V_i_liver_sp mL/g 0.2 Interstitial volume on per mass basis (60) 
V_v_spleen_sp mL/g 0.1 Vascular volume on per mass basis (60) 
V_i_spleen_sp mL/g 0.2 Interstitial volume on per mass basis (60) 
V_v_heart_sp mL/g 0.046 Vascular volume on per mass basis (156) 
V_i_heart_sp mL/g 0.125 Interstitial volume on per mass basis (156) 
V_v_lung_sp mL/g 0.093 Vascular volume on per mass basis (156) 
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Parameters Units Value Description References 
V_i_lung_sp mL/g 0.279 Interstitial volume on per mass basis (156) 
mass_kidney g 0.304 mass of organ (60) 
mass_carcass g 21.304 mass of organ (60) 
mass_liver g 1.272 mass of organ (60) 
mass_spleen g 0.127 mass of organ (60) 
mass_heart g 0.152 mass of organ (161) 
mass_lung g 0.204 mass of organ (161) 
Q_kidney mL/s 0.0122 Flowrate to kidney Calculated 
Q_carcass mL/s 0.0362 Flowrate to carcass Calculated 
Q_liver mL/s 0.0153 Flowrate to liver Calculated 
Q_spleen mL/s 0.0011 Flowrate to spleen Calculated 
Q_heart mL/s 0.0047 Flowrate to heart Calculated 
Q_lung mL/s 0.0728 Flowrate to lung Calculated 
L_kidney mL/s 2.45 x 10-05 Lymph flowrate in kidney Calculated 
L_carcass mL/s 7.24 x 10-05 Lymph flowrate in carcass Calculated 
L_liver mL/s 3.06 x 10-05 Lymph flowrate in liver Calculated 
L_spleen mL/s 2.12 x 10-06 Lymph flowrate in spleen Calculated 
L_heart mL/s 9.30 x 10-06 Lymph flowrate in heart Calculated 
L_lung mL/s 1.46 x 10-04 Lymph flowrate in lung Calculated 
V_plasma mL 0.572 Volume of plasma Calculated 
V_v_kidney mL 0.036 Vascular volume of kidney Calculated 
V_i_kidney mL 0.103 Interstitial volume of kidney Calculated 
V_v_carcass mL 0.426 Vascular volume of carcass Calculated 
V_i_carcass mL 2.301 Interstitial volume of carcass Calculated 
V_v_liver mL 0.127 Vascular volume of liver Calculated 
V_i_liver mL 0.254 Interstitial volume of liver Calculated 
V_v_spleen mL 0.013 Vascular volume of spleen Calculated 
V_i_spleen mL 0.025 Interstitial volume of spleen Calculated 
V_v_heart mL 0.007 Vascular volume of heart Calculated 
V_i_heart mL 0.019 Interstitial volume of heart Calculated 
V_v_lung mL 0.019 Vascular volume of lung Calculated 
V_i_lung mL 0.057 Interstitial volume of lung Calculated 
k_deg_liver mL/s 7.369 x 10-06 Liver degradation rate in organ Fit to experimental data 
k_deg_FcRn mL/s 5.220 x 10-03 FcRn degradation rate (60) 
k_deg_organ mL/s 3.176 x 10-07 Organ degradation rate Fit to experimental data 
k_int mL/s 2.450 x 10-05 Internalization rate (166) 
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Parameters Units Value Description References 
k_rec 1/s 5.75 x 10-05 FcRn recycle rate (166) 
U 1/s 6.963 x 10-04 Urinary excretion rate Fit to experimental data 
k_loss 1/s 5.244 x 10-05 Metabolite loss rate Fit to experimental data 
J_iso_kidney_sp mL/s/g 4.18 x 10-06 Fluid recirculation flowrate on mass basis (60) 
J_iso_carcass_sp mL/s/g 2.42 x 10-06 Fluid recirculation flowrate on mass basis (60) 
J_iso_liver_sp mL/s/g 1.93 x 10-06 Fluid recirculation flowrate on mass basis (60) 
J_iso_spleen_sp mL/s/g 2.67 x 10-07 Fluid recirculation flowrate on mass basis (60) 
J_iso_heart_sp mL/s/g 5.60 x 10-05 Fluid recirculation flowrate on mass basis (156) 
J_iso_lung_sp mL/s/g 5.00 x 10-04 Fluid recirculation flowrate on mass basis (156) 
PSL_sp mL/s/g 4.44 x 10-08 Permeability surface area product for large pores (156) 
PSS_sp mL/s/g 1.30 x 10-07 Permeability surface area product for small pores (156) 
sigma_L dimensionless 0.26 
Reflection coefficient for large 
pores (166) 
sigma_S dimensionless 0.98 
Reflection coefficient for small 
pores (166) 
alpha_L dimensionless 0.042 
Fraction extravasation occurring 
via large pores (60) 
alpha_L_kidney dimensionless 0.002 
Fraction extravasation occurring 
via large pores (60) 
B_max_heart mol/mL 1.00 x 10-12 Antigen concentration  Assumed 
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Appendix C – PBPK-Krogh Cylinder Model Equations 
 
Krogh Cylinder Tissue Model Equations 
Free mAb 𝜕𝐶,-.𝜕𝑡 = 	𝐷122 31𝑟 𝜕𝜕𝑟 6𝑟 𝜕𝐶,-.𝜕𝑟 78 − 𝑘;( 𝐶,-.𝜀 𝑇2>11 + 𝑘;22𝐵,-.	 
Free ADC 𝜕𝐶ABC𝜕𝑡 = 	𝐷122 31𝑟 𝜕𝜕𝑟 6𝑟 𝜕𝐶ABC𝜕𝑟 78 − 𝑘;( 𝐶ABC𝜀 𝑇2>11 + 𝑘;22𝐵ABC 
Free Target 𝜕𝑇2>11𝜕𝑡 = 	𝑅E − 𝑘;( 𝐶,-.𝜀 𝑇2>11 − 𝑘;( 𝐶ABC𝜀 𝑇2>11 + 𝑘;22𝐵,-. + 𝑘;22𝐵ABC − 𝑘1𝑇2>11	 
Bound mAb 𝜕𝐵,-.𝜕𝑡 = 𝑘;( 𝐶,-.𝜀 𝑇2>11 − 𝑘;22𝐵,-. − 𝑘F(G𝐵,-.	 
Bound ADC 𝜕𝐵ABC𝜕𝑡 = 𝑘;( 𝐶ABC𝜀 𝑇2>11 − 𝑘;22𝐵ABC − 𝑘F(G𝐵ABC	 
Internalized mAb 𝜕𝐶F(G, -.𝜕𝑡 = 𝑘F(G𝐵,-. − 𝑘I;EE𝐶F(G, -.	 
Internalized ADC 𝜕𝐶F(G,ABC𝜕𝑡 = 𝑘F(G𝐵ABC − 𝑘I;EE𝐶F(G,ABC	 
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Boundary Conditions 
1. 
−𝐷122 𝑑𝐶2>11𝑑𝑟 K>LMNOPQRROST = 𝑃 6𝐶VI-E,- − 𝐶2>11𝜀(1 + 𝑅)7 
 
2. 
𝐷122 𝑑𝐶𝑓𝑟𝑒𝑒𝑑𝑟 K>LM[S\]^ = 0 
3.  𝐶VI-E,-,F( = 𝐶VI-E,-,`a`b 
Krogh cylinder exit concentration derivation 
Although antibodies are permeability limited and do not possess significant axial 
gradients along the length of the blood vessel (90), the exchange with the tumor must be 
quantified to satisfy the mass balance. Here we assume pseudo-steady state, constant capillary 
length, capillary radius, Krogh cylinder radius, free fraction equals 1, and constant blood flow 
rate to the tumor.  𝑑𝐶VI-E,-𝑑𝑡 = 	−𝑣 ∗ 𝜕𝐶VI-E,-𝜕𝐿 − 2𝑃(1 − 𝐻)𝑅&-V 6𝑓2>11𝐶VI-E,-,F( − 𝐶2>11, -.𝜀 7 
𝑣 ∗ 𝐶VI-E,-,;hG − 𝐶VI-E,-,F(𝐿 = − 2𝑃(1 − 𝐻)𝑅&-V 6𝐶VI-E,-,F( − 𝐶2>11, -.𝜀 7 
𝐶VI-E,-,;hG = 𝐶VI-E,-,F( − 𝐿𝑣 2𝑃(1 − 𝐻)𝑅&-V 6𝐶VI-E,-,F( − 𝐶2>11, -.𝜀 7 
𝑣 = 𝑄 ∗ 𝑅j>;kl%𝐿𝑅&-V% 	 
𝐶VI-E,-,;hG = 𝐶VI-E,-,F( − 2𝑃(1 − 𝐻)	 𝑅&-V𝑅j>;kl%	𝑄 6𝐶VI-E,- − 𝐶2>11, -.𝜀 7 
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PBPK Model Equations 
The general structure of this model was based on Ferl et al. 2006 (60). The equations 
describing the ADC portion of the model are identical to the free antibody PBPK model 
described below. The list of parameters used in the model can be found in Appendix B.  
Kidney 𝑑𝑁b,n𝑑𝑡 = 𝑄jFo(1p𝑉VI-E,- 𝑁VI-E,- −	𝑄jFo(1p − 𝐿jFo(1p𝑉n,jFo(1p 𝑁b,n − 𝐽F,n − 𝑘o1k,jFo(1p𝑁b,n  𝑑𝑁b,F𝑑𝑡 = 𝐽F,n −	 𝐿jFo(1p𝑉F,jFo(1p 𝑁s,F 𝑑𝑁b,t𝑑𝑡 = 		𝑄jFo(1p𝑉VI-E,- 𝑁t,VI-E,- + 𝑘o1k,jFo(1p𝑁b,n − 𝑈𝑁b,t 
Carcass 𝑑𝑁C,n𝑑𝑡 = 𝑄&->&-EE𝑉VI-E,- 𝑁VI-E,- + 𝑘>1&𝑁C,v −	𝑄&->&-EE − 𝐿&->&-EE𝑉n,&->&-EE 𝑁C,n −	 𝑘F(G𝑉n,&->&-EE 𝑁C,n − 𝐽F,n 𝑑𝑁C,F𝑑𝑡 = 𝐽F,n −	 𝐿&->&-EE𝑉F,&->&-EE 𝑁C,F 𝑑𝑁C,v𝑑𝑡 = 𝑘F(G𝑉n,&->&-EE 𝑁C,n − 𝑘>1&𝑁C,v − 𝑘o1k,w&M(𝑁C,v 𝑑𝑁C,t𝑑𝑡 = 		 𝑘o1k,w&M(𝑁C,v − 𝑘I;EE,C𝑁C,t 
Liver 𝑑𝑁',n𝑑𝑡 = 𝑄IFn1>𝑉VI-E,- 𝑁VI-E,- +	𝑄EVI11( − 𝐿EVI11(𝑉n,EVI11( 𝑁!,n − 𝑄IFn1> − 𝐿IFn1> − (𝑄EVI11( − 𝐿EVI11()𝑉n,IFn1> 𝑁',n
−	𝑘o1k,IFn1>𝑉n,IFn1> 𝑁',n − 𝐽F,n 
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𝑑𝑁',F𝑑𝑡 = 𝐽F,n −	 𝐿IFn1>𝑉F,IFn1> 𝑁',F 𝑑𝑁',t𝑑𝑡 = 		 𝑘o1k,IFn1>𝑉n,IFn1> 𝑁',n − 𝑘I;EE,'𝑁',t 
Spleen 𝑑𝑁!,n𝑑𝑡 = 𝑄EVI11(𝑉VI-E,- 𝑁VI-E,- −	𝑄EVI11( − 𝐿EVI11(𝑉n,EVI11( 𝑁!,n −	𝑘o1k,EVI11(𝑉n,IFn1> 𝑁!,n − 𝐽F,n 𝑑𝐶!,F𝑑𝑡 = 𝐽F,n −	 𝐿EVI11(𝑉F,EVI11( 𝑁!,F 𝑑𝐶!,t𝑑𝑡 = 		 𝑘o1k,EVI11(𝑉n,EVI11( 𝑁!,n − 𝑘I;EE,!𝑁!,t 
 
Plasma 𝑑𝐶VI-E,-𝑑𝑡 = 𝐿jFo(1p𝑉F,jFo(1p 𝑁b,F + 𝐿&->&-EE𝑉F,&->&-EE 𝑁C,F + 𝐿l1->G𝑉F,l1->G 𝑁x,F + 𝐿Ih(k𝑉F,Ih(k 𝑁',F + 𝐿EVI11(𝑉F,EVI11( 𝑁!,F
+ 𝐿IFn1>𝑉F,IFn1> 𝑁',F + 𝑄jFo(1p − 𝐿jFo(1p𝑉n,jFo(1p 𝑁b,n + 𝑄&->&-EE − 𝐿&->&-EE𝑉n,&->&-EE 𝑁C,n
+ 𝑄l1->G − 𝐿l1->G𝑉n,l1->G 𝑁x,n + 𝑄Ih(k − 𝐿Ih(k𝑉n,Ih(k 𝑁',n
+ (𝑄IFn1> − 𝐿IFn1> − (𝑄EVI11( − 𝐿EVI11())𝑉n,IFn1> 𝑁',n − 𝑄IFn1>𝑉VI-E,- 𝑁VI-E,-
− 𝑄jFo(1p𝑉VI-E,- 𝑁VI-E,- − 𝑄&->&-EE𝑉VI-E,- 𝑁VI-E,- − 𝑄EVI11(𝑉VI-E,- 𝑁VI-E,- − 𝑄l1->G𝑉VI-E,- 𝑁VI-E,-
− 𝑄Ih(k𝑉VI-E,- 𝑁VI-E,- + 𝐷𝑂𝑆𝐸(𝑡) − 𝑄Gh,;>𝑉VI-E,- 𝑁VI-E,- + 𝑄Gh,;>𝐶VI-E,-,b>;kl_1}FG 
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𝑑𝑁t,VI-E,-𝑑𝑡 = 𝑘I;EE,C𝑁C,t + 𝑘I;EE,'𝑁',t + 𝑘I;EE,!𝑁!,t + 𝑘I;EE,x𝑁x,t +	𝑘I;EE,'𝑁',t
+ 𝑘I;EE,s𝑁s,t − 𝑄jFo(1p𝑉VI-E,- 𝑁t,VI-E,-  
Heart 𝑑𝑁x,n𝑑𝑡 = 𝑄l1->G𝑉VI-E,- 𝑁VI-E,- −	𝑄l1->G − 𝐿l1->G𝑉n,l1->G 𝑁x,n − 𝐽F,n − 𝑘o1k,l1->G𝑁x,n 𝑑𝑁x,F𝑑𝑡 = 𝐽F,n −	 𝐿l1->G𝑉F,l1->G 𝑁x,F 𝑑𝑁x,t𝑑𝑡 = 	𝑘o1k,l1->G𝑉n,l1->G 𝑁x,n − 𝑘I;EE,x𝑁x,t 
Lung 𝑑𝑁',n𝑑𝑡 = 𝑄Ih(k𝑉VI-E,- 𝑁VI-E,- −	𝑄Ih(k − 𝐿Ih(k𝑉n,Ih(k 𝑁',n − 𝐽F,n − 𝑘o1k,Ih(k𝑁',n 𝑑𝑁',F𝑑𝑡 = 𝐽F,n −	 𝐿Ih(k𝑉F,Ih(k 𝑁',F 𝑑𝑁',t𝑑𝑡 = 	𝑘o1k,Ih(k𝑉n,Ih(k 𝑁',n − 𝑘I;EE,'𝑁',t  𝑉VI-E,- = 𝑇𝑜𝑡𝑎𝑙	𝑏𝑙𝑜𝑜𝑑 − 𝑉n,jFo(1p − 𝑉n,&->&-EE − 𝑉n,IFn1> − 𝑉n,EVI11( −	𝑉n,l1->G −	𝑉n,Ih(k  
Two-pore 
𝐽F,n = 𝐽',;>k-((1 − 𝜎') 𝑁;>k-(,n𝑉n,;>k-(  + 𝑃𝑆',;>k-( 𝑁;>k-(,n𝑉n,;>k-( − 𝑁;>k-(,F𝑉F,;>k-(   𝑃𝑒',;>k-(𝑒`1,\S]O − 1
+ 𝐽!,;>k-((1 − 𝜎!) 𝑁;>k-(,n𝑉n,;>k-( 
+ 𝑃𝑆!,;>k-( 𝑁;>k-(,n𝑉n,;>k-( − 𝑁;>k-(,F𝑉F,;>k-(   𝑃𝑒!,;>k-(𝑒`1,\S]O − 1 
𝑃𝑒',;>k-( = 𝐽',;>k-((1 − 𝜎')𝑃𝑆',;>k-(  
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𝑃𝑒!,;>k-( = 𝐽!,;>k-((1 − 𝜎!)𝑃𝑆!,;>k-(  𝑃𝑆',;>k-( = 𝑃𝑆'𝑀𝑎𝑠𝑠;>k-( 𝑃𝑆!,;>k-( = 𝑃𝑆!𝑀𝑎𝑠𝑠;>k-( 𝐽',;>k-( = 	 𝐽FE;,;>k-( + 𝛼',;>k-(𝐿;>k-( 𝐽!,;>k-( = 	 𝐽FE;,;>k-( + 𝛼!,;>k-(𝐿;>k-( 𝐽FE;,;>k-( = 	 𝐽FE;,;>k-(,EV𝑀𝑎𝑠𝑠;>k-( 𝛼! = 1 − 𝛼'  𝛼!,jFo(1p = 1 − 𝛼',jFo(1p  
Heart with Bound Compartment  𝑑𝑁x,n𝑑𝑡 = 𝑄l1->G𝑉VI-E,- 𝑁VI-E,- −	𝑄l1->G − 𝐿l1->G𝑉n,l1->G 𝑁x,n − 𝐽F,n − 𝑘o1k,l1->G𝑁x,n 
 𝑑𝑁x,F𝑑𝑡 = 𝐽F,n −	 𝐿l1->G𝑉F,l1->G 𝑁x,F + 	𝑘;22𝑁x,. −	𝑘;( 𝐵,-} − 𝑁x,.𝑉F,l1->G 𝑁x,F 
 𝑑𝑁x,a𝑑𝑡 = 	𝑘;( 𝐵,-} − 𝑁x,.𝑉F,l1->G 𝑁x,F − 	𝑘;22𝑁x,. 	− 𝑘o1k,l1->G𝑉F,l1->G 𝑁x,n 
 𝑑𝑁x,t𝑑𝑡 = 	𝑘o1k,l1->G𝑉F,l1->G 𝑁x,n − 𝑘I;EE,x𝑁x,t 
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